---
document_datetime: 2023-09-21 17:49:19
document_pages: 112
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/reasanz-epar-public-assessment-report_en.pdf
document_name: reasanz-epar-public-assessment-report_en.pdf
version: success
processing_time: 56.2793246
conversion_datetime: 2025-12-28 01:25:11.951989
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 May 2014 EMA/303748/2014 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Reasanz

International non-proprietary name: serelaxin

Procedure No. EMEA/H/C/002817

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Product information

| Name of the medicinal product:                 | Reasanz                                                                                                                     |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                     | Novartis Europharm Ltd Wimblehurst Road Horsham West Sussex RH12 5AB UNITED KINGDOM                                         |
| Active substance:                              | serelaxin                                                                                                                   |
| International Nonproprietary Name/Common Name: | serelaxin                                                                                                                   |
| Pharmaco-therapeutic group (ATC Code):         | C01DX21                                                                                                                     |
| Therapeutic indication (as applied for) :      | Reasanz is indicated for the treatment of acute heart failure and to reduce mortality in patients with acute heart failure. |
| Pharmaceutical form:                           | Concentrate for solution for infusion                                                                                       |
| Strengths:                                     | 1 mg/ml                                                                                                                     |
| Route of administration:                       | Intravenous use                                                                                                             |
| Packaging:                                     | vial (glass)                                                                                                                |
| Package size:                                  | 1 vial                                                                                                                      |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure............................................                                     | 10                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................10       |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.......................................................11                |                                                                                                          |
| Steps taken for the re-examination procedure..............................................................12               |                                                                                                          |
| 2. Scientific discussion..............................................................................                     | 12                                                                                                       |
| 2.1. Introduction.......................................................................................................12 |                                                                                                          |
| 2.2. Quality aspects                                                                                                       | ..................................................................................................13     |
| 2.2.1. Introduction....................................................................................................14  |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................14     |                                                                                                          |
| 2.2.3. Finished Medicinal Product................................................................................15        |                                                                                                          |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................17                       |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ......................17                                                                                 |
| 2.3. Non-clinical aspects                                                                                                  | ............................................................................................17           |
| 2.3.1. Introduction....................................................................................................17  |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                        | .................................................................................................18      |
| 2.3.3. Pharmacokinetics.............................................................................................20     |                                                                                                          |
| 2.3.4. Toxicology                                                                                                          | ......................................................................................................22 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                           | .........................................................23                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................23          |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................24            |                                                                                                          |
| 2.4. Clinical aspects                                                                                                      | ..................................................................................................24     |
| 2.4.1. Introduction....................................................................................................24  |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................28     |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................31        |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................33            |                                                                                                          |
| Pharmacokinetics......................................................................................................33   |                                                                                                          |
| Pharmacodynamics                                                                                                           | ...................................................................................................34    |
| 2.4.5. Conclusions on clinical pharmacology.................................................................35             |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                     | ..................................................................................................35     |
| 2.5.1. Dose response study (Pre-RELAX)                                                                                     | .....................................................................36                                  |
| 2.5.2. Main study (RELAX-AHF)                                                                                              | ..................................................................................39                     |
| 2.5.3. Discussion on clinical efficacy............................................................................63       |                                                                                                          |
| 2.5.4. Conclusions on the clinical efficacy.....................................................................69         |                                                                                                          |
| 2.6. Clinical safety                                                                                                       | ....................................................................................................69   |
| 2.6.1. Discussion on clinical safety                                                                                       | ..............................................................................86                         |
| 2.6.2. Conclusions on the clinical safety.......................................................................88         |                                                                                                          |
| 2.7. Pharmacovigilance..............................................................................................88     |                                                                                                          |
| 2.9. User consultation                                                                                                     |                                                                                                          |
|                                                                                                                            | ...............................................................................................92        |

<div style=\"page-break-after: always\"></div>

| 3. Benefit-Risk Balance.............................................................................       | 92                                                                                                         |
|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 4. Recommendations................................................................................. 99     | 4. Recommendations................................................................................. 99     |
| 5. Re-examination of the CHMP opinion of 23 January 2014................... 101                            | 5. Re-examination of the CHMP opinion of 23 January 2014................... 101                            |
| 5.1 Detailed grounds for re-examination submitted by the applicant ............................. 101       | 5.1 Detailed grounds for re-examination submitted by the applicant ............................. 101       |
| 5.2 Scientific Advisory Group on Cardiovascular Issues (SAG CVS)................................ 106       | 5.2 Scientific Advisory Group on Cardiovascular Issues (SAG CVS)................................ 106       |
| 5.3 Overall conclusion on grounds for re-examination.................................................. 108 | 5.3 Overall conclusion on grounds for re-examination.................................................. 108 |
| 5.4 Recommendations following re-examination ......................................................... 110 | 5.4 Recommendations following re-examination ......................................................... 110 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AA

Aldosterone antagonists

ACE

Angiotensin converting enzyme

AE

Adverse event

AHF

Acute Heart Failure

AR

Assessment report

ARB

Angiotensin receptor blocker

Asp

Aspartate, Aspartic acid

AUC

Area under the concentration-time curve

AUC0-t Area under the serum concentration-time curve from time zero to time t, using the linear trapezoidal rule. Concentrations below the LLOQ are set to zero and therefore excluded from the calculation. Actual sample collection times are used. Where 0-t is shown as τ this denotes the AUC under a dosing interval

AUCinf from linear regression of the terminal elimination phase

BET

Area  under  the  serum  concentration-time  curve  from  time  zero  to infinity.  For  extrapolation to  infinity  Clast  /  λz  is  used,  where  Clast  is the estimated concentration at the last sample time point above LLOQ

Bacterial endotoxins test

BNP

B-type natriuretic peptide

BP

Blood Pressure

bpm

beats per minute

BUN

Blood urea nitrogen

C48hr

The observed serum concentration at 48 hours after the start of drug administration

CBL

Chesapeake biological laboratories

CBPDE

Confirmed Blood Pressure Decrease Event

CCU

Coronary Care Unit

CEC

Clinical Endpoint Committee

CHF

Chronic Heart Failure

cGMP

Current good manufacturing practice

CI

Cardiac Index

CL

Rate of clearance (serum or systemic)

CL and CL/F Systemic (or total body) clearance, calculated as Dose / AUCinf following intravenous   administration. For extravascular administration where absolute bioavailability is less

than

100%, clearance is represented as CL/F

Clast

Last observed serum concentration

CLCR

Creatinine clearance

Cmax

Maximum serum concentration after a single dose

CMO

Contract manufacturing organisation

CNS

Central nervous system

CO

Cardiac output

CPP

Critical process parameter

CRF

Case Report Form

CRL

Charles River Laboratories

Css

Steady-state concentration

CTD

Common technical document

CV

Coefficient of variation

CV

Cardiovascular

CYP

Cytochrome P450

DBP

Diastolic Blood Pressure

DDI

Drug-drug interactions

DNA

Deoxyribonucleic acid

DO

Dissolved oxygen

DP

Drug product

DRE

Disease-related event

DS

Drug substance

## E. coli Escherichia coli

ECG

Electrocardiogram

eGFR

Estimated glomerular filtration rate

ELISA

Enzyme-linked immunosorbent assay

EMA

European Medicines Agency

ERK1/2

Extracellular-signal-regulated kinases

ET

Endothelin

ET-1

Endothelin isoform 1

ETA

Endothelial endothelin type A receptor

ETB

Endothelial endothelin type B receptor

FDA

Food and Drug Administration

GCP

Good clinical practice

GD

Gestational Day

GFR

Glomerular filtration rate

GLP

Good Laboratory Practice

hERG

human Ether-à-go-go-Related Gene

HF

Heart Failure

HR

Hazard ratio

hs-cTnT

High-sensitivity cardiac troponin T

IC50

Inhibitory Concentration 50%

ICH

International conference on harmonisation

ICU

Intensive Care Unit

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| IGF                                                 | Insulin-like growth factor                                  |
|-----------------------------------------------------|-------------------------------------------------------------|
| INN                                                 | International non-proprietary name                          |
| INSL                                                | Insulin-like                                                |
| IPC                                                 | In-process control                                          |
| Iso-Asp                                             | Isoaspartate, isoaspartic acid                              |
| IU                                                  | International units                                         |
| IV                                                  | Intravenous(ly)                                             |
| JVP                                                 | Jugular venous pulse                                        |
| kDA                                                 | kilo Dalton                                                 |
| K-M                                                 | Kaplan-Meier                                                |
| LFT                                                 | Liver function test                                         |
| LGR7                                                | Leucine-rich repeat-containing G-protein-coupled receptor 7 |
| LLOQ                                                | Lower limit of quantification                               |
| LO                                                  | Low volume light obscuration                                |
| LOD                                                 | Limit of detection                                          |
| LoQ                                                 | List of questions                                           |
| LOS                                                 | Length of Stay                                              |
| LVEF                                                | Left ventricular ejection fraction                          |
| M                                                   | Methionine                                                  |
| MAA                                                 | Marketing authorisation application                         |
| MAP                                                 | Mean arterial pressure                                      |
| MAPK                                                | Mitogen-activated protein kinases                           |
| MCB                                                 | Master cell bank                                            |
| Mfg                                                 | Manufacturing                                               |
| MMPs                                                | Matrix metalloproteinases                                   |
| MRT                                                 | Mean residence time                                         |
| NA                                                  | Not applicable                                              |
| NAS                                                 | New active substance                                        |
| NCE                                                 | New chemical entity                                         |
| NF                                                  | National Formulary                                          |
| NMR                                                 | Nuclear magnetic resonance                                  |
| NMT                                                 | Not more than                                               |
| NNT                                                 | Number needed to treat                                      |
| NO                                                  | Nitric oxide                                                |
| NOAEL                                               | No Adverse Effect Level                                     |
| NOEL                                                | No Effect Level                                             |
| NOS                                                 | Nitric oxide synthase                                       |
| NT-pro-BNP N-terminal pro-brain natriuretic peptide | NT-pro-BNP N-terminal pro-brain natriuretic peptide         |
| NTU                                                 | Nephelometric turbidity units                               |
| NWP                                                 | Normalized water permeability                               |
| NYHA                                                | New York Heart Association                                  |
| O/N                                                 | Non-key operational parameter                               |
| OMCL                                                | Official medicines control laboratory                       |
| OOS                                                 | Out of specification                                        |

PC

Process control

PCWP

Pulmonary capillary wedge pressure

PD

Pharmacodynamic(s)

Ph. Eur.

European Pharmacopoeia

Ph. Helv.

Pharmacopoeia Helvetica

PK

Pharmacokinetic(s)

PT

Preferred terms

PV

Process validation

PVR

Pulmonary vascular resistance

QC

Quality control

QRD

Quality review of documents

RBC

Red blood cells (erythrocytes)

RBF

Renal blood flow

rDNA

Recombinant DNA

RH

Relative humidity

rhRlx

Recombinant human relaxin-2 (manufactured by single chain process)

rhRlx*

Recombinant human relaxin-2 (manufactured by double chain process)

RLX

Relaxin

RLX030

Serelaxin

RMP

Risk management plan

rpm

Revolutions per minute

RS

Reference standard

RSD

Relative standard deviation

RXFP1

Relaxin/insulin-like family peptide receptor 1

RXFP2

INSL3 receptor, has limited serelaxin binding

SAE

Serious adverse event

SBP

Systolic Blood Pressure

SC

Subcutaneous

sCR

serum creatinine

SCS

Summary of clinical safety

SD

Standard deviation

sMDRD

Simplified modification of diet in renal disease formula

SOC

System organ class

SPC

Summary of product characteristics

SST

System suitability test

SUSAR

Suspected Unexpected Serious Adverse Reaction

SVR

Systemic vascular resistance

T½, λz

Terminal  elimination  half-life  (T½  )  or  rate  constant  (λz)  of  the  semilogarithmic concentration-time  curve  Tmax  Time  to  reach  the  maximum  observed  serum concentration

tmax

Time to the maximum observed serum concentration

TSE

Transmissible spongiform encephalopathies

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| URL   | Upper reference limit                             |
|-------|---------------------------------------------------|
| USP   | United States Pharmacopoeia                       |
| VAS   | Visual Analog Scale                               |
| Vc    | Volume of distribution in central compartment     |
| VEGF  | Vascular endothelial cell growth factor           |
| Vp2   | Peripheral volume of distribution                 |
| Vss   | (Apparent) Volume of distribution at steady state |
| W     | Tryptophan                                        |
| WCB   | Working cell bank                                 |
| WFI   | Water for injection                               |
| WHF   | Worsening Heart Failure                           |
| WRF   | Worsening renal function                          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Novartis Europharm Ltd submitted on 24 December 2012 an application for Marketing Authorisation  to  the  European  Medicines  Agency  (EMA)  for  Reasanz,  through  the  centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.

The applicant applied for the following indication:

'Reazanz is indicated for the treatment of acute heart failure and to reduce mortality in patients with acute heart failure.'

## The legal basis for this application refers to:

Article 8(3) of Directive 2001/83/EC - complete and independent application. The applicant indicated that serelaxin was considered to be a new active substance.

The  application  submitted  is  composed  of  administrative  information,  complete  quality  data,  nonclinical  and  clinical  data  based  on  applicants'  own  tests  and  studies  and/or  bibliographic  literature substituting/supporting certain tests or studies.

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0288/2012 on the agreement of a paediatric investigation plan (PIP).

At  the  time  of  submission  of  the  application,  the  PIP  EMEA-001168-PIP01-11-M01  was  not  yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant  did  not  submit  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## New active Substance status

The applicant requested the active substance serelaxin contained in the above medicinal product to be considered as a new active substance in itself, as the applicant claims that it is not a constituent of a product previously authorised within the Union.

## Scientific Advice

The applicant received Scientific Advice from the CHMP on 16 December 2010. The Scientific Advice pertained to non-clinical and clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## Licensing status

A new application was filed in the following countries: the United States of America.

The product was not licensed in any country at the time of submission of the application.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur: Pieter de Graeff Co-Rapporteur: Daniela Melchiorri

- The application was received by the EMA on 24 December 2012.
- The procedure started on 30 January 2013.
- The Rapporteur's first  Assessment Report was circulated to all CHMP members on 18 April 2013  (Annex  1).  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 19 April 2013 (Annex 2).
- PRAC RMP Advice and assessment overview adopted by PRAC on 16 May 2013 (Annex 3).
- During the meeting on 30 May 2013, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 31 May 2013 (Annex 4).
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  27 August 2013.
- The  summary  report  of  the  inspection  carried  out  at  the  following  sites:  two  investigators sites  (in  Italy  and  Hungary)  and  one  sponsor  site  (Novartis  USA)  between  6  May  and  6 August 2013 was issued on 4 September 2013.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 1 October 2013 (Annex 5).
- During  the  CHMP  meeting  on  24  October  2013,  the  CHMP  agreed  on  a  list  of  outstanding issues to be addressed in writing and during oral explanation by the applicant (Annex 6).
- PRAC RMP Advice and assessment overview adopted by PRAC on 05 December 2013 (Annex 7).
- The applicant submitted the written responses to the CHMP List of Outstanding Issues on 22 November 2013.
- During a meeting of a SAG on 9 December 2013, experts were convened to address questions raised by the CHMP (Annex 8).
- Joint  Rapporteur/Co-Rapporteur  Assessment  Report  on  the  responses  provided  by  the applicant, dated 26 November 2013 (Annex 9).
- During the CHMP meeting on 19 December 2013, the outstanding issues were addressed by the applicant during an oral explanation before the CHMP.
- Updated Joint  Rapporteur/Co  Rapporteur  Assessment  Report on  the  responses  provided  by the applicant dated 5 January 2014 (Annex 10).

<div style=\"page-break-after: always\"></div>

- During the meeting on 23 January 2014, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion for granting a Marketing Authorisation to Reasanz.

## Steps taken for the re-examination procedure

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur: Kristina Dunder Co-Rapporteur: Andrea Laslop

- The  applicant  submitted  written  notice  to  the  EMA  on  28  January  2014  to  request  a  reexamination of Reasanz CHMP opinion of 23 January 2013.
- During its meeting on 20 February 2014 the CHMP appointed Kristina Dunder as Rapporteur and Andrea Laslop as Co-Rapporteur.
- The  applicant  submitted  the  detailed  grounds  for  the  re-examination  on  27  March  2014 (Appendix 2 of Final Opinion) including the justification for consideration of its application for conditional marketing authorisation. The re-examination procedure started on 28 March 2014.
- The  Rapporteur's  Assessment  Report  was  circulated  to  all  CHMP  members  on  22  April  2014 (Annex 11). The Co Rapporteur's Assessment Report was circulated to all CHMP members on 23 April 2014 (Annex 12).
- During a meeting of the Scientific Advisory Group (SAG) CVS on 12 May 2014, experts were convened to consider the grounds for re-examination (Annex 13).
- The Rapporteurs circulated the Joint Assessment Report on the applicant's detailed grounds for re-examination to all CHMP members on 13 May 2014 (Annex 14).
- During  the  CHMP  meeting  on  20  May  2014,  the  detailed  grounds  for  re-examination  were addressed by the applicant during an oral explanation before the CHMP.
- During the meeting on 22 May 2014, in the light of the scientific data available and the scientific discussion within the Committee, the CHMP re-examined its initial opinion and in its final opinion concluded  that  the  application  did  not  satisfy  the  criteria  for  authorisation  and  did  not recommend the granting of the conditional marketing authorisation.

## 2. Scientific discussion

## 2.1. Introduction

Heart failure (HF) is a major worldwide health problem and the most frequent cause of admission to hospital  in  patients  older  than  65  years  ( Roger  VL  Circulation  2012 ).  Although  existing  treatments substantially improve the clinical course and prognosis of ambulatory patients with chronic heart failure (CHF),  treatment  of  patients  admitted  to  hospital  for  acute  heart  failure  (AHF)  has  not  changed  in recent  decades  ( McMurray, Eur  Heart  J  2012;  Damasceno  A,  Arch  Intern  Med  2012;  Chen  J,  JAMA 2011 ) with no treatments showing safe improvement in outcomes. Despite a favourable response to initial  treatment,  most  patients  remain  symptomatic  at  24  h  and  up  to  25%  develop  worsening

<div style=\"page-break-after: always\"></div>

symptoms  during  the  hospital  stay.  Sustained  relief  of  these  signs  and  symptoms  remains  an important goal of treatment ( Gheorghiade M, JAMA 2007 ).  Admission to hospital for HF portends an increased  risk  of  poor  outcomes,  with  a  5-15-times  increase  in  the  risk  of  death  compared  with ambulatory  patients  and  a  mortality  rate  of  10-20%  in  the  6  months  after  hospital  discharge ( Gheorghiade M, J Am Coll Cardiol 2009; Solomon SD, Circulation 2007 ). Although hospital admission could simply herald disease progression, this event and the related interventions might also directly contribute to poor outcomes through increased neurohormonal and inflammatory activation, haemodynamic compromise, and consequent end-organ damage.

Relaxin  (H2)  is  a  naturally  occurring  peptide  hormone  (molecular  weight  of  5963  Daltons)  that  has been associated with many of the maternal physiological responses to pregnancy. The investigational product, serelaxin, is produced by recombinant DNA technology in a bacterial expression system and is identical in amino acid sequence and structure to the mature, naturally occurring human relaxin-H2. Relaxin plays a central role in the hemodynamic and reno-vascular adaptative changes: as early as the first  trimester  of  pregnancy,  coincident  with  the  rise  in  circulating  endogenous  relaxin  levels, glomerular filtration rate (GFR) and renal blood flow (RBF) increase, cardiac output and global arterial compliance  both  rise,  and  systemic  vascular  resistance  falls.  Triggering  similar  hemodynamic  and adaptive changes as seen in pregnancy could potentially be beneficial in the treatment of patients with acute heart failure.

The  development  of  serelaxin  was  currently  focused  on  the  treatment  of  patients  with  AHF.  The pharmacological  effects  of  relaxin  include  the  production  of  nitric  oxide,  inhibition  of  endothelin-1, inhibition of angiotensin II, production of VEGF, and production of matrix metallo-proteinases. These effects lead to arterial vasodilation, increased arterial compliance, and improved renal hemodynamics.

The proposed indication for serelaxin at the submission of this application was: 'Reasanz is indicated for the treatment of acute heart failure and to reduce mortality in patients with acute heart failure.' The dosing recommendation in the proposed SmPC was: 'Serelaxin is intended for hospital use only in patients with signs and symptoms of acute heart failure who have dyspnoea at rest or with minimal exertion,  normal  to  elevated  blood  pressure,  and  mild  to  moderate  renal  insufficiency.  It  should  be used concomitantly with standard of care, including loop diuretics. Systolic blood pressure should be stable and above 125 mmHg prior to administration of serelaxin. Serelaxin has not been studied in patients with systolic blood pressure below 125 mmHg. Reasanz should be administered on the basis of body weight and given via intravenous infusion for 48 hours.'

At day 120 the MAH decided to modify the proposed therapeutic indication to: 'Reasanz is indicated for the treatment of acute heart failure and to reduce mortality in adult patients with acute heart failure and normal to elevated blood pressure. Reasanz should be used on top of standard of care, including loop diuretics.' This was proposed to be further modified at day 180 to: 'Reasanz is indicated for the symptomatic  treatment  of  acute  heart  failure  in  adults  with  normal  to  elevated  blood  pressure. Reasanz  should  be  used  on  top  of  standard  of  care,  including  loop  diuretics'.  Finally,  following  the suggestion from the Scientific Advisory Group experts the proposed indication was further modified to:

'Reasanz is indicated for the symptomatic treatment of acute heart failure in adults with normal to elevated  blood  pressure  systolic  blood  pressure  above  125  mmHg.  It  should  be  used  on  top  of standard of care, including loop diuretics.'

## 2.2. Quality aspects

<div style=\"page-break-after: always\"></div>

## 2.2.1. Introduction

Serelaxin is a recombinant human form of human relaxin-H2, a naturally occurring peptide hormone. Serelaxin is initially synthesized as a pre-pro-peptide, which is a single-chain peptide precursor, composed of 185 amino acids comprising a leader sequence, B-chain, C-peptide and A-chain. The leader sequence is cleaved off to yield pro-relaxin, which shows structural homology to pro-insulin, insulin-like growth factor and nerve growth factor. After removal of the leader sequence and C-peptide, the mature serelaxin molecule is obtained.

## 2.2.2. Active Substance

Serelaxin is produced by recombinant DNA technology in Escherichia coli ( E. Coli ) and it has an identical amino acid sequence and structure to the mature naturally occurring human relaxin-H2 molecule. Serelaxin is a 2-chain heterodimeric molecule, containing a 24-amino acid A-chain and a 29amino acid B-chain, covalently bound by 2 disulfide bridges. The A-chain has one additional internal disulfide bridge.

The structural elucidation and the physico-chemical and biological characterisation using adequate analytical methods presented in the application have confirmed that the structure and properties of serelaxin active substance have identical features to the mature naturally occurring human peptide hormone relaxin (H2).

## Manufacture

## Development genetics and cell bank system

Serelaxin is produced in recombinant E. coli. using a two-tiered cell banking system of MCB and WCB. The medium used to cultivate and freeze the Manufacturer's MCB and WCBs contained no human or animal derived materials. Procedures followed for the preparation of MCB and WCB were appropriately described. MCB and WCB have been extensively characterized with regards to product identity, genetic consistency and absence of microbial contaminants. Genetic stability at large scale fermentation conditions has been demonstrated by characterization of end of fermentation cultures.

The commercial manufacturing process for serelaxin active substance mainly consists of fermentation, recovery and purification. The manufacturing process is overall well described and sufficiently detailed.

## Comparability exercise for Active Substance

The active substance used to manufacture the material used in the phase 3 pivotal trial was manufactured by process 1a. Minor changes were made to the manufacturing process (process 1b). Additional minor changes were made to the downstream process, resulting in process 1c, the validated commercial active substance manufacturing process.

Comparability of active substance obtained from manufacturing process 1a, 1b and 1c (commercial process) has been extensively assessed using three batches from each process. Comparability was demonstrated with release tests, additional side by side characterization, comparison of process performance (impurities) and comparative stability (including degradation behaviour and photostability).

<div style=\"page-break-after: always\"></div>

## Specification

The active substance specification includes test methods for appearance, pH, identity, quantity, potency, purity, endotoxins and microbial count.

The analytical methods specifically developed for release and stability testing of serelaxin active substance are detailed in the dossier and have been validated in accordance with the principles outlined in ICH Q2 (R1).

The applicant provided an extensive statistical justification of specifications. The presented analytical results demonstrated that serelaxin active substance has the expected primary, secondary and tertiary structures and physical-chemical and biological properties. The biological activity of serelaxin is measured by a cell-based bioassay.

## Stability

Based on the data provided the proposed shelf-life for the active substance is considered acceptable.

## 2.2.3. Finished Medicinal Product

Reasanz finished product is presented as a clear sterile, concentrate for solution for infusion containing the active substance in sodium acetate buffer solution.

The container closure system for Reasanz consists of 6 mL colourless type I glass vials closed with a rubber stopper. The rubber stopper is sealed with a flip-off crimp cap. Vials and stoppers are in compliance with the requirements of the European Pharmacopoeia (Ph. Eur.) Compatibility of the primary packaging materials was evaluated for any potential extractables or leachables and is sufficiently addressed in the dossier.

## Pharmaceutical Development

The excipients of the finished product are water for injections as solvent, sodium acetate/sodium acetate trihydrate as buffering agent, and hydrochloric acid and sodium hydroxide for pH adjustment.

Compatibility of serelaxin active substance with excipients has been established during the formulation development, finished product development and stability studies. The excipients used are standard pharmacopoeial excipients. The excipients were chosen taking into account compatibility with serelaxin, stability, solubility and local tolerance.

The information provided on pharmaceutical development is considered satisfactory.

## Adventitious agents

## TSE compliance and Virus safety

The active substance is manufactured and purified in the absence of human or animal-derived materials. All raw materials used in the production of serelaxin active substance are either of compendial quality or tested according to internal specifications. No raw materials of human or animal

<div style=\"page-break-after: always\"></div>

origin have been used in the process. In addition, the medium used to cultivate and freeze the cell banks contained no human or animal-derived materials and therefore presents no concerns with regard to TSE risk.

E. coli cells do not support the replication of mammalian viruses. Therefore, there is no contamination risk from adventitious animal viruses during the production of serelaxin active substance and finished product. The only virus-like agents that can infect E. coli are bacteriophages. In order to ensure microbial safety of serelaxin active substance and finished product, the Master Cell Bank (MCB), Working Cell Banks (WCB) and end of fermentation cultures were analyzed for non-host contaminants and bacteriophages. Testing results showed absence of non-host contamination and absence of bacteriophages for MCB, WCB and end of fermentation cultures.

The information provided confirmed the safety of Reasanz regarding adventitious agents.

## Manufacture of the product

The manufacturing process consists of formulation/mixing with excipients, sterile filtration and fillfinish into vials.

Adequate critical process parameters (CPPs) and in-process controls (IPCs) are in place for the filtration and filling steps. The omission of CPPs and/or IPCs for formulation/mixing is considered acceptable as the mixing process is extensively validated (both by characterisation and verification) and robustness of the mixing process and the process parameters have been appropriately demonstrated.

Three validation batches were manufactured which comply with the specifications and pre-defined validation limits. Overall the finished product manufacturing process is generally well described and satisfactorily validated.

## Comparability Exercise for Finished Medicinal Drug Product

An extensive comparability exercise has been submitted, which included not only (comparative) release and stability testing, but also extended side-by-side characterisation of batches. Finished product comparability of batches manufactured at the commercial site and batches used in pivotal clinical studies is sufficiently demonstrated.

## Product specification

The applicant has provided an extensive (statistical) justification of specifications for the finished product. The information is appropriate and valid and overall the tests selected for release and stability testing of the finished product are adequate.

## Stability of the product

Stability studies were performed according to the current ICH guidelines.  The results generated during the stability studies support the proposed shelf life and storage conditions.

<div style=\"page-break-after: always\"></div>

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information about the active substance, serelaxin, was of acceptable quality. Sufficient evidence regarding the manufacturing process has been provided. Specification limits and analytical methods are suitable to control the quality of the active substance.

The finished product was well characterised. The manufacturing process has been satisfactorily described and the validation data shows consistent manufacture. The proposed specifications for the finished product were justified based on batch and stability results, and are in general adequate for assuring the product quality and therefore were accepted.

The stability program is in general considered satisfactory. The results generated during the stability studies support the proposed shelf life and storage conditions.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The active substance (serelaxin) and the finished product have been appropriately characterised and in general satisfactory documentation has been provided. The manufacturing process is overall, well described. The IPC tests are described and deemed suitable for controlling and monitoring the manufacturing process. The results indicate that serelaxin as well as the finished product can be reproducibly manufactured.

At the time of the opinion the CHMP has identified and recommended an additional point for further investigation.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Serelaxin has been investigated for a number of indications. Therefore clinical experience was available before the product was developed for currently applied indication. As a consequence the non-clinical package  consists  of  many  studies,  some  of  which  are  not  relevant  or  not  needed  for  the  current indication  (short-time  exposure  following  heart  failure).  In  this  report  those  studies  that  were considered not being relevant for the current indication have not been evaluated and the assessment focussed on those studies needed to support the current Application.

The synthetic and recombinant forms of serelaxin (all processes) are identical in amino acid sequence to  each  other  and  to  the  naturally  occurring  human  hormone  (A24B29),  except  hRlx-2  that  has  an additional four amino acids on its B-chain (A24B33). Even though hRlx-2 is 4-amino acids longer than the endogenous human H2 relaxin, it contains the complete receptor binding site and is biologically active  (Hossain  et  al  2011)  however  its  kinetic  profile  it's  somewhat  different  from  the  naturally occurring hormone. The B33 and B29 forms of relaxin have been shown to have similar potencies in an in  vitro  rat  atrial  bioassay  (Tan  et  al  2000)  and  an  ex  vivo  uterine  bioassay  (Tan  et  al  1998).  The Applicant considered the data generated using hRlx-2 as supportive information (see the Pharmacology section of this report).

<div style=\"page-break-after: always\"></div>

One toxicity study (4 weeks monkey) has been performed with a recent (clinical) batch of serelaxin. All other  studies  have  been  performed  with  earlier  batches  of  serelaxin.  According  to  the  Applicant, sufficient  non-clinical  data  has  been  generated  to  support  the  conclusion  that  the  materials  used  in nonclinical  studies  of  serelaxin  were  both  similar  to  each  other  and  representative  of  the  clinical material, so that data from these studies can be extrapolated to the commercial recombinant single chain  Process  1c  material.  The  process  1c  material  has  not  been  tested  in  in  vivo  non  clinical  and clinical studies. The CHMP agreed that additional nonclinical in vivo studies using Process 1c material would add nothing meaningful to the overall evaluation of safety or PK/PD relationships of serelaxin.

## 2.3.2. Pharmacology

Serelaxin, also referred to as RLX030, is an E. coli-synthesized protein identical to human relaxin 2.

Relaxin  is  a  naturally  occurring  peptide/protein  with  pleiotropic  effects  within  the  cardiovascular system. Its most widely recognized role is in mediating vasodilation that is a circulatory adaptation to pregnancy.  Relaxin  is  a  general  vasodilatator,  reducing  systemic  vascular  resistance  and  increasing cardiac  output.  This  is  due  to  effects  on  the  renal  vasculature,  yet  other  vasculature  is  likely  to  be involved  as  well.  Relaxin's  activity  is  initiated  by  binding  to  its  cognate  receptor,  RXFP1,  previously called LGR7, which is present in the renal and systemic vasculature. Nitric oxide and the endothelin type  B  receptor  are  believed  to  act  as  mediators  of  relaxin's  vasodilatatory  effect.  Other  potential mediators  of  relaxin's  vasodilatatory  activity  are  locally  produced  matrix  metalloproteinases  (MMPs) and vascular endothelial growth factor (VEGF).

In  addition,  relaxin  affects  the  reproductive  organs  (cervix,  pubic  symphysis,  vagina,  uterus,  and mammary apparatus), but the precise effects depend on the species. Also the profiles of relaxin levels in the peripheral blood throughout pregnancy differ strikingly among species. While it appears that the species differences mainly concern the role of relaxin in reproduction/pregnancy, also caution should be exercised when interpreting the clinical relevance of the (animal) hemodynamic effects.

The data provided in the pharmacodynamics section is mainly based on publication available in the public domain with almost no studies performed by Applicant. It is agreed that sufficient relevant data is available, and repetition of (animal) studies is not needed (nor ethical). Reasanz was evaluated in single  and  repeat  dose  studies  of  up  to  6  months  in  mice,  rats,  rabbits,  dogs  and  monkeys  using several routes of administration, including intravenous, subcutaneous bolus, topical (intravaginal and intracervical) and intra-gingival administration.

## Primary pharmacodynamic studies

The Applicant provided only two original reports covering primary pharmacodynamics, a GLP in vitro immunohistochemistry study (study 1280531), and an in vivo study on effects of i.v. serelaxin (study RLX030) on cardiac output, total peripheral resistance, and blood pressure in conscious, aged, male spontaneously  hypertensive  rats  (study  RD-2012-50361).  All  other  aspects  of  pharmacology  were documented based on published data, considering that the naturally occurring hormone relaxin has a well-known number of biological effects that indicate a role in regulating vascular tone.

The relaxin receptor, RXFP1 (LGR7), is believed to mediate the physiological effects of relaxin ( Hsu et al 2002, Halls et al 2007 ). Relaxin binding sites have been detected in blood vessels from humans, as well as in cells and tissues from the human heart ( Hsu et al 2002, Dschietzig et al 2011 ). Orthologues of RXFP1 have also been identified in mice and rats as cognate relaxin receptors ( Scott et al 2004 ). RXFP2 (LGR8), a receptor closely related to RXFP1, has a binding affinity approximately 10-fold lower

<div style=\"page-break-after: always\"></div>

than RXFP1, but is believed to activate a similar, although not identical, signalling pathway ( Halls et al 2009 ). RXFP2 receptors are localized in tissues with a distribution pattern similar to that of RXFP1 ( Hsu et al 2002 ).

Serelaxin binds with almost equal affinity to either human or rat relaxin receptors, and human relaxin is  shown to be highly bioactive in vivo in rodents as well as in vitro in rodent test systems. In vitro data indicate the off-rate of relaxin from its receptor increases at increasing amount of relaxin. This has been suggested as possible cause for the observed U-shaped haemodynamic dose-response curves observed in some non-clinical and clinical studies.

Multiple  studies  on  the  effect  of  relaxin  on  the  haemodynamic  parameters  have  been  performed  in rats, and effects on blood pressure have been included in several monkey toxicity studies. Overall it appears  that  relaxin  induces  a  systemic  vasodilation  that  leads  to  decreased  systemic  vascular resistance (SVR) and subsequent increase in (heart) stroke volume (SV) which leads to an increase in cardiac  output  (CO).  Effects  on  haemodynamic  parameters  in  monkeys  were  less  clear.  No  major effects on blood pressure and heart rate were seen.

Renal effects of serelaxin include marked increases in glomerular filtration rates and increases in renal plasma flow. These effects appear to be rapid, and may persist for several hours following serelaxin treatment. Relaxin has been shown to have an anti-fibrotic effect in rodents. The Applicant appears to suggest that the anti-fibrotic and potential effects on the extracellular matrix of relaxin may support the  long  term  benefit  of  serelaxin  treatment  following  AHF.  However  serelaxin  did  not  demonstrate sufficient  efficacy  in  studies  where  this  substance  was  used  to  assess  its  anti-fibrotic  activity. Furthermore, based on the level and duration of serelaxin exposure proposed for the current indication significant effect on angiogenesis and or fibrosis is not to be expected.

## Secondary pharmacodynamic studies

## Angiogenesis

Serelaxin  has  been  shown  to  stimulate  VEGF  secretion  from  certain  cell  types  in  vitro  including endometrial stromal and epithelial cells (Unemori et al 1999, Palejwala et al 2002) and macrophages (Unemori et al 2000). Serelaxin induces new blood vessel formation in specific sites containing target cells for relaxin, such as the endometrium (Goldsmith and Weiss 2009). Given the effect of relaxin on VEGF secretion, it is not surprising that serelaxin might have an effect on angiogenesis.

## Anti-inflammatory effects

Relaxin  has  been  shown  to  interact  with  cells  of  the  immune  system.  Relaxin  stimulates  leukocyte adhesion  and  migration  (Figueiredo  et  al  2006)  and  counteracts  activation  of  human  basophils activated  by  phorbol ester  (Bani  et  al  2002).  It  also  inhibits  lipopolysaccharide  induced  adhesion  of neutrophils to coronary endothelial cells (Nistri et al 2003) and promotes migration and activation of monocytes (Figueiredo et al 2006). Although not well understood, an interaction between relaxin and the glucocorticoid receptor has also been reported (Dschietzig et al 2004, Dschietzig et al 2009a).

## Antifibrotic efects

Relaxin  has  been  shown  to  have  anti-fibrotic  activity  in  lung,  liver,  kidney,  skin,  heart  when administered in vivo (Bennett 2009). The clinical relevance of these effects noted in rodent is not clear.

<div style=\"page-break-after: always\"></div>

## Safety pharmacology programme

The cardiovascular safety of serelaxin has been characterized in four dedicated safety pharmacology studies:  three in  vitro in  ion  channel  studies  and  one in  vivo in  one  dedicated  telemetry  study  in cynomolgus monkeys as well as in acute and sub-chronic multiple dose toxicity studies presented in the toxicology section.

No  significant  effects  on  ion  current  were  found.  In  rats  effects  on  blood  pressure  have  been documented,  but  no  clear  effects  were  observed  in  the  monkey.  No  clinically  significant  effects  on heart rate were observed, while hypotension was noted as an identified risk of serelaxin.

In some monkeys exposed to serelaxin a small and inconsistent effect on body temperature was noted. No such effects were seen in the clinical studies.

Assessment of respiratory- and CNS-related safety pharmacology end-points were not specifically addressed in the nonclinical safety program with serelaxin. This is agreed, considering the nature of the product and the results of the toxicity studies.

## Pharmacodynamic drug interactions

The use of serelaxin in combination with other agents has not been evaluated in preclinical models but serelaxin  was  used  in  combination  with  standard  of  care  (nitrates,  diuretics,  etc)  in  Phase  2  and  3 clinical trials.

## 2.3.3. Pharmacokinetics

The intended clinical route is intravenous administration; therefore this assessment of the PK studies focusses  on  the  pharmacokinetics  of  serelaxin  following  IV  administration.  Also  studies  using  SC  as route of administration are evaluated. Other routes of administration (vaginal, gingival) are not found relevant for the evaluation of the current application.

## Assay methods

Data were obtained with various ELISA methods. In contrast to what is suggested by the Applicant, not all  methods used to detect serelaxin in animal species have been validated. In fact the mostly used method (Q8278/SRLX:4) has only been qualified for human use and for a slightly alternative form of serelaxin  (+  4  amino  acids).  While  formally  not  validated  the  Applicant  has  provided  sufficient assurance over the performance of the assays used in the non-clinical studies.

## Absorption

Following single IV administration, serelaxin was rapidly cleared from the body. The majority of the administered dose (&gt;90%) was cleared within the first 2 to 3 hours post-dose. In general, exposure increased dose-dependently in a dose proportional manner. It appears that there is little or no change in  PK  following  repeated  administration.  However  both  in  rats  and  monkeys  accumulation  was  seen following prolonged administration. This increase in exposure coincides with the detection of anti-drugantibodies (ADA). We therefore agree with the Applicant that the increased exposure was most likely due  to  the  slower  clearance  of  the  antibody-bound  RLX030  immunocomplexes  compared  to  the clearance  of  the  free  unbound  serelaxin.  In  rats  exposure  in  males  seems  lower  than  in  females, however,  no  gender  differences  were  apparent  in  cynomolgus  monkey  following  daily  repeated administration.  Also  in  humans  no  effect  of  gender  on  exposure  was  apparent.  The  absorption  of serelaxin following SC administration was rapid and SC bioavailability was high (67-96%) across the species tested (mice, rats and rabbits). Similar to the PK following IV administration, there was a dose-

<div style=\"page-break-after: always\"></div>

proportional increase in exposure following SC administration and there was no apparent impact on kinetics  after  repeated  administration  of  relaxin  (excluding  animals  which  showed  an  anti-serelaxin antibody response). The effect of (late) pregnancy on pharmacokinetics has intensively been studied. In general, no significant differences were seen in exposure/plasma levels between pregnant and nonpregnant animals. The data also indicate that while foetuses are exposed during pregnancy exposure to serelaxin is likely to be limited (when administered late during pregnancy).

## Distribution

Following single i.v. 35S hRlx-2 bolus at GD 19, quantifiable levels of radioactivity were found in all tissues,  except  pituitary.  Levels  decreased  slowly  in  all  tissues  over  time,  but  remained  above quantifiable limits in nearly all tissues at 120 hours. The highest levels were seen in the kidneys, liver, serum, total  body  muscle,  and  placenta.  Lower  levels  were  found  in  the  uterus  and  total  body  fat, mammary gland, lung, brain, fetus, spleen, heart and ovary.

In the second study employing 35S rhRlx (89-029-0350-569) quantifiable levels of radioactivity were found in liver, muscle, kidneys, and skin, however after completion of the tissue radioanalyses several weeks later and determination of the material balance for the individual animals, it was shown that the recovery of the 35S for group 1 and 4 was close to 200%.

## Metabolism

No studies on metabolism and elimination have been performed which is acceptable for this type of product.

## Pharmacokinetic drug interactions

In light of the type of product it is expected that interaction with CYP 450 is very low, and the lack of non-clinical DDI studies are justified.

Pharmacokinetic bridging studies to support manufacturing changes:

-  hRlx  form  versus  hRrlx-2  rats:  the  AUC  for  hRlx  form  (17.2+2.6  µg.min/mL)  was  statistically significant  higher  (42%)  than  AUC  of  hRrlx-2  (10.1+  1.5),  Cl  of  hRlx  (5.9  +  0.9  ml/min/kg)  was statistically significant lower (41%) than Cl of Rhlx-2 (10.0 + 1.3 ml/min/kg), and Vss of hRlx (294+37 ml/kg) was statistically significant lower (23%) than Vss of hRlx-2 (380+53 ml/kg).

- rhRlx* form versus hRrlx non pregnant resus monkeys: the AUC, terminal half life, CL, Vc and Vss for rhRlx* were respectively 1.3 lower, 1.9 fold longer, 1.3 fold faster, 1.2 and 2.2 fold larger than for hRlx.

-  hRlx-2  form  versus  hRrlx  pregnant  and  non  pregnant  resus  monkeys.  There  were  significant differences in Cl between hRlx (3-1-3.4 mL/min/kg) and hRlx-2 (6.2-6.5 mL min/kg). The 4 amino acid longer relaxin Cl was almost 2 fold higher the Cl of hRlx, in both pregnant and non pregnant animals.

Overall the non-clinical PK parameter comparison between serelaxin synthetic forms (hRlx and hRlx2h,  4  aa  longer)  after  i.v.  administration  in  rats  and  rhesus  monkeys  (pregnant  and  non  pregnant) showed a statistically significant difference in AUC, Cl and Vss parameters in rats (around 40%), and in Cl in both pregnant and non pregnant animals (around 50%).

Furthermore the PK parameter comparison between serelaxin synthetic and recombinant forms (hRlx and rhRlx* double chain process) after i.v. administration in non pregnant rhesus monkeys showed statistically  significant  difference  in  AUC,  terminal  half  life,  CL,  Vc  and  Vss  (around  26-50%).  The ranking order for different serelaxin forms Cl value is hRlx-2 &gt; rhRlx*&gt; hRlx.

<div style=\"page-break-after: always\"></div>

Different batches of rhRlx (Recombinant Human Relaxin single chainCBL Lot #1168-1 versus CBL Lot #65802) showed a comparable PK profile.

No PK bridging study is available comparing the two recombinant forms (rhRlx and rhRlx*) after i.v. administration,  supportive  single  s.c.  bolus  mouse  study  indicated  broadly  comparable  PK  between rhRlx*  and  rhRlx,  but  these  date  are  limited  to  Cmax  and  half  life  measurements  and  they  are considered scarcely informative.

Based  on  the  PK  bridging  studies  data  supporting  the  manufacturing  changes,  the  non  clinical  PK parameter of the different serelaxin synthetic forms used in non clinical programme (hRlx-2, rhRlx*, hRlx ) cannot be considered totally equivalent and comparable. However, this issue can be considered overcome in the light of data derived from the 4-week GLP cynomolgus monkey general toxicology study  (S630919)  which  used  the  newer  material  (rhRlx-1b)  administered  i.v,  showing  a  toxicology profile consistent with the previous toxicological studies. Therefore, only this study is considered to be the pivotal study supporting the proposed single use of a 48-hr i.v. infusion of serelaxin in the present clinic application. Moreover, clinical comparability between rhRlx, rhRlx(1a) and rhRlx(1b) and in vitro analytical comparability between all single-chain processes including the proposed commercial process rhRlx(1c) are available.

## 2.3.4. Toxicology

## Single dose toxicity

No  treatment  related  findings  were  noted  in  single  dose  toxicity  studies  in  mice,  rats  and (cynomolgus and rhesus) monkeys with observation periods up to 14 days.

## Repeat dose toxicity

In  the  rat,  following  repeated  administration,  consistent  dose-dependent  increases  in  body  weight, absolute and/or relative uterine weights, prominence of mammary nipples, and endometrial changes were noted in females. In males and females, slight decreases in serum sodium and chloride relative to vehicle  controls  were  observed.  These  effects  are  consistent  with  the  known  biological/physiological effect  of  relaxin.  In  monkey,  no  signs  of  potential  safety  issues  were  noted,  except  for  occasional diarrhoea.  However  this  was  not  observed  in  the  clinical  studies,  so  the  clinical  relevance  of  this observation is limited.

Most of the toxicity studies were old using serelaxin batches from previous manufacturing processes. However, one recent toxicity study (4-week IV monkey study, S630919) was performed with a clinicalgrade batch. This study is therefore considered pivotal. In this study a dose reduction of the highest dose has been introduced because of on injection site observations possibly due to the daily dosing of relative  large  volumes  with  low  pH  (pH  5).  In  this  study  serelaxin  induced  an  inflammation  and indurated  injection  site  (highly  frequent  at  high  dose,  present  also  in  control),  accompanied  by reversible increase in neutrophil count (2 animals high dose). Diarrhea was present in all dosed with sporadically  presence  of  blood  in  feces  (and  urine).  Diarrhoea  was  significantly  more  pronounced  in animals receiving serelaxin compared to controls, thus allowing to hypothesise at least a potentiating serelaxin effect on diarrhoea. In clinical studies with serelaxin, fewer patients treated with serelaxin vs. placebo experienced diarrhoea. (1.9% vs. 3.5%) and constipation (2.3% vs. 2.8%). This indicates that the clinical relevance of the observed diarrhoea in animals is limited.

<div style=\"page-break-after: always\"></div>

Macroscopic and microscopic findings were primarily related to vessel injury partially reversible. This effect  is  probably  an  exacerbation  of  the  injection  site  trauma.  The  NOAEL  in  this  species  was considered to be 3 mg/kg/day.

## Genotoxicity

No  studies  on  genotoxicity  have  been  performed  by  the  Applicant.  This  is  agreed,  considering  the nature of the product.

## Carcinogenicity

No studies on carcinogenicity have been performed by the Applicant. This is agreed, considering the nature of the product.

## Reproduction Toxicity

A relatively large set of reproductive toxicity studies has been performed. Exposures in these studies focused on early pregnancy (including implantation and the early period of organogenesis) and late pregnancy. No adverse effects of treatment were identified on either dams or their offspring. There was  no  apparent  effect  on  pregnancy  maintenance  when  serelaxin  was  administered  early  in pregnancy  and  no  induction  of  early  labour  when  serelaxin  or  hRlx-2  was  administered  late  in pregnancy in rhesus monkeys.

## 2.3.5. Ecotoxicity/environmental risk assessment

According  to  Directive  2001/83/EC  and Guideline  on  Environmental  Risk  Assessment  of  medicinal products for human use (CHMP/SWP/4447/00) , medicinal products consisting of substances occurring naturally  in  the  environment,  such  as  electrolytes,  vitamins,  proteins  etc.  do  not  need  to  be accompanied by an environmental risk assessment, if it can be shown that there is no likely risk to the environment. Hence no Environmental Risk Assessment (ERA) was submitted with this application. This was considered acceptable by the CHMP.

## 2.3.6. Discussion on non-clinical aspects

Reasanz was evaluated in single and repeat dose studies of up to 6 months in mice, rats, rabbits, dogs and monkeys using several routes of administration, including intravenous, subcutaneous bolus, topical (intravaginal and intracervical) and intra-gingival administration.

Following intravenous administration, the no observed adverse effects level dose in rats was 300 times the human recommended dose and in monkeys was 500 times the human recommended dose.

The data provided in the pharmacodynamics section is mainly based on data available in the public domain with almost no studies performed by the Applicant. The CHMP agreed that sufficient relevant data is available, and repetition of studies in animals is not needed (nor ethical). The vasodilatatory effect of relaxin is well known. The precise haemodynamic responses to serelaxin treatment appear to depend on the study design but also on used strains and species, which hamper the interpretation of the  non-clinical  studies.  In  rats,  the  systemic  vasodilation  leads  to  decreased  systemic  vascular resistance (SVR) and subsequent increase in (heart) stroke volume (SV) which leads to an increase in cardiac output (CO). The effects on haemodynamic parameters in monkeys were less clear, however, no major effects on blood pressure (BP) and heart rate (HR) were seen. The clinical significance of the

<div style=\"page-break-after: always\"></div>

serelaxin effects on HR and mean arterial pressure (MAP) observed in rats is unclear since they are not observed in clinical trials.  They cannot be defined as rodent specific effects since, although slightly, they are also observed in monkeys.

It  was  noted  by  the  CHMP  that  the  effect  of  serelaxin  treatment  on  heart  function  has  not  been investigated in an animal model of AHF (animal models with myocardial infarction are available), which may have been the most relevant disease model for the current indication. Despite the fact that the interpretation of the non-clinical studies is hampered by differences in haemodynamic effects between species,  and  given  the  current  clinical  experience,  no  further  non-clinical  pharmacology  studies  are required in the opinion of the CHMP.

## 2.3.7. Conclusion on the non-clinical aspects

Preclinical studies did not reveal any findings of significance for human use at the recommended dose, based on conventional studies of safety pharmacology and repeated dose toxicity. In a 6-month study in rats, long bone  fractures were  observed  following daily subcutaneous  injections at  doses representing  3  -  30-fold  margins  in  mg/kg  to  the  human  dose.  There  was  no  evidence  of  time dependence or histological correlates. Similar findings  have  not  been  observed  in 4-week  studies  in rats or in monkeys. Standard reproductive toxicity studies on fertility, embryofoetal development and peri/postnatal  effects  have  not  been  performed.  However,  studies  conducted  in  monkeys  covering implantation,  early  organogenesis  and  late  pregnancy  did  not  show  adverse  effects  of  treatment  in mothers  or  offspring.  No  formal  genotoxicity  or  carcinogenicity  studies  have  been  performed  with serelaxin. However the non-clinical and clinical data available to date have not indicated any risk for carcinogenicity. The CHMP therefore concluded that the non-clinical development and presented data of serelaxin was satisfactory.

## 2.4. Clinical aspects

## 2.4.1. Introduction

The  serelaxin  clinical  development  was  originally  conducted  by  Corthera,  Inc.,  and  clinical  study reports have been obtained by the Applicant as part of the acquisition agreement in 2010.

The  serelaxin  clinical  program  in  the  AHF  patient  population  consists  of  one  phase  II/III  study (RLX.CHF.003 including a phase II Pre-RELAX-AHF and a phase III RELAX-AHF), and one pilot dose escalating  (RLX.CHF.001)  trial.  One  additional  phase  II  study  (RLX.  CHF.002)  in  decompensated congestive heart failure patients has been prematurely terminated by the Sponsor due to a changed drug development strategy.

In  particular,  results  from  the  phase  II  (Pre-RELAX-AHF)  and  the  phase  III  (RELAX-AHF)  studies conducted in subjects with AHF have been submitted to support the MAA of serelaxin in the sought indication.

## GCP

The clinical trials were performed in accordance with GCP as claimed by the applicant. The applicant has provided a statement to the effect that clinical trials conducted outside the Union were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

Three of the main and all of the supportive studies are referred to as 'legacy' studies since they were conducted by various companies over a considerable time period prior to the acquisition of serelaxin by Novartis. To the best of applicant's knowledge, all clinical studies were conducted in accordance with regulatory requirements, with the principles of the Declaration of Helsinki in effect at the time and following Good Clinical Practice.

A  routine  GCP  inspection  was  considered  necessary  for  the  RELAX-AHF  trial  before  a  marketing authorisation could be granted. The outcome of this inspection and the satisfactory responses to its findings  are  considered  an  integral  part  of  this  procedure.  It  was  considered  especially  important because:

- -the dossier is based on a single pivotal trial,
- -a validation issue was suspected in a co-primary endpoint,
- -a claim was based on an exploratory endpoint,

-high percentages of patients were affected by 'significant protocol violations' including 'GCP breaches' that were not further discussed.

The Integrated Inspection Report was circulated on 10 September 2013. The inspection revealed no critical,  but  8  major  findings.  According  to  the  Inspection  Report,  none  of  the  findings  identified were assessed as having any effect in this study on the safety or integrity of the patients or any effect on the quality of data obtained. On the basis of the inspection results it was considered that the data obtained in the clinical trial can be used for evaluation and assessment of the marketing authorisation application. The study Sponsor Corthera Inc has been acquired by the Applicant when approximately 700 patients had been enrolled and about 450 had completed the study. Moreover, site  monitoring  has  been  performed  by  3  different  independent  Contract  Research  Organisations (Covance, PPD and Tango). In general, as result of the set of inspections performed, an adequate oversight  of  the  clinical  trial  was  demonstrated  for  both  periods,  before  and  after  Novartis acquisition of Corthera. Based on the observations and findings identified during the inspections and the  character  of  these  findings  the  inspection  team  is  of  the  opinion,  on  the  basis  of  the  sample inspected, that the clinical trial was performed in compliance with GCP requirements and that the data obtained, documented and reported are reliable.

- Tabular overview of clinical studies

## Clinical pharmacology studies

A number of clinical pharmacology studies have been conducted in healthy subjects and in different patient populations, using different routes of administration. In the overview, the applicant addresses only clinical pharmacology data from studies which are relevant for the use of serelaxin as continuous IV infusion in patients with AHF (Table 2.4.1.1).

## Table 2.4.1.1  Overview of studies providing clinical pharmacology data.

<div style=\"page-break-after: always\"></div>

| Sponsor                                                                | Study(Numberof subjects/patients)                                      | Manufacturing process                                                  | Population                                                                          | Posology                                                               | PK andPD measures relevantto clinical                                  |
|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| pharmacology StudiesinhealthyvolunteersprovidingcriticalPKandlorPDdata | pharmacology StudiesinhealthyvolunteersprovidingcriticalPKandlorPDdata | pharmacology StudiesinhealthyvolunteersprovidingcriticalPKandlorPDdata | pharmacology StudiesinhealthyvolunteersprovidingcriticalPKandlorPDdata              | pharmacology StudiesinhealthyvolunteersprovidingcriticalPKandlorPDdata | pharmacology StudiesinhealthyvolunteersprovidingcriticalPKandlorPDdata |
| Genentech                                                              | [R0006g] (n=25)                                                        | rhRIx*                                                                 | Healthy subjects                                                                    | SingleIV bolus/ topical                                                | PK, immunogenicity and safety                                          |
| Corthera/ Novartis                                                     | [CRLX030A2103] (n=40)                                                  | rhRIx (1a)                                                             | Healthy Japanese and Caucasian subjects                                             | 48-hr IV infusion                                                      | PK, PD, immunogenicity and safety                                      |
| Novartis                                                               | [CRLX030A2101] (n=49)                                                  | rhRIx (1b)                                                             | Patientswith mild,moderate orsevere hepatic impairment matchedwith healthy controls | 24-hr IV infusion                                                      | PK, immunogenicity andsafety                                           |
| StudiesinpatientswithheartfailureprovidingPKand/orPDdata               | StudiesinpatientswithheartfailureprovidingPKand/orPDdata               | StudiesinpatientswithheartfailureprovidingPKand/orPDdata               | StudiesinpatientswithheartfailureprovidingPKand/orPDdata                            | StudiesinpatientswithheartfailureprovidingPKand/orPDdata               | StudiesinpatientswithheartfailureprovidingPKand/orPDdata               |
| Novartis                                                               | [CRLX030A2201] (n=16 for interim PK analysis)                          | rhRIx(1b)                                                              | AHF                                                                                 | 20-hr IV infusion                                                      | PK                                                                     |
| BAS Medical/ Cortherat                                                 | [RLX CHF.001] (n=16)                                                   | rhRIx (1a)                                                             | CHF                                                                                 | 24-hr IV infusion                                                      | PK, PD, immunogenicity and safety                                      |
| Corthera                                                               | [Pre-RELAX-AHF] (n=229)                                                | rhRIx (1a)                                                             | AHF                                                                                 | 48-hr IV infusion                                                      | Cssand PD                                                              |
| Cortheral Novartis                                                     | [RELAX-AHF] (n=1,161)                                                  | rhRIx(1a)                                                              | AHF                                                                                 | 48-hr IV infusion                                                      | Css, immunogenicity andPD                                              |
| StudiesprovidingsupportivePKand/orPDdata                               | StudiesprovidingsupportivePKand/orPDdata                               | StudiesprovidingsupportivePKand/orPDdata                               | StudiesprovidingsupportivePKand/orPDdata                                            | StudiesprovidingsupportivePKand/orPDdata                               | StudiesprovidingsupportivePKand/orPDdata                               |
| BAS Medical/ Cortherat                                                 | [RLX.CR.001]                                                           | rhRIx(1a)                                                              | Healthy pregnant womenat full term                                                  | 24-hr IV infusion                                                      | PK and immunogenicity                                                  |
| Connetics                                                              | [R9401]                                                                | rhRIx*                                                                 | Scleroderma                                                                         | 28-day SC infusion                                                     | PK, immunogenicity and safety                                          |
|                                                                        | [RLXN.C.002 + Extension]                                               | rhRIx (initial process)                                                | Scleroderma                                                                         | 24-48 weekSC infusion                                                  | PK, immunogenicity andsafety                                           |
| Connetics                                                              | [RLXN.C.003]                                                           | rhRIx (initial process)                                                | Scleroderma                                                                         | 24-week SC infusion                                                    | PK, PD and immunogenicity PK and immunogenicity                        |
|                                                                        | [RLXN.C.004]                                                           | rhRlx (initial process)                                                | Scleroderma                                                                         | 24-week SCinfusion                                                     | PK,PD and                                                              |
|                                                                        | [RLXN.C.005] [RLXN.C.006]                                              | rhRIx (initial process) rhRlx(initial process and 1a)                  | Scleroderma Scleroderma                                                             | 24-week SC infusion 24-week SC infusion                                | immunogenicity PK and immunogenicity                                   |
|                                                                        | [RLIF.C.001] [RLFM.C.001]                                              | rhRlx(initial process and 1a) rhRIx                                    | Healthyegg donors Fibromyalgia                                                      | (not completed) 14-day SC infusion 8-week SC infusion                  | PK and immunogenicity PK and immunogenicity                            |
| Genentech                                                              | [R0187g]                                                               | (initial process) rhRIx*                                               | Healthy subjects                                                                    | Topical                                                                | Immunogenicity                                                         |
|                                                                        | [R0261g]                                                               | rhRIx*                                                                 | Healthy subjects                                                                    | Topical                                                                | Immunogenicity                                                         |
|                                                                        | [R0204g]                                                               | rhRIx*                                                                 | Healthy pregnant womenatfull term                                                   | Topical                                                                | Immunogenicity                                                         |
|                                                                        | [R0279g]                                                               | rhRlx*                                                                 | Healthy pregnant womenat full term                                                  | Topical                                                                | Immunogenicity                                                         |
|                                                                        | [R0282g]                                                               | rhRIx*                                                                 | Healthy pregnant womenat full term                                                  | Topical                                                                | Immunogenicity                                                         |
| BAS Medical/ Cortherat                                                 | [RLX.ORTH.001]                                                         | rhRlx(1a)                                                              | Healthy orthodontic patients                                                        | 8weekly intra- gingival injections                                     | PK and immunogenicity                                                  |

Css,serum concentration at steady state;IV,intravenous;n.a.not applicable;PD

pharmacodynamic(s);PK,pharmacokinetic(s);SC, subcutaneous

<div style=\"page-break-after: always\"></div>

Table 2.4.1.2   Completed clinical studies pertaining or relevant to the HF program.

| Study Code (Study name, Sponsor#)              | Study Design/Objectives                                                                                                                                                                                                                             | Study Population                                                                                                        | Dose Regimen (# subjects)                                                                                                                          |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Completed studies                              | Completed studies                                                                                                                                                                                                                                   | Completed studies                                                                                                       | Completed studies                                                                                                                                  |
| RLX.CHF.001 (Pilot Study in CHF) (Corthera)    | Phase 1 open label single centre safety and haemodynamic study (PCWP, CO/CI and SVR, serum creatinine, BUN and uric acid).                                                                                                                          | 16 patients with stable congestive heart failure (CHF)                                                                  | Serelaxin IV infusion, 24-hour, (8-hour intervals) escalating doses 10, 30 100 µg/kg/day (n = 4) 250, 480, 960 µg/kg/day (n=6) 960 µg/kg/day (n=6) |
| RLX.CHF.003.PRE (Pre-RELAX-AHF) (Corthera)     | Phase 2 multicentre, randomised, double-blind, placebo- controlled safety and efficacy study: Dose-finding study evaluated from a number of clinical outcomes, including improvement in dyspnoea, in- hospital outcomes, CV & all- cause mortality) | 234 randomised patients hospitalised with AHF, normal to elevated blood pressure, and mild to moderate renal impairment | IV infusion, 48-hour Placebo (n=62) Serelaxin*: 10 µg/kg/day (n=40) 30 µg/kg/day (n=43) 100 µg/kg/day (n=39) 250 µg/kg/day (n=50)                  |
| RLX.CHF.003 (RELAX-AHF ) (Corthera / Novartis) | Phase 3 multicentre, randomised, double-blind, placebo-controlled safety and efficacy study: Pivotal, Phase 3 study confirming the safety and efficacy observed in Pre-RELAX- AHF                                                                   | 1161 patients hospitalised with AHF, normal to elevated blood pressure, and mild to moderate renal impairment           | IV infusion, 48-hour Placebo (n=580) Serelaxin*: 30 µg/kg/day nominal dose rate (n=581)                                                            |
| RLX.CHF.002 (Corthera)                         | Phase 2 Placebo-controlled, double-blind, multicentre haemodynamic and safety study (Study stopped prior to completion due to a change in corporate strategy)                                                                                       | 11 patients with AHF enrolled up to 80 planned; study terminated to initiate RLX.CHF.003                                | IV infusion, 48-hour Placebo (n=3) Serelaxin: 100 µg/kg/day (n=4) 500 µg/kg/day (n=4)                                                              |
| CRLX030A2103 (Corthera / Novartis)             | A Phase 1 exploratory, double- blind, placebo-controlled, parallel group study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous infusions of                                                                      | 32 Japanese male and female healthy subjects and 8 Caucasian male and female healthy subjects.                          | IV infusion, 48-hour Placebo (n=8) Serelaxin: 10 µg/kg/day (n=8) 30 µg/kg/day (n=16)                                                               |

<div style=\"page-break-after: always\"></div>

| Study Code (Study name, Sponsor#)   | Study Design/Objectives                                                                                                                                                                                                                                  | Study Population                                                                                                                 | Dose Regimen (# subjects)                                          |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|
|                                     | Serelaxin at three dose levels in Japanese healthy subjects with an open-label comparison to Caucasian subjects at one dose level                                                                                                                        |                                                                                                                                  | 100 µg/kg/day (n=8)                                                |
| CRLX030A2101 (Novartis)             | A Phase 1 single-dose, open- label parallel study to assess the pharmacokinetics of Serelaxin in subjects with mild, moderate and severe hepatic impairment compared to healthy control subjects                                                         | 25 subjects with mild (n=9), moderate (n=8) and severe hepatic (n=8) impairment 24 matched subjects with normal hepatic function | IV infusion, 24-hour Serelaxin: 30 µg/kg/day (n=49)                |
| CRLX030A2201 (Novartis)             | A Phase 2 multicentre, double blind, randomised, parallel group, placebo-controlled study to evaluate the haemodynamic responses to intravenous Serelaxin infusion in subjects with acute heart failure (AHF)                                            | 70 subjects hospitalised with AHF                                                                                                | IV infusion, 20-hour Placebo (n=35) Serelaxin: 30 µg/kg/day (n=35) |
| CRLX030A2202 (Novartis)             | A Phase 2 multicentre, randomised, double-blind, parallel group, placebo-controlled study to evaluate the renal haemodynamic effects of Serelaxin at a dose of 30 μg/kg/day or placebo infused for 24 hours in subjects with chronic heart failure (CHF) | 88 subjects with CHF, worsening symptoms and mild to moderate renal impairment                                                   | IV infusion, 24-hour Placebo (n=44) Serelaxin: 30 µg/kg/day (n=44) |

PCWP: Pulmonary capillary wedge pressure, SVR: Systemic vascular resistance, CO: Cardiac output,

## 2.4.2. Pharmacokinetics

The  serelaxin  pharmacokinetics  (PK)  has  been  characterized  through  seven  clinical  pharmacology studies across the dose range from 10 to 960 μg/kg/day i.v.. In addition, further 15 clinical studies provided supportive data for PK, PD or immunogenicity in other patient populations and/or following non IV routes of administration.

<div style=\"page-break-after: always\"></div>

Clinical  studies  in  the  target  HF  population  provided  also  PK  data,  which  allowed  a  sufficient characterisation  of  the  PK  in  the  target  population.  CL  was  similar  in  both  healthy  subjects  and  HF patients. Vss was larger in the target population than in healthy subjects, which has been attributed to fluid retention in the HF patients. It is not known whether or not this difference is linked to a difference in  the  exposure  because  comparison  of  exposures  between  healthy  subjects  and  HF  patients  was hindered by differences in doses and dosing schedules.

## Population pharmacokinetic analysis

The  pharmacokinetics  of  serelaxin  could  be  adequately  described  in  the  population  pharmacokinetic analysis by a two or a three compartment disposition model depending on the density of PK sampling used in the different studies.

## Absorption

Following intravenous infusion, steady-state serum concentrations were reached 12 to 24 hours after the start of infusion. Serelaxin has shown comparable steady-state exposure and systemic clearance following intravenous administration to healthy volunteers or heart failure patients.

## Distribution, Elimination, Metabolism

Following IV bolus of 10 μg/kg administration, serelaxin was eliminated rapidly; serum clearance was 168  ±  47  mL/hr/kg,  and  the  mean  residence  time  was  1.6  ±  0.3  hr.  The  volume  of  the  central compartment and the volume of distribution at steady state were estimated to be 78 ± 39 and 278 ± 95 mL/kg, respectively. The elimination was triphasic with half-lives for the initial, intermediate, and terminal phases of 0.090 ± 0.036, 0.72 ± 0.11, and 4.6 ± 1.2 hr, respectively, with 85% of the area under the serum concentration-versus-time curve due to the first 2 phases. In some studies steady state was considered to be achieved at 8 hours after start of the infusion. However, in other studies with longer infusion periods steady state was reached between 12 and 24 hours (see Figure 2 below). With  a  molecular  weight  of  5.96  kDa  and  a  structure  identical  to  the  endogenous  human  peptide, serelaxin  is  expected  to  be  first  filtered  via  glomerular  filtration  and  then  metabolized  via  either intraluminal  metabolism  or  intracellular  lysosomal  metabolism  in  the  tubular  region  of  the  kidneys. Hence, it is highly unlikely to be detected intact in the urine. No absorption, metabolism or excretion studies  have  been  conducted,  considering  the  biological  nature  of  the  molecule  and  route  of administration.  In  the  figure  below  a  typical  concentration-time  curve  of  serelaxin  after  intravenous infusion over a period of 48 hours is given.

Figure 2: Typical concentration-time curve of serelaxin after intravenous infusion

<!-- image -->

<div style=\"page-break-after: always\"></div>

The main elimination pathway of serelaxin is believed to be catabolism by peptidases/proteases across the body including the liver and kidneys. Catabolized fragments of serelaxin are not expected to impact the safety of the patients, as peptide catabolism occurs naturally. Serelaxin is identical in sequence and structure to the endogenously occurring peptide. In women, relaxin is expressed and circulates at low levels in the luteal phase of the menstrual cycle (~50 pg/mL) and is elevated in pregnancy (~1 ng/mL) over a wide range of concentrations (means of 1.2-5.7 ng/mL).

It  is  not  expected  that  any  degradation  products  of  serelaxin  are  different  from  those  of  the endogenous relaxin, due to the comparability of serelaxin with endogenous relaxin.

As serelaxin being a protein will be catabolised to small amino acids that are not active, measurement of these amino acids will not be relevant. Therefore, the lack of data on the pharmacokinetics of these degradation products was considered acceptable by the CHMP.

The pharmacokinetics of serelaxin after subcutaneous and intravenous administration is more or less proportional with the dose administered. Only slight deviation from formal linearity was observed.

## Dose proportionality and time dependencies

There  was  an  approximately  dose-proportional  increase  in  serelaxin  exposure  (AUC  and  Css). Estimates for clearance and Vss were constant across the dose range of 10-960 µ g/kg/day.

## Special populations

The  pharmacokinetics  of  serelaxin  in  heart  failure  patients  the  mean  clearance  was  115  mL/hr/kg. Apparent volume of distribution at steady state largely exceeded blood volume (geometric mean = 591 mL/kg), indicating extra-vascular penetration.

Relatively large inter-individual variability was observed for both pharmacokinetic profiles and variables estimates,  especially  in  Vss  (CV%  were  74%  and  116%  for  arithmetic  and  geometric  means, respectively), at least partially due to the atypical values in 6 out of the 16 (erratic values in the two first samples) subjects who received serelaxin.

In renal impaired patients the clearance of serelaxin is not influenced in a clinical significant way. This was  confirmed  in  the  population  pharmacokinetic  analysis.  Also  in  hepatic  impaired  patients  the pharmacokinetics of serelaxin were not affected.

The  population  pharmacokinetic  analysis  showed  that  gender,  race,  and  age  also  did  not  affect  the pharmacokinetics of serelaxin in a clinical significant way.

As  serelaxin  is  in  all  studies  dosed  on  body  weight,  the  influence  of  weight  cannot  be  estimated adequately and is of no clinical relevance.

## Pharmacokinetic interaction studies

As with other endogenous proteins and peptides, there is a lack of a potential mechanism for direct interaction of serelaxin with CYP P450 enzymes (inhibition or induction). Elimination of serelaxin by the liver is expected to be mostly based on receptor-mediated endocytosis and/or nonselective pinocytosis, and then catabolism by proteolysis. CYP P450 enzymes are, therefore, not expected to contribute to the degradation and elimination of serelaxin. Interactions are therefore unlikely to occur and the lack of interaction studies is considered acceptable.

<div style=\"page-break-after: always\"></div>

## 2.4.3. Pharmacodynamics

## Mechanism of action

Serelaxin  is  a  recombinant  form  of  the  naturally  occurring  human  relaxin-2  peptide  hormone. Preclinical studies show that relaxin-2 binds to its cognate G-protein coupled receptor, RXFP1, in the renal and systemic vasculature and in the epithelium of the kidney. Upon receptor binding, relaxin-2 stimulates rapid signalling pathways, leading to activation of nitric oxide synthase as well as sustained signalling pathways with the stimulation of the endothelin type B receptor and expression of angiogenic growth factors and matrix gelatinases. These pathways mediate systemic and renal vascular relaxation along  with  increased  global  arterial  compliance  and  cardiac  output.  The  vasoactive  properties  of relaxin-2  have  been  substantiated  by  preclinical or clinical  investigations  of  the  maternal  circulatory adaptation  to  pregnancy.  The  temporal  expression  of  relaxin-2  reaching  plasma  concentrations  of approximately 6 ng/ml in the first trimester is believed to reduce systemic vascular resistance and to increase cardiac output, assuring adequate oxygen transport to the foetoplacental unit.

## Primary and Secondary pharmacology

Relaxin  is  believed  to  regulate  maternal  adaptations  to  pregnancy  with  several  effects  potentially relevant to the treatment of AHF.

In animals, relaxin has a broad spectrum of pharmacologic effects. There is a broad variation among species, making extrapolation of data between species or to humans difficult. In humans, important pharmacologic differences may exist between healthy volunteers and HF patients. These differences could (e.g.) be related to neurohormonal activation or exhausted auto-regulation in HF patients. The PD effects of serelaxin that are measured in clinical pharmacology studies are related to its effects on systemic and renal circulation.

In  a  randomised,  controlled  study  in  patients  hospitalized  with  AHF  (CRLX030A2201),  serelaxin 30 μg/kg/day was administered as a 20-hour IV infusion with the following results:

- Treatment with serelaxin decreased pulmonary capillary wedge pressure (PCWP). The onset of serelaxin's  effect  was  fast  (treatment  difference  at  2  hours:  -  2.4  mmHg)  and  the  largest treatment difference in PCWP change from baseline was -3.93 mmHg at 4 hours. The reduction in PCWP change from baseline was sustained after infusion was stopped in the serelaxin group, though no longer statistically significant compared to placebo.
- Serelaxin decreased mean pulmonary artery pressure (PAP). Mean PAP change from baseline was statistically significant at individual time points as early as 30 minutes and up to 21 hours in  favour  of  serelaxin.  The  peak  mean  PAP  change from baseline over the first 8 hours was (also exactly) -3.93 mmHg.
- No consistent treatment effect was observed in cardiac index (CI).
- Systemic vascular resistance (SVR) and peripheral systolic and diastolic blood pressure (BP) were  reduced  in  serelaxin-treated  patients.  The  effects  of  serelaxin  on  SVR  occurred  within hours from the start of the infusion and were sustained for up to 24 hours after the infusion was stopped.

In an earlier, pilot, open-label study of IV serelaxin spanning a dose range of 10-960 μg/kg/day, no clear  dose-response  could  be  established,  but  dose  rates  of  10,  30  and  100  μg/kg/day  were pharmacologically active. Generally the haemodynamic effects were observed within hours from start of  infusion  and  lasted  4-8  hours  following  cessation  of  the  infusion.  In  AHF  patients  with  normal  to

<div style=\"page-break-after: always\"></div>

elevated BP, the RELAX-AHF (RLX.CHF.003) and Pre-RELAX-AHF (RLX.CHF.003.PRE) studies demonstrated  greater  decreases  in  systolic  blood  pressure  (SBP)  compared  to  placebo.  Suggesting greater  decongestion  in  patients  treated  with  serelaxin,  there  was  reduction  in  signs  of  congestion, e.g., oedema, rales, orthopnoea, jugular venous pressure (JVP) and dyspnoea on exertion. Improved signs and symptoms of congestion may have contributed to the improved liver and cardiac function observed in RELAX-AHF. Serelaxin improved multiple markers of renal function compared to placebo. In the Pre-RELAX-AHF study (RLX.CHF.003.PRE) the pharmacology of serelaxin can be described by a U- or bell-shaped dose-response curve, with the dose response observed in the 30 μg/kg/day group favoured by the Applicant.

In  patients  with  Chronic  Heart  Failure  (CHF)  and  mild  to  moderate  renal  impairment  (Study CRLX030A2202), serelaxin 30 μg/kg/day administered as a 24-hour IV infusion increased renal plasma flow (RPF). The treatment difference in average RPF change from baseline was 13-16% (depending on the  exact  interval)  compared  to  placebo.  There  was  no  treatment  difference  in  GFR  change  from baseline. For filtration fraction, there were treatment differences in change from baseline over of -16% to  -22%  with  smaller  increases  in  the  serelaxin  group.  One  site  was  excluded  from  the  efficacy evaluation in this trial because most (20/21) outliers originated here.

These results in  CHF  were  consistent  with  an  early  trial  in  healthy  subjects:  increased  RPF  by  47% from baseline was observed with IV infusion of serelaxin at a dose rate of 0.5 μg/kg/hr over 5 hours, following  a  bolus  of  0.2  μg/kg  over  5  minutes  (Smith  et  al  2006).  Serelaxin  was  also  modestly natriuretic in this trial.

The human data presented in the Summary of Clinical Pharmacology (SCP) show a clear BP lowering effect. This effect is larger in  hypertensive  than  in normotensive  patients.  The  results  from RLX.CHF.001  in  HF  patients  confirm  that  this  BP  decrease  can  be  attributed  to  vasodilatation (decreased SVR). Neither in the RLX030 Population PK Report (based on data from the studies Study CRLX030A2101,  Study  CRLX030A2103,  Pre-RELAX-AHF  [Study  RLX.CHF.003.PRE]  and  RELAX-AHF [Study RLX.CHF.003]) nor in RLX.CHF.001 a significant correlation between serelaxin concentrations and CV parameters was found. Based on weight changes as an indirect assessment of possible antidiuretic effects of serelaxin secondarily leading to haemodilution, no definite conclusions can be made based on current data on whether such an effect exists.

Although BP changes occur within hours, relief of dyspnoea seems more delayed (see e.g. the Likert endpoint in trial RELAX-AHF). Although vasodilatation and lower BP may be involved in dyspnoea relief, other factors seem to play a role. Such factors are not yet elucidated.

Renal blood flow was assessed in the healthy volunteer trial of Smith 2006 and increased by 47% at a serelaxin dose of 12 µg/kg/day. In this same trial, an increase in GFR was absent. These results were confirmed  in  CRLX030A2202.  Creatinine  clearance  may  be  increased  temporarily  during  use  of serelaxin; it cannot be excluded that this reflects changes in tubular creatinine secretion.

Study  RLX.CHF.001  seems  to  suggest  that  high  doses  (e.g.  960  µg/kg/day)  of  serelaxin  are unfavourable with respect to renal function, which is not further explained or understood. In the PreRELAX trial, the parameter 'Persistent renal Impairment' showed an adverse trend at the highest dose and mean change from baseline in creatinine showed no clear pattern or dose-response. In the RELAX program, temporary decreases (improvements) of serum creatinine values were observed but these are  not  supported  by  urinary  data.  Thus,  no  definitive  conclusions  on  renal  haemodynamics  in  HF patients can be drawn.

<div style=\"page-break-after: always\"></div>

Serelaxin has an immunogenic potential as is clear from 'legacy' trials, e.g. in systemic sclerosis. The risk of immunogenicity of serelaxin after repeated IV administration cannot be assessed currently due to  the  lack  of  data.  The  risk  is  addressed  in  the  Risk  Management  Plan  by  a  proposed  randomised controlled trial, the results of which are to be submitted by Q4 2016.

The PD findings that were the basis of the (failed) development of serelaxin in other indications, e.g. the immune-modulatory effect that was possibly beneficial in systemic sclerosis, are not addressed in this dossier. However, the safety of serelaxin as observed in RELAX-AHF (e.g. the absence of findings in AEs) is reassuring.

A  concentration-effect  relationship  has  not  been  established  for  serelaxin.  It  is  acknowledged  that establishing such a relationship may be difficult, because U- or bell-shaped relations may be involved and the concentration with the maximum response may depend on the population (patient, healthy volunteer) and parameter studied.

Only PK, but almost no PD data for genetic differences were provided. Only small numbers of nonCaucasian subjects were included in the trials. As it is known from the experience in ACE inhibitors, race could influence the response to drugs. The currently available data are inconclusive. 'Use in nonCaucasian patients' is included in the RMP as 'missing information'.

## 2.4.4. Discussion on clinical pharmacology

## Pharmacokinetics

Due to the nature of the product (being a small protein, the intravenous route of administration and the only-once dose frequency) the pharmacokinetics (PK) were investigated only to a limited extent. Clearance and volume of distribution were estimated adequately in healthy volunteers. With respect to the population PK analysis, it would have been more useful if for all study data one type of model was developed by the Applicant. In general the models have well described the experimental data, as for the different covariates the visual checks are acceptable. Due to the fact that for the different studies different models were used, no general conclusion can be drawn from the population PK analysis and therefore  this  analysis  will  only  be  used  for  confirming  the  influence  of  co-variables  on  the  PK  of serelaxin.

In the study comparing the exposure after administration of the different serelaxin products: rhRlx* and rhRlx, the number of subjects was low and the variability high. Therefore any conclusion from this study should be considered as a rough estimate and not as proof of similarity. The Applicant agreed that there is only limited data available with respect to the comparison of the two forms of serelaxin and  stated  that  the  studies  with  rhRlx*  are  only  supportive  studies  for  this  application.  The  CHMP agreed that there should be no large differences.

In some PK studies steady state was considered to be achieved at 8 hours after start of the infusion. However, this assumption is considered not correct as in other studies it is clear that after 8 hours the concentration of serelaxin in serum did still increase. Taking only the 8 hour serum concentration for calculating  the  clearance  of  serelaxin  will  contribute  to  a  high  variability  in  the  estimation  of  this clinically  relevant  PK  parameter  and  may  lead  to  discrepancy  in  the  PK  parameters  between  the studies.

The data in renally impaired patients should be interpreted with care as the study design (single timepoint PK) and the analytical methods used are sources for uncertainties. However, as these results do

<div style=\"page-break-after: always\"></div>

not indicate any evidence for an effect of renal impairment on the PK of serelaxin, no further studies were considered necessary by the CHMP.

## Pharmacodynamics

The clinical development program of serelaxin has evaluated the potential use of serelaxin for cervical ripening, pre-eclampsia, infertility, fibromyalgia, orthodontic therapy, systemic sclerosis, and AHF since the late 1980s. However, the development programs of all non-HF indications were terminated due to an  insufficient  efficacy  profile,  except  for  the  first  study  on  pre-eclampsia  which  was  stopped  for strategical reasons. There is an ongoing Novartis-sponsored clinical trial studying pre-eclampsia.

PD effects of serelaxin in the vasculature are initiated upon binding to its G-protein coupled receptor RXFP1 and trigger the activation of the endothelial endothelin type B receptor (ETB) and nitric oxide (NO) synthase. The NO mediated vasorelaxation results in a reduction of Pulmonary Capillary Wedge Pressure (PCWP), mean Pulmonary Arterial Pressure (PAP) and systemic Blood Pressure (BP). These changes were confirmed in the central haemodynamic study in patients with AHF using a 30 μg/kg/day dose administered as a 20 hours IV infusion [Study CRLX030A2201]. In this trial no change in Cardiac Index (CI) was found. These data support a haemodynamic rationale for the development of serelaxin in AHF.

Serelaxin has been shown to increase Renal Blood Flow (RBF) but not glomerular filtration rate (GFR) in  a  small  open  label  healthy  volunteer  study  (Smith  et  al  2006)  although  only  at  a  low  dose  (12 µg/kg/day)  and  after  a  short  infusion  lasting  for  5  hours.  This  result  was  confirmed  in  study CRLX030A2202, a placebo-controlled study investigating the renal haemodynamic effects of serelaxin at the dose rate of 30 μg/kg/day as iv infusion for 24 hrs compared to placebo in patients with chronic heart failure (CHF).

A clear dose-response relationship for serelaxin is not established with the available PD data. In human data, the exposure-response curve for effects on BP is almost flat. Non-clinical data may indicate a Ushaped or bell -shaped dose-response curve which is potentially the result of negative receptor cooperativity. The results of the human dose-finding trial Pre-RELAX-AHF seem to confirm this U-shaped dose response curve. Therefore, doses higher than 30 μg/kg/day albeit well tolerated may not show greater efficacy.

Anti-drug  antibodies  have  not  been  observed  in  studies  with  IV  administration  of  serelaxin  which supports  the  low  immunogenicity  potential  of  the  proposed  dosing  regimen:  48-hour  IV  infusion. Antibodies have been observed in the studies of longer duration, after at least 2 weeks of dosing with the  SC  route  of  administration  and  in  patients  with  a  potentially  greater  possibility  for  immune response  (scleroderma).  The  identified  antibodies  were  non-neutralizing  yet  led  to  higher  serelaxin levels likely by slowing the clearance. However, no toxicity or altered pharmacology was observed in the  presence  of  the  antibodies.  These  findings  in  scleroderma  patients  following  repeated  SC administration  are  of  limited  relevance  for  the  proposed  dosing  regimen  (48  hours)  and  route  of administration (IV infusion) in patients with AHF. Proposals for future actions to evaluate immunogenicity of serelaxin after repeated IV administration were included in the proposed RMP and include a randomised clinical trial.

In the past, the relation between PD findings and confirmatory trials has been disappointing in the field of Heart Failure. Therefore, the weight of PD evidence in this dossier is relatively small, but these data - specifically effects on PCWP - support potential efficacy as indicated in the EMA Guidance on clinical investigations  of  medicinal  products  for  the  treatment  of  cardiac  failure/Addendum  on  acute  heart

<div style=\"page-break-after: always\"></div>

failure (CPMP/EWP/2986/03) . The Guideline considers that positive effects on PCWP and symptomatic improvement  (dyspnoea)  may  support  a  symptomatic  indication,  provided  there  are  no  deleterious effects  on  mortality.  However,  the  PD  results  do  not  provide  adequate  support  for  any  long-term efficacy of this drug after administration over a short time-frame. The Applicant could have calculated the tissue oxygen delivery based on the CRLX030A2201 data, but such an analysis was not presented. Interpretation  of  such  an  analysis  may  be  hampered  by  baseline  differences  that  occurred  in CRLX030A2201 despite randomisation.

## 2.4.5. Conclusions on clinical pharmacology

Data on pharmacokinetics of serelaxin are limited but in the context of its short-term IV administration the PK is adequately characterised in the opinion of the CHMP. However, discrepancies may be present between  the  various  serelaxin  products.  Serelaxin  is  a  vasodilatator  through  the  activation  of  NOsynthase. This may induce changes in SBP, SVR, RAP and PCWP but probably not CO/CI. There is also an  effect  on  renal  blood  flow  but  not  on  GFR.  This  could  be  explained  by  different  effects  of  the medicinal  products  on  venous  and  arterial  systems.  Also  other  effects  observed  in  humans,  in particular  related  to  the  organ  preservation  need  further  elucidation  and  have  not  been  yet  shown conclusively.

## 2.5. Clinical efficacy

The efficacy of serelaxin in subjects with HF have been studied in PD trials discussed above and in 3 Corthera/Novartis-sponsored trials: (1) RLX.CHF.001, (2) Pre-RELAX-AHF, and (2) RELAX-AHF.

(1) In the Phase 1 RLX.CHF.001 study 16 patients were treated with escalating doses to establish a dose range to be tested.

(2)  In  the  Phase  2,  Pre-RELAX-AHF  study,  a  total  of  234  subjects  with  HF  were  randomised  to treatment, and  230 were analysable for safety. This study evaluated 4 doses of serelaxin (approximately  10,  30,  100,  and  250  µg/kg/day)  vs.  placebo  and  thus  provided  data  to  select  the optimal IV dose to be taken forward for use in the subsequent Phase 3 RELAX-AHF study.

(3) The Phase 3 RELAX-AHF study enrolled 1161 patients with AHF to treatment, of whom 581 patients were randomised to receive IV serelaxin, and 580 to receive matching placebo (both administrated on top  of  the  current  standard-of-care  treatment  for  AHF  that  included  loop  diuretics).  Serelaxin  was administered according to a weight-range adjusted dosing table, based upon the dose with the best benefit/risk assessment from the Pre-RELAX-AHF study.

In  the  serelaxin  AHF  program,  the  Applicant  chose the  IV  route  over  the  SC  route  to  allow  a  rapid onset of effect, which would be appropriate for acute therapy in AHF patients. This motivation is valid and in addition the IV route may allow dose titration in case of hypotension. In the Pre-RELAX trial, serelaxin was administered using a syringe pump, but in the RELAX trial and in the currently proposed SmPC a 250 ml dextrose infusion was used. This choice seems not further justified. Both options were considered acceptable by the CHMP, but the fluid restriction achieved by using a syringe pump seems preferable in this disease condition.

The  interpretation  of  RLX.CHF.001  with  respect  to  the  optimal  dose  is  difficult,  because  the  middle dose group was not comparable to the lower and higher dose groups with respect to some disease characteristics.  During  the  design  of  (aborted)  trial  RLX.CHF.002,  dose  levels  of  100  and  500 µg/kg/day  were  selected,  while  during  the  design  of  Pre-RELAX-AHF  lower  dose  levels  of  10-250

<div style=\"page-break-after: always\"></div>

µg/kg/day were selected based on the same trial. Based on the data from Pre-RELAX-AHF, the dose range studied in that trial should include the optimal dose for serelaxin in AHF, but further tuning of the dose in the range 10-100 µg/kg/day appears possible.

The Applicant defined a number of categorical weight ranges used to determine dose and fixed infusion volume and speed. The alternative would have been to use a fixed solution with the infusion speed adapted  to  the  patient's  weight.  The  Applicant's  proposal  was  considered  acceptable  by  the  CHMP, because there seem to be no data supporting either choice. The variation in doses administered in the RELAX program could possibly be leveraged as an additional dose optimisation effort. This could allow evaluating long-term outcomes (e.g. Day 180 mortality) to be used for dose selection or optimisation.

The mainstay of the development program for serelaxin in AHF were a single Phase II trial (Pre-RELAXAHF) and a single pivotal Phase III trial (RELAX-AHF).

## 2.5.1. Dose response study (Pre-RELAX)

Study  Pre-RELAX  was  a  Phase  II,  randomised,  double-blind,  study  with  234  patients  receiving  a continuous intravenous (IV) infusion for up to 48 hours, of placebo or serelaxin (10, 30, 100 or 250 μg/kg/day) in a randomised ratio of 3:2:2:2:2. Patients in all treatment groups also received standard therapy for AHF.

As  the  design  and  the  populations  studied  of  the  Pre-RELAX  and  RELAX  trials  were  very  similar, comments with respect to these are included in connection to the main study, and omitted here for brevity.

A  large  number  of  variables  were  tested  statistically.  No  correction  was  done  for  multiplicity  and  p values  up  to  0.20  were  considered  a  'trend'.  As  a  dose-finding  technique,  these  choices  may  be acceptable,  but  the  exploratory  nature  of  the  findings  and  the  possibility  (probability)  of  chance findings should be clearly kept in mind.

There  are  some  differences  between  treatment  groups  in  baseline  characteristics  of  the  Pre-RELAX mITT  population,  e.g.  median  age  (70  to  74  years),  or  NT-proBNP  (2791  to  4065  pg/ml).  This  is inevitable, but stresses again that the results should be interpreted only in an exploratory sense.

Taking this into consideration, the 10, 30 and 100 μg/kg/day dose levels showed promising results with safety comparable to placebo (Table 1).

<div style=\"page-break-after: always\"></div>

Table 1 Pre-RELAX-AHF: Serelaxin effects on primary treatment targets by dose (with RELAX results for comparison)

|                                                                                                  | Placebo           | Serelaxin                | Serelaxin                | Serelaxin                | Serelaxin                | RELAX             | RELAX                     |
|--------------------------------------------------------------------------------------------------|-------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------------------|---------------------------|
| Dose µg/kg/d                                                                                     |                   | 10                       | 30                       | 100                      | 250                      | Placebo           | Ser. 30                   |
| N =                                                                                              | 61                | 40                       | 42                       | 37                       | 49                       | 580               | 581                       |
| Proportion of subjects with moderate/marked dyspnoea improvement at 6, 12, and 24 hours (Likert) | 23%               | 27.5% p=0.50             | 40.5% p=0.037            | 13.5% p=0.27             | 22.4% p=0.88             | 25.9%             | 26.9% p=0.70              |
| Mean VAS AUC Change from baseline to Day 5 (mm*hour) (95% CI)                                    | 1679 (1024- 2334) | 2500 (1570- 3430) p=0.15 | 2567 (1664- 3470) p=0.11 | 2486 (1531- 3441) p=0.16 | 2155 (1483- 2826) p=0.31 | 2308 (2057- 2559) | 2756 (2545- 2966) p=0.007 |
| Worsening heart failure through Day 5                                                            | 21%               | 20% p=0.75               | 12% p=0.29               | 14% p=0.40               | 10% p=0.15               | 12%               | 6% P<0.001                |
| Length of hospital stay (days) (95% CI)                                                          | 12.0 (10.1- 13.9) | 10.9 (8.1-13.6) p=0.36   | 10.2 (8.3-12.1) p=0.18   | 11.1 (8.9-13.3) p=0.75   | 10.6 (8.7-12.4) p=0.20   | 10.5 (9.7-11.3)   | 9.6 (8.9-10.4) p=0.039    |
| Persistent renal Impairment (Creatinine increase of 0.3 mg/dL or more at day 5 AND 14)           | 7%                | 8% p=0.87                | 7% p=0.90                | 11% p=0.47               | 15% p=0.19               | 14%               | 14% 0=0.92                |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                      | Placebo           | Serelaxin                        | Serelaxin                     | Serelaxin                        | Serelaxin                        | RELAX   | RELAX                           |
|--------------------------------------------------------------------------------------------------------------------------------------|-------------------|----------------------------------|-------------------------------|----------------------------------|----------------------------------|---------|---------------------------------|
| Dose µg/kg/d                                                                                                                         |                   | 10                               | 30                            | 100                              | 250                              | Placebo | Ser. 30                         |
| Days alive and out of hospital through Day 60 (95% CI)                                                                               | 44.2 (40.6- 47.8) | 47.0 (42.9- 51.2) p=0.40         | 47.9 (44.7- 51.0) p=0.16      | 48.0 (44.6- 51.3) p=0.40         | 47.6 (44.1- 51.0) p= 0.048       | 47.7    | 48.3 p=0.37                     |
| CV death or HF/RF re-hospitalisation through Day 60 (K-M estimate %) Cox proportional HR (95% Wald CI)                               | 17.2              | 10.1 0.55 (0.17- 1.77) p=0.32    | 2.6 0.13 (0.02- 1.03) p=0.053 | 8.4 0.46 (0.13- 1.66) p=0.23     | 6.2 0.32 (0.09- 1.17) p=0.085    | 12.9    | 13.1 1.02 (0.74- 1.41) P=0.895  |
| CV mortality to Day 60 (K-M estimate %) …to Day 180 (K-M estimate %) Cox proportional hazard ratio (95% Wald CI) Fisher's exact test | 6.9 14.3          | 2.5 2.5 0.19 (0.02- 1.57) p=0.14 | 0.0 0.0 0.00 NA p=0.04        | 2.9 2.9 0.22 (0.03- 1.76) p=0.15 | 6.2 6.2 0.49 (0.13- 1.90) p=0.51 | 4.7 9.6 | 3.3 6.1 0.63 (0.41- 0.96) 0.028 |

Data shown in shaded boxes are those that were statistically significant vs. placebo or trends (p&lt;0.2). HF/RF: heart failure or renal failure; HR: hazard ratio Source: [SCE-Table 2-1]

<div style=\"page-break-after: always\"></div>

Relief of dyspnoea by Likert scale was assessed as the primary outcome measure. The proportion of subjects  with  a  marked  or  moderate  improvement  in  subject-reported  dyspnoea  score  using  the Likert 7-point scale at both 12 and 24 hours in the absence of WHF symptoms was 40.0%, 50.0%, 24.3%, and 40.8% in the 10, 30, 100, and 250 µg/kg/day groups respectively compared to 44.3% in the placebo group. The mean change in dyspnoea (VAS AUC, another endpoint) at 24 hours was 326.6,  319.2,  277.2,  and  278.0  mm*hour  in  the  10,  30,  100,  and  250  µg/kg/day  groups respectively compared to 262.4 mm*hour in the placebo group.

The trial  failed  to  identify  a  dose-response  relationship.  Higher  doses  were  not  consistently  more effective.  The  Applicant  describes  this  as  a  U-shaped  curve,  but  the  optimum  of  the  curve  may depend on the parameter studied.

## 2.5.2. Main study (RELAX-AHF)

Study  RELAX-AHF  (RLX.CHF.003)  was  a  Phase  III,  randomised,  double-blind  study  with  patients receiving  a  continuous  intravenous  (IV)  infusion  for  up  to  48  hours,  of  placebo  or  serelaxin (nominally  30  μg/kg/day)  in  a  randomised  ratio  of  1:1.  Patients  in  both  treatment  groups  also received standard therapy for AHF.

## Methods

## Study Participants

Patients  were  selected  based  on  a  clinical  diagnosis  of  heart  failure  (supported  by  X-Ray  and laboratory investigations) and the need for intravenous diuretic therapy. As serelaxin decreases BP, selection of patients that were not hypotensive (SBP ≥ 125 mmHg) was appropriate. There was no central adjudication of X-Rays. Inclusion required an estimated glomerular filtration rate between 30 and  75  mL/min/1.73m².  Exclusion  criteria  concerned  (among  others)  recent  neurologic  events, recent acute coronary syndrome, and hepatic impairment.

In general it seems that the definition of the population includes no effective measure of severity besides 'need for hospitalisation', which is highly subjective, and 'need for IV diuretics', which may be chosen for practical reasons besides medical need. Hypotensive patients or patients in need of intravenous circulatory support were excluded. The burden of an informed consent procedure may also have excluded some severely ill patients, but these may have improved during the 16 hours that  were  allowed  for  randomisation.  Although  dyspnoea  at  rest  or  with  minimal  exertion  was required for inclusion, 38% of the included subjects were in NYHA class I-II. The ejection fraction (EF) was &gt;40% in 45% of patients.

Moreover, it is not clear whether the selected patients were really 'acute', as this was only defined by the 'intravenous diuretic' requirement. Not all patients were treated in the ICU or CCU. Also, 16 hours could pass between presentation and randomisation, which is a long time in acute medicine.

The entry criteria of RELAX-AHF are reflected in the proposed SmPC; important groups of patients that were not studied are mentioned in Section 4.4, e.g. subjects with severe renal impairment.

<div style=\"page-break-after: always\"></div>

## Treatments

The study drug serelaxin was provided as a 1 mg/mL clear, colourless solution in 5 mL vials (3.5 mL fill).  Matching placebo was provided in identical vials. Based upon a weight based dosing chart, a specified  volume  of  serelaxin  solution  was  withdrawn  from  the  vials  using  aseptic  technique,  and injected  into  a  250  mL  IV  bag  of  5%  dextrose  solution  in  water,  according  to  instructions  in  the Pharmacy Manual. For brevity, the nominal dose rate of serelaxin in RELAX-AHF is referred to as 30 μg/kg/day. Batch numbers were 2008-101 for Serelaxin 1 mg/mL (in 20mM sodium acetate) and 2083-103 for matching placebo (20mM sodium acetate). The IV infusion was administered for 48 hours (IV infusion).

## Outcomes/endpoints

## Primary endpoints:

1. Sustained relief of dyspnoea, measured by VAS (5 days).
2. Short term improvement in dyspnoea, measured using the Likert Scale.

## Criteria for efficacy:

1. AUC representing the change in patient-reported dyspnoea from baseline measured by 100-mm VAS through Day 5
2. Moderately or markedly better dyspnoea relative to the start of study drug on the 7-point Likert scale at 6, 12 and 24 hours (required at all 3 time-points)

## Criteria for positive study:

Based on criteria pre-specified in the study protocol and statistical analysis plan, the study was to have met the primary study objective of demonstrating efficacy of serelaxin in dyspnoea relief if either primary endpoint was statistically significant at the two-sided 0.025 level, or if both tests were significant at the two-sided 0.05 level. (Hochberg procedure)

## Secondary endpoints:

1. Days alive and out of hospital through Day 60
2. CV death or re-hospitalisation due to HF or renal failure through Day 60.

## Additional endpoints

In  the  final  amended  version  of  the  protocol  (amendment  5),  18  additional  endpoints  were specified. Some of these endpoints were assessed at multiple time-points or were composites of 2 or more components.

<div style=\"page-break-after: always\"></div>

## Biomarkers

Three biomarkers were pre-defined and measured at baseline and at various time points during the follow-up period.

1. Cardiac  troponin  T,  measured  with  a  high  sensitivity  assay  (high-sensitivity  cardiac troponin T, hs-cTnT) was an indicator of myocardial damage;
2. NT-pro-BNP was an indicator of the degree of congestion and
3. cystatin-C was an indicator of kidney injury.

Although all-cause mortality at 30 days is the preferred endpoint in the EMA Guidance on clinical investigations  of  medicinal  products  for  the  treatment  of  cardiac  failure/Addendum  on  acute heart failure (CPMP/EWP/2986/03) , dyspnoea as assessed by VAS or Likert scale was considered acceptable. This was also concluded in the EMA/CHMP scientific advice (2010), with the addition that additional efficacy and safety data would be required for authorisation.

Although both the Likert scale and the VAS assess dyspnoea, according to the Applicant they are used complementarily and measure different entities: early and sustained relief. In the scientific advice  (SA),  the  CHMP  considered  that  the  primary  endpoint  should  also  include  persistent improvement  in  clinical  signs  of  congestion  and  evidence  of  short-term  safety.  However, congestion was captured in exploratory endpoints only, without further justification.

The  CHMP  SA  suggested  two  alternatives  for  the  Hochberg  approach  as  proposed  by  the company: Choosing the Likert scale as single primary endpoint would be more in line with the EMA guideline, which requires benefit between 6 and 24 hours to be shown if dyspnoea is chosen as  the  primary  endpoint.  Alternatively,  a  positive  trial  could  be  defined  to  require  a  positive outcome  on  both  Likert  and  VAS  scales.  The  company  decided  to  maintain  the  originally proposed  Hochberg  approach,  without  further  justification.  However,  it  seems  that  persistent improvement  in  dyspnoea  (during  the  hospital  stay)  could  serve  as  a  primary  endpoint  if supported  by  improvement  in  clinical  signs  of  congestion  according  to  the  recently  published concept  for revision of the current guideline. These  physician-assessed  clinical signs of congestion were captured in RELAX-AHF as additional endpoints.

Data on length of hospitalisation and CCU stay, re-hospitalisations and mortality (both all-cause and cardio-vascular) are  captured in the secondary and additional endpoints. These endpoints are suggested in the guideline and thus indeed relevant. The 60-day observation period for the secondary endpoints is appropriate in this disease as any potential additional beneficial effects of serelaxin may take longer than the 30-days period advised by the guideline to become evident.

As  a  large  number  of  additional  endpoints  was  included,  and  no  correction  was  done  for multiplicity, these endpoints can only be interpreted in an exploratory sense and should be used for hypothesis generation only. Claims based on these exploratory endpoints are not acceptable.

Adjudication of deaths occurring between 60 and 180 days after randomisation was added to the evaluations at a later stage. The results of this additional adjudication only impact an exploratory endpoint  and  the  results  strongly  resemble  the  investigator  assessment  of  cause  of  death. Therefore this additional adjudication can be accepted. Of note, hospitalisations between 60 and 180 days after randomisation were not captured.

<div style=\"page-break-after: always\"></div>

## Sample size

Power for the primary and secondary efficacy endpoints was estimated using simulations. In the clinical overview, the sample size is described as adequate to detect a treatment effect size of 28% increase in the VAS AUC score; in the CSR, the sample size is described as adequate to detect a minimum clinically meaningful treatment difference of 468 mm-hour (4 mm difference at  individual  time-points  on  average)  in  the  VAS-AUC  endpoint.  The  clinical  relevance  of  this definition is not well justified and is also difficult to imagine. An effect size of 15 to 20% of the placebo response was considered clinically relevant by the RELAX-AHF executive committee. (The values finally obtained were 447.7 mm-hour for improved AUC over placebo, 3.8 mm on average higher than placebo, or 19.4% increase).

The original sample size calculation, as described in Amendment 2, mentioned a 92% power to detect  a  mean  6  mm  increase  at  2-sided  p=0.025  or  80%  power  to  detect  a  mean  7  mm increase at 2-sided p=0.000625

## Randomisation

Patient numbers were assigned sequentially at each study site through the IVRS. The patients were assigned a blinded study drug kit through the IVRS based on the randomisation plan. Each site  was  assigned  a  block  of  the  randomisation  scheme  upon  activation;  up  to  one  additional block  could  be  assigned  automatically  by  the  IVRS  using  a  predefined  algorithm  based  on enrolment.  Each  study  drug  kit  was  labelled  with  a  unique  kit  identification  number  and contained 1 vial of serelaxin or placebo. The two types of vials (serelaxin and placebo), as well as the kits, were indistinguishable. The site personnel were instructed to access the IVRS to request assignment  of  study  drug  kits  for  each  24  hour  period  of  dosing.  Once  the  IVRS  had  been accessed, the caller was asked a series of questions, including whether the weight of the subject was ≥115 kg. If the response was no, a single study drug kit was assigned for each 24-hour dosing period; if the response was yes, 2 kits were assigned for each 24-hour dosing period. For each 24-hour infusion period, study drug was withdrawn from the vial(s) contained in the blinded kit(s)  and  injected  into  a  250  mL  IV  bag  of  5%  dextrose  solution  in  water  according  to instructions in the Pharmacy Manual.

## Blinding (masking)

The  clinical  database  was  locked  twice.  The  first  database  lock  occurred  when  all  patients completed the 60 day evaluation period of the study and all data had been monitored, all data queries were resolved. All follow-up between Day 60 and Day 180 available at that 1st database lock, including Day 180 and interim contacts, were included in the Day 60 database. All planned analyses  summarising  results  by  treatment  group  were  performed  after  the  last  patient  had completed the 60 day evaluation period of the study. For this analysis, group summaries were presented. Individual  patient  treatment  assignments  (e.g.,  listings)  were  not  provided prior  to the Day 180 lock. Only members of the data analysis team had access to patient level data and these personnel had no direct role in study operations. These results were shared with a limited group of people the identities of whom have been documented by the Sponsor.

All personnel involved in the operations of the study or with any potential site contact, such as medical monitors, remained blinded to treatment assignments from the time of randomisation until the Day 180 database lock according to the Corthera Unblinding Plan, using the following methods: (1) Randomisation data were kept strictly confidential until the time of unblinding at

<div style=\"page-break-after: always\"></div>

Day 180, and were not accessible by anyone else involved in the study with the exceptions noted below. The identity of the treatments was concealed by the use of indistinguishable vials and labels (for vials and for kits).

In  the  event  of  a  medical  emergency,  the  investigator  was  to  contact  the  medical  monitor  to discuss the need to unblind the patient's treatment assignment. Several medical monitors were identified  so  that  one  would  be  available  at  all  times.  The  treatment  assignments  were  to  be made accessible to the investigator should a patient need to be unblinded in an emergency. If it was determined that unblinding was required, the medical monitor would drop off the line and the  investigator  would  be  unblinded  via  the  IVRS.  Almac  recorded  all  such  interactions  that occurred via the helpline.

The  statistical  centre  reporting  to  the  DSMB  was  also  unblinded  to  individual  treatment assignments. The centre provided monthly unblinded reports of safety and protocol compliance to the chairman of the DSMB and a report to all of the members of the Board for interim safety meetings, according to the DSMB charter.

## Statistical methods

## Analysis sets

Statistical analyses were conducted for the primary efficacy outcomes with the ITT set, FAS, and PPS-1 and -2. Efficacy outcomes for the ITT set constituted the main outcomes for this study. The analysis sets used are appropriate.

## Primary endpoints

The  AUC  representing  the  change  from  baseline  in  dyspnoea  VAS  score  through  Day  5  (VAS AUC)  was  compared  using  a  two-sided  two-sample  t-test  as  the  primary  method  of  analysis. Additional  analyses  were  performed  to  assess  the  underlying  assumptions  of  the  statistical analysis method. If results suggested noteworthy departures from the assumptions underlying the  t-test,  supportive  analyses  such  as  the  Wilcoxon  rank  sum  test  or  a  randomisation-based determination of the p-value for the t-test were to be conducted.

Unless  otherwise  specified,  treatment  comparisons  for  continuous  outcomes  were  made  using two-sided two-sample t-tests assuming pooled variances. If the distribution of the responses was markedly non-normal (e.g., highly skewed or contains outliers) then results of the Wilcoxon rank sum tests were reported as well. Tests for the normal distribution of results were conducted by treatment using the Shapiro-Wilk test. Because the Shapiro-Wilk test tends to be overly sensitive to departures from normality in large samples sizes, a more restrictive alpha level was used as the  critical  value  for  claiming  non-normality  (p ≤ 0.005).  Equality  of  variances  was  assessed using  an  F  statistic.  If  the  variances  were  unequal  (p ≤ 0.005)  then  the  results  of  the  t-test using the Satterthwaite method were to be presented in addition to results using the method for pooled variances.

The proportion of patients with moderately or markedly better dyspnoea on the Likert scale at 6, 12, and 24 hours (all three time points) was compared between treatment groups using a chisquare test. The odds ratio and 95% confidence interval (95% CI) were presented.

<div style=\"page-break-after: always\"></div>

To control the type 1 error, for the two co-primary endpoints the Hochberg method was used and the  secondary  endpoints  were  tested  hierarchically.  Statistically,  this  approach  preserves  the type I error at 0.05. However, as was written in the EMA scientific advice, using two potentially correlated  co-primary  endpoints  and  considering  the  trial  to  be  positive  if  either  endpoint  is positive, is questioned. It would mean the trial is positive provided the treatment is beneficial in either one of these aspects - it is also not necessary for it to be shown to be effective in both, nor is it specified that any particular one of them must be positive.

The pre-specified α-level is usually not suitable for an application based on a single pivotal trial.

## Imputations

Scores for all VAS and Likert assessments following death or the onset of WHF (either during the index hospitalisation or re-hospitalisation due to HF) were imputed as the worst score observed in  any patient at any time point and were carried forward for all time points after the time of onset of the event, regardless of whether the actual score was missing or not.

The  rationale  for  the  data  imputation  in  the  presence  of  WHF  is  that  WHF  is  defined  as  the patient deteriorating to the point of requiring 'rescue' therapy with pharmacological  or mechanical intervention. Thus, symptom scores reported by the subject following WHF no longer represent  the  effect  of  the  study  drug  but  the  effect  of  the  rescue  therapy.  The  imputation assumes  that  patients  with  WHF  have  experienced  the  worst  response;  therefore,  the  worst value observed in the population is imputed from that point forward.

For post-baseline values otherwise missing, a missing score was  imputed using linear interpolation  between  the  last  preceding  and  first  following  non-missing  value;  if  no  following non-missing value was available, the last available preceding value was carried forward.

Scores for VAS and Likert assessments following death or the onset of WHF were imputed as the worst score observed in any patient at any time point, regardless of whether the actual score was missing or not. This approach was seriously questioned by the CHMP, formed the basis for major objection during the procedure and the grounds for refusal of this application.

## Sensitivity analysis

A  sensitivity  analysis  of  the  VAS  AUC  endpoint  using  the  FAS  was  conducted  to  examine  the effect of data handling conventions on the results. For this analysis, scores for all assessments following a death were imputed as the worst observed value in the analysis population while the baseline observations were imputed for patients with WHF from the time of WHF through to the end of the evaluation period.

More sensitivity analyses were provided in the Day 121 responses, for example an analysis using observed values.

## Secondary endpoints

Days alive and out of hospital were compared using the Wilcoxon rank sum test as the primary analysis  method.  In  addition,  the  median  of  differences  and  corresponding  95%  CI  were presented using the Hodges-Lehmann estimator of shift.

The days from the baseline date to the date of the first event (death due to cardiovascular cause, or re-hospitalisation due to HF or RF, CEC classified) were used for analysis. Patients who died

<div style=\"page-break-after: always\"></div>

from a non-cardiovascular cause before Day 60 without an event were censored at the time of death; patients otherwise without an event were censored at the earlier of the last contact date or Day 60. Kaplan-Meier estimates of the rates of the composite event and its components were presented, and treatment groups were compared using a log rank test. Kaplan-Meier plots were presented. Hazard ratios and 95% CIs were estimated from a Cox proportional hazard regression model with treatment as a factor.

## Additional (exploratory) efficacy endpoints

Time to event variables were analysed presenting Kaplan-Meier estimates and testing with the log rank test. Change from baseline variables were analysed using t-tests. Variables representing the number of days or multi-categorical variables were analysed using the Wilcoxon rank-sum test. The categorical variables were analysed using chi-squared tests.

Due  to  the  large  number  of  these  exploratory  variables,  and  the  lack  of  type-I  error-control, chance findings would be expected.

## Interim analysis

Four interim examinations of key safety data were planned for the purpose of reporting to the DSMB. All analyses related to the DSMB were carried out by an independent statistical group.

At  each  interim  examination,  the  DSMB  assessed  safety  and  protocol  compliance,  but  could request summaries of the efficacy data to provide an overall assessment of risk versus benefit. For  each  review  of  the  primary  outcomes,  an  alpha  of  0.00001  was  considered  to  have  been spent, and the significance level for the final analysis adjusted accordingly. In the responses to the CHMP Day 120 List of Questions, the applicant shows that the adjustment of p-values leads to a very small adaptation, easily hidden after rounding.

Apart  from  these  comments,  the  statistical  methods  used  are  adequately  described  and  are standard and, in general, are considered acceptable.

## Results

## Participant flow

A  total  of  1161  patients  were  randomised  to  the  study.  A  total  of  1035  patients  (89.1%) completed the study. The remaining 126 patients (10.9%) who did not complete Day 180 had an interim  contact  at  the  time  of  this  data  analysis  (122  patients,  10.5%),  died  (106  patients, 9.1%) withdrew consent from follow-up (18 patients, 1.6%), or were lost to follow-up (2 patients 0.2%). A higher proportion of patients in the placebo group died compared to the serelaxin group (11.2%  vs.  7.1%).  The  proportions  of  patients,  who  either  completed  the  study,  withdrew consent or were still followed, were similar for the serelaxin and placebo treatment groups. The vital status could not be ascertained in 14 patients (12 patients withdrew from follow-up and 2 were lost to follow-up; 1.2%).

Randomisation and treatment all occurred within 72 hours during a single disease episode; as could be expected most subjects who were randomised were also treated. Vital status at Day 180 was not available for 14 (1.2%) patients only, indicating adequate follow-up Table 2 ).

<div style=\"page-break-after: always\"></div>

Table 2 Study Pre-RELAX-AHF and RELAX-AHF patient disposition - n (%) of patients (ITT analysis set)

|                                         | RELAX-AHF             | RELAX-AHF               | Pre-RELAX-AHF          | Pre-RELAX-AHF                         |
|-----------------------------------------|-----------------------|-------------------------|------------------------|---------------------------------------|
|                                         | Placebo (N=580) n (%) | Serelaxin (N=581) n (%) | Placebo (N = 62) n (%) | Serelaxin 30 µg/kg/day (N = 43) n (%) |
| Completed Day 180                       |                       |                         |                        |                                       |
| Yes                                     | 505 (87.1)            | 530 (91.2)              | 52 (83.9)              | 37 (86.0)                             |
| No                                      | 75 (12.9)             | 51 (8.8)                | 10 (16.1)              | 6 (14.0)                              |
| Primary reason for not completing study |                       |                         |                        |                                       |
| Death                                   | 65 (11.2)             | 41 (7.1) 3              | 8 (12.9)               | 3 (7.0)                               |
| Withdrew Consent from Follow- up        | 9 (1.6) 1,2           | 9 (1.5) 1,2             | 2 (3.2)                | 2 (4.7)                               |
| Lost to Follow-up                       | 1 (0.2)               | 1 (0.2)                 | 0                      | 1 (2.3)                               |

Source: [SCE-Table 3-7, Table 3-3]

## Recruitment

The study was conducted at 96 centres in 11 countries: 10 centres in Argentina, 4 centres in France, 7 centres in Germany, 7 centres in Hungary, 9 centres in Israel, 6 centres in Italy, 5 centres  in  Netherlands,  9  centres  in  Poland,  8  centres  in  Romania,  4  centres  in  Spain,  27 centres  in  United  States  of  America.  The  first  patient  was  enrolled  on  11-Oct-2009  (first patient first visit) and the last patient completed the trial on 14-Aug-2012 (last patient last visit). Although AHF is a common disorder, 96 centres recruited and treated 1161 patients in a period of 28 months, averaging 12 patients per centre and in each centre 1 patient every 71 days.

## Conduct of the study

The protocol was amended 3 times after study initiation. The assessment of the trial is based on the final amended version. The amendments (including the addition of exclusion criterion #20 on hypersensitivity) are not believed to have influenced the validity of the trial.

The  CSR  of  RELAX-AHF  lists  1064  significant  protocol  violations  (Listing  16.2.2-1)  in  215/580 (37.1%) placebo and 233/581 (40.1%) serelaxin patients. The Applicant has given reassurance that very general terms like 'Any serious breach of the conditions and principles of Good Clinical

<div style=\"page-break-after: always\"></div>

Practice', refer to administrative deficiencies only. It is not necessary to exclude the data of these patients from the final analysis.

## Baseline data

The population in the trial is well-representative of the target population for the drug as defined in the proposed SmPC section 4.1

The  majority  of  participants  were  elderly,  and  subjects  up  to  97  years  of  age  were  included. Participation  of  non-Caucasians  was  minimal;  this  point  is  addressed  in  the  RMP.  As  subjects were  sought  with  normal  or  elevated  BP,  a  history  of  hypertension  was  present  in  87%  of subjects.  Atrial  fibrillation,  ischaemic  cardiac  diseases,  and  heart  failure  were  also  frequently reported.  Baseline  medications  seem  in  line  with  current  recommendations  for  these  patients (Table 3 ).

Table 3 Demographic and baseline disease characteristic summary by treatment group - Study Pre-RELAX-AHF and RELAX-AHF (ITT analysis set)

|                                     | RELAX-AHF   | RELAX-AHF         | RELAX-AHF         | Pre-RELAX-AHF    | Pre-RELAX-AHF               |
|-------------------------------------|-------------|-------------------|-------------------|------------------|-----------------------------|
| Parameter                           | Statistic   | Placebo N=580     | Serelaxin N=581   | Placebo N=61     | Serelaxin 30 µg/kg/day N=42 |
| Age (years)                         | Mean (SD)   | 72.5 (10.8)       | 71.6 (11.7)       | 68.4 (9.9)       | 71.6 (9.2)                  |
| Gender - n (%)                      | Male        | 357 (61.6)        | 368 (63.3)        | 40 (65.6)        | 18 (42.9)                   |
|                                     | Female      | 223 (38.4)        | 213 (36.7)        | 21 (34.4)        | 24 (57.1)                   |
| Race - n (%)                        |             |                   |                   |                  |                             |
| American Indian or Alaska           | Native      | 0                 | 1 (0.2)           |                  |                             |
| Asian                               |             | 2 (0.3)           | 2 (0.3)           |                  |                             |
| Black or African American           |             | 23 (4.0)          | 29 (5.0)          | 3 (4.9)          | 0 (0.0)                     |
| Native Hawaiian or Pacific Islander |             | 0                 | 1 (0.2)           |                  |                             |
| White                               |             | 552 (95.2)        | 544 (93.6)        | 58 (95.1)        | 42 (100)                    |
| Multi-Racial                        |             | 1 (0.2)           | 1 (0.2)           |                  |                             |
| Other                               |             | 2 (0.3)           | 3 (0.5)           |                  |                             |
| Systolic BP at baseline             | n'          | 578               | 577               |                  |                             |
| (mmHg)                              | Mean        | 142.1             | 142.2             | 147.5            | 150.3                       |
| HF hospitalisation (in              | (SD) n (%)  | (17.0) 181 (31.2) | (16.2) 216 (37.2) | (20.3) 18 (29.5) | (19.5) 16 (38.1)            |

<div style=\"page-break-after: always\"></div>

|                                                | RELAX-AHF    | RELAX-AHF         | RELAX-AHF       | Pre-RELAX-AHF   | Pre-RELAX-AHF               |
|------------------------------------------------|--------------|-------------------|-----------------|-----------------|-----------------------------|
| Parameter                                      | Statistic    | Placebo N=580     | Serelaxin N=581 | Placebo N=61    | Serelaxin 30 µg/kg/day N=42 |
| Number of hospitalisations in past year        | n'           | 180               | 214             | n/a             | n/a                         |
|                                                | Mean (SD)    | 1.5 (1.13)        | 1.7 (1.48) 196  |                 |                             |
| Days since discharge from last hospitalisation | n' Mean (SD) | 156 125.2 (123.6) | 118.1 (112.8)   | 149.7 (114.2)   | 109.4 (103.9)               |
| Most recent ejection fraction < 40%            | n (%)        | 295 (54.7)        | 303 (54.9)      | 19 (44.2)       | 15 (53.6)                   |
| NYHA* (most recent prior to admission)         |              |                   |                 |                 |                             |
| I                                              | n (%)        | 11 (2.6)          | 12 (2.7)        | 2 (3.3)         | 0                           |
| II                                             | n (%)        | 140 (33.0)        | 164 (37.5)      | 16 (26.2)       | 6 (14.3)                    |
| III                                            | n (%)        | 198 (46.7)        | 191 (43.7)      | 23 (37.7)       | 17 (40.5)                   |
| IV                                             | n (%)        | 72 (17.0)         | 63 (14.4)       | 12 (19.7)       | 14 (33.3)                   |
| hsTroponin T levels (µg/L)                     | n'           | 541               | 533             | **              | **                          |
| Geometric mean                                 |              | 0.0361            | 0.0341          |                 |                             |
| NT-pro-BNP (pg/L)                              | n'           | 551               | 550             |                 |                             |
| Geometric mean                                 |              | 5003.5            | 5125.5          |                 |                             |
| Medical history                                |              | n (%)             | n (%)           |                 |                             |
| Hypertension                                   |              | 510 (87.9)        | 496 (85.4)      | 50 (82.0)       | 38 (90.5)                   |
| Stroke or other cerebrovascular                | event        | 84 (14.5)         | 73 (12.6)       | 13 (21.3)       | 8 (19.0)                    |
| Peripheral vascular disease                    |              | 82 (14.1)         | 73 (12.6)       | 6 (9.8)         | 8 (19.0)                    |
| Malignancy                                     |              | 38 (6.6)          | 41 (7.1)        | 2 (3.3)         | 2 (4.8)                     |
| Mitral stenosis                                |              | 6 (1.0)           | 8 (1.4)         | 1 (1.6)         | 0                           |
| Mitral regurgitation                           |              | 182 (31.4)        | 179 (30.8)      | 14 (23.0)       | 13 (31.0)                   |
| Ischaemic heart disease                        |              | 307 (52.9)        | 296 (50.9)      | 41 (67.2)       | 33 (78.6)                   |

<div style=\"page-break-after: always\"></div>

|                                                                           | RELAX-AHF   | RELAX-AHF     | RELAX-AHF       | Pre-RELAX-AHF   | Pre-RELAX-AHF               |
|---------------------------------------------------------------------------|-------------|---------------|-----------------|-----------------|-----------------------------|
| Parameter                                                                 | Statistic   | Placebo N=580 | Serelaxin N=581 | Placebo N=61    | Serelaxin 30 µg/kg/day N=42 |
| Atrial fibrillation/flutter                                               |             | 305 (52.6)    | 297 (51.1)      | 26 (42.6)       | 18 (42.9)                   |
| Diabetes mellitus                                                         |             | 272 (46.9)    | 279 (48.0)      | 30 (49.2)       | 22 (52.4)                   |
| Congestive Heart Failure (CHF) within the last 1-month prior to admission |             | 424 (73.1)    | 437 (75.2)      | 53 (86.9)       | 38 (90.5)                   |
| Angina pectoris                                                           |             | 66 (11.4)     | 72 (12.4)       | 20 (32.8)       | 11 (26.2)                   |
| Cigarette smoking                                                         |             | 81 (14.0)     | 72 (12.4)       | 11 (18.0)       | 5 (11.9)                    |
| Hyperlipidaemia                                                           |             | 313 (54.0)    | 304 (52.3)      | 33 (54.1)       | 21 (50.0)                   |
| Pacemaker                                                                 |             | 58 (10.0)     | 63 (10.8)       | 7 (11.5)        | 5 (11.9)                    |
| Biventricular pacing                                                      |             | 52 ( 9.0)     | 61 (10.5)       | 5 (8.2)         | 2 (4.8)                     |
| Auto. internal cardiac defibrillator                                      |             | 75 (12.9)     | 79 (13.6)       | 7 (11.5)        | 5 (11.9)                    |

Source: [SCE-Table 3-1, Table 3-2, Table 3-4 and Table 3-5]

Randomisation has worked well and no important differences between the treatment groups were found.

The ITT and safety sets were defined as usual. In this trial, they were largely similar. Two 'Per protocol' sets were defined to address protocol deviations. Analyses in these sets are presented in the CSR. As they are similar to the main analyses, the results are not further discussed in this overview AR.

## Numbers analysed

Additional exploratory analyses were conducted to evaluate the robustness of the findings and to assess the role of compliance and dose adjustment with the treatment regimen in the results. These  analyses  excluded  further  from  the  FAS  population  patients  who  had  any  of  the  major protocol deviations from the lists below. Two per-protocol analysis sets (PPS) were defined:

- (1) PPS1 excluding only patients with pre-randomisation protocol deviations identified in the SAP, and
- (2)  PPS2  excluding  patients  with  both  pre-randomisation  and  post-randomisation  protocol deviations specified in the SAP.

The following major pre-randomisation deviations excluded patients from PPS1:

<div style=\"page-break-after: always\"></div>

- Screening blood pressure measurement &lt;125 mm Hg (deviation of Inclusion Criterion 3)
- BNP &lt; 350 pg/mL or NT-pro-BNP &lt;1400 pg/mL (deviation of Inclusion Criterion 4)
- Randomised more than 16 hours from presentation (deviation of Inclusion Criterion 5)
- Use  of  disqualifying  IV  vasodilators,  positive  inotropes,  vasopressors  or  mechanical support during screening (deviation of Exclusion Criterion 4)
- Known significant pulmonary disease (deviation of Exclusion Criterion 6)
- AHF  due  to  known  significant  valvular  disease  as  defined  in  protocol  (deviation  of Exclusion Criterion 7)
- AHF  due  to  current  (at  the  time  of  screening)  acute  coronary  syndrome  (deviation  of Exclusion Criteria 12, 13)
- AHF due to significant arrhythmia as defined in protocol (deviation of Exclusion Criteria 14)

Additionally, the following post-randomisation deviations excluded subjects from PPS2:

- Non-compliance  with  study  drug  administration,  i.e.,  receipt  of  less  than  75%  of  the intended amount of study drug. For the primary Likert dyspnoea efficacy endpoint during the first 24 hours, the minimum duration of study drug infusion required is 18 hours. For the 3 remaining efficacy endpoints, the minimum duration of study drug infusion required is  36 hours, i.e. 75% of the intended amount. Subjects whose dose of study drug was appropriately reduced or discontinued will not be excluded.
- Failure  to  reduce  or  discontinue  study  drug  administration  in  the  presence  of  a  blood pressure decrease event.

Patients were analysed by the group to which they were randomised. Key primary and secondary efficacy endpoints, as well as Day 180 mortality were examined in both PPS1 and PPS2. Patients who were missing the baseline dyspnoea VAS score were excluded from the PP analyses of the VAS AUC to Day 5 endpoint.

As  presented  in  Table  22,  there  were  no  major  differences  between  the  ITT  set  (serelaxin: N=581; placebo: N=580) and the Safety set (serelaxin: N=568; placebo: N=570). The Safety set consisted of all patients who received treatment and patients were summarized based on the actual treatment received. There were 14 and 9 patients in the serelaxin and placebo groups, respectively, who were included in the ITT set, but excluded from the Safety set because they did not receive any study medication (reasons included patient refusal, physician discretion, or SBP &lt;100 mmHg). One patient randomised to placebo who received serelaxin, was summarised under serelaxin for safety evaluation.

## Table 4 Analysis sets - n (%) of patients

|                               | Placebo   | Serelaxin   | Total   |
|-------------------------------|-----------|-------------|---------|
| Intent-to-Treat (ITT) Set [1] | 580       | 581         | 1161    |
| Actual Treatment Received [2] |           |             |         |

<div style=\"page-break-after: always\"></div>

| • Placebo                     | 570 (98.3)   | 0 ( 0.0)   | 570 (49.1)   |
|-------------------------------|--------------|------------|--------------|
| • Serelaxin                   | 1 ( 0.2)     | 567 (97.6) | 568 (48.9)   |
| • Not treated                 | 9 ( 1.6)     | 14 ( 2.4)  | 23 ( 2.0)    |
| Full Analysis Set (FAS) [3]   | 562 (96.9)   | 560 (96.4) | 1122 (96.6)  |
| Per Protocol Set 1 (PPS1) [4] | 532 (91.7)   | 538 (92.6) | 1070 (92.2)  |
| Per Protocol Set 2 (PPS2) [5] | 513 (88.4)   | 509 (87.6) | 1022 (88.0)  |

- [1] ITT Set includes all randomised patients.
- [2] Safety Set includes all randomised patients who received any amount of study drug. Patients will be analysed as treated.
- [3] FAS Set includes all randomised patients who were treated with any amount of study drug, and did not have any of 5 pre-specified major pre-randomisation eligibility protocol deviations, as defined in Section 9.7.2. Patients will be analysed as randomised.
- [4] PPS1 Set includes all randomised patients who were treated with any amount of study drug, and did not have any major pre-randomisation protocol deviations, as defined in Section 9.7.2. Patients will be analysed as randomised.
- [5] PPS2 Set includes all randomised patients who were treated with any amount of study drug, and  did  not  have  any  major  pre-  and  post-randomisation  protocol  deviations,  as  defined  in Section 9.7.2. Patients will be analysed as randomised.

Source: PT-Table 14.1-1

The CHMP concluded that in this study the ITT and safety sets were defined as usual. In this trial, they  were  largely  similar.  Two  'Per  protocol'  sets  were  defined  to  address  protocol  deviations. Analyses in these sets are presented in the CSR. As they are similar to the main analyses, the results are not further discussed in this AR.

## Outcomes and estimation

The first co-Primary Endpoint, the mean AUC of change from baseline in VAS through Day 5 was 2756  mm-hours  and  2308  mm-hours  in  the  serelaxin  and  placebo  groups,  respectively.  The mean difference in VAS AUC between treatment groups was 447.7 mm-hours (95% CI 120.0, 775.4;  t-test  p=0.0075).  Applying  the  Hochberg  procedure  as  specified  in  the  protocol,  this allowed  concluding  superiority  of  serelaxin  over  placebo  for  dyspnoea  relief.  Several  problems with the evaluation of this endpoint were evaluated:

## Imputation

The  results  are  driven  by  the  values  that  were  imputed  after  the  subject  was  classified  as 'Worsening Heart Failure' (WHF). Figure 3 shows the AUCs as they were used for the primary endpoint analysis. In Figure 4 (drafted by assessor), these same imputed VAS data are shown (dotted  lines,  non-linear  X-axis  extended to  Day  14).  In  addition,  the  actually  observed  (nonimputed) data are shown (solid lines). The treatment effect in the observed data is much smaller than after imputation.

Figure 3 Mean change from baseline (mm) of dyspnoea Visual Analogue Scale (VAS) Study RELAX-AHF (ITT analysis set)

<div style=\"page-break-after: always\"></div>

*P-value  is  based  on  a  two-sided  two  sample  t-test  for  serelaxin  vs.  placebo  comparing  area under the mean curve (AUC, mm-hours) of change from baseline in dyspnea visual analog scale (VAS) through Day 5. Source: [SCE-Figure 3-1]

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 4 VAS in RELAX-AHF showing observed and imputed data

<!-- image -->

Notes: Non-linear X-Axis. Dotted lines correspond to Figure 3

Figure 5 and Figure 6 show the mean time course of dyspnea VAS stratified by experience of WHF through Day 5 and by treatment group using observed data and imputed data respectively.

Figure 5 Change from Baseline of Dyspnea VAS by WHF through Day 5 and treatment group:  Observed data - Population: Intent-to-Treat Set

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note: Observed VAS data is presented, without any imputations, LOCF, linear interpolation, or baseline imputation

Note: WHF is defined as having an event through Day 5.

Source: [SCS-Appendix 1 Figure 132-1]

Figure 6 Change from Baseline of Dyspnea VAS by WHF through Day 5 and treatment group:  Imputed data - Population: Intent-to-Treat Set

<!-- image -->

Note:  Imputed  VAS  data  (as  in  the  primary  analysis)  is  presented;  this  includes  LOCF,  linear interpolation, baseline imputation, and worst post-baseline imputation for patients from WHF or

<div style=\"page-break-after: always\"></div>

## death onwards

Note: WHF is defined as having an event through Day 5.

Source: [SCS-Appendix 1 Figure 132-2]

Both figures indicate that there is virtually no difference in mean VAS scores between treatment groups in the group of patients who did not experience WHF through Day 5.

The Applicant has justified the imputations, explaining that a WHF event and associated rescue therapy, would make a 'fair' evaluation of the treatment effect of relaxin impossible. Therefore, after such an event, the worst VAS value that was observed in the trial was imputed at all timepoints after WHF. This imputed value was zero. However, in reality, the patients did not feel so dyspnoeic and the dyspnoea levels in the serelaxin and placebo groups were quite comparable. It is clear that the VAS endpoint actually measured WHF, not dyspnoea.

The Applicant has failed to show that the clinical state (symptomatic burden) of the patient at time of WHF and the impact of administered rescue therapy justify ignoring the subsequent VAS values that were observed. Although the diagnosis of WHF may have prognostic significance, this does not indicate symptomatic improvement or worsening. Bearing all these factors in mind, a reasonable ITT approach after WHF would be to impute missing values within the stratum of WHF patients (but not discard any values that were actually observed). The results of such an analysis would be very similar to Figure 5

## Statistical analysis

Figure 7 shows a histogram of all observed VAS scores during the trial. It is clear that multiples of 5 and especially multiples of 10 occur more frequently than expected. The VAS worksheet, as reproduced in the CSR and below (Figure 8), shows that the VAS instrument had tick marks at 10, 20 etc. millimetres, which could explain this. This observation suggests that the VAS results in  this  trial  were  not  a  continuous,  approximately  normally  distributed  variable,  but  rather  an ordinal  scale.  With  the  Day  121  responses,  the  Applicant  did  not  document  validation  of  the instrument before the trial. Still, the Applicant has provided an extensive post-hoc analysis of the performance of the VAS instrument which provides reassurance as to its usability for this MAA.

## Figure 7 Histogram of all VAS dyspnoea values RELAX-AHF

<div style=\"page-break-after: always\"></div>

Figure 8 VAS tool used in RELAX-AHF

<!-- image -->

Figure 9 plot of area under the curve (AUC, mm-hr) of change from baseline of dyspnea visual analog scale (VAS) from baseline to Day 5 (population: Intent-to-Treat Set)

<!-- image -->

Placebo treatment group

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Serelaxin 30 µg/kg/day treatment group

<!-- image -->

Source: [SCS-Appendix 1 Figure 100c-2]

Because  of  the  large  number  of  imputed  zero  values,  the  assumption  of  normality  for  the resulting  VAS  data,  and  possibly  also  for  the  corresponding  AUC  VAS  data,  was  further investigated.  A  Q-Q  plot  of  area  under  the  curve  (AUC,  mm-hr)  of  change  from  baseline  of dyspnoea VAS is shown in Figure 9.

The p-value associated with the Shapiro-Wilk test was below the predefined alpha-level of 0.005, suggesting  a  departure  from  normality.  This  departure  is  also  visible  in  the  above  Q-Q  plots, clearly  showing  a  deviation  from  normality  on  the  negative  side,  which  is  most  likely  due  to imputation with the worst observed score after death or WHF. As defined in the protocol, the applicant  provided  a  Wilcoxon  test  'to  be  reported  as  well'  which  failed  to  show  a  significant treatment difference.

<div style=\"page-break-after: always\"></div>

However  the  Applicant  argued  that  the  t-test  can  still  be  considered  as  the  primary  test  for drawing conclusions from the study. Indeed, with randomisation and with larger sample sizes, through the central limit theorem, t-tests are relatively robust to deviations from normality of individual subjects' data. This is supported by the randomisation-based t-test, which produced a p-value close to that of the primary analysis. Furthermore, the Shapiro-Wilk statistics in are close to 1. This indicates that the data distribution is close to normal even though the p-values are below 0.0001. With larger sample sizes, it is not uncommon that Shapiro-Wilk detects a small deviation from normality and produces a high Shapiro-Wilk statistic coupled with a low p-value. In conclusion, it is agreed with the Applicant that the t-test is relatively robust to deviations from the normal distribution and that the t-test can be accepted for the primary analysis.

## Clinical relevance

The clinical relevance of the AUC of VAS change of baseline as reported is not clear. The AUCdifference that was termed clinically relevant in the sample size calculation was not reached. The sample size was adequate to detect a minimum clinically meaningful treatment difference of 468 mm-hour  (4  mm  difference  across  time  points  on  average,  by  trapezoidal  rule,  assuming  no difference at baseline and 4 mm from 6 hours to Day 5). Compared to a mean improvement in VAS of 30 or more (Figure 4) this difference seems rather limited.

The second co-Primary Endpoint, dyspnoea by Likert scale, did not reach statistical significance. The  requirement  of  moderate  or  marked  improvement  of  dyspnoea  at  each  of  the  three  time points  of  6,  12,  and  24  hours  was  reached  similarly  in  both  trial  groups.  (placebo:150/580 (25.9%),  serelaxin:  156/581  (26.9%),  p=0.702,  Chi-square  test).  The  applicant  has  stressed that the Likert scale and the VAS score are distinct entities. In this trial, the main difference is the timeframe for the observation (VAS: 0-5 days, Likert: 6-24 hours). The Likert scale endpoint worked  as  a  responder  analysis  and  required  moderate  or  marked  improvement  at  all  the measured endpoints.

The Likert endpoint as used in the trial was not so sensitive to the WHF imputation, because WHF affected only 4% of subjects at the 24 hour time point. For the Likert endpoint, the impact of imputation was also less than for the VAS, because WHF-subjects were counted as 'did not reach moderate or marked improvement' (or 'non-responder').

In additional documentation (Patient Reported Outcomes report) supplied with the responses to the CHMP D 120 List of Questions, the Applicant has shown that the VAS and the Likert results show an acceptable level of correlation, meaning that the patients have understood the questions and  usually  responded  in  the  same  direction.  The  fact  that  in  the  primary  analysis  the  VAS endpoint was positive and the Likert endpoint was not positive confirms that the VAS endpoint was driven primarily by the WHF imputations and that the clinical relevance (e.g. in terms of responders) was rather limited.

The  secondary  endpoint  Days  Alive  and  Out  of  Hospital  did  not  reach  statistical  significance (p=0.3682).  The  numerical  outcome  was  slightly  in  favour  of  serelaxin  (48.3  vs.  47.7  days). Although the components 'duration of index hospitalisation' (8.9 vs. 9.5 days) and 'average time dead' (1.2 vs. 1.8 days) worked in favour of serelaxin, re-hospitalisations counted in favour of placebo (2.6 vs. 1.9 days).

<div style=\"page-break-after: always\"></div>

The other secondary endpoint CV Mortality or HF/RF Rehospitalisation showed a similar outcome, because most death and re-hospitalisations were for CV or renal reasons. The HR for serelaxin vs.  Placebo  was  1.02  (95%  CI:  0.74,  1.41;  p=0.89).  CV  deaths  were  27  (placebo)  vs.  19 (serelaxin)  and  HF/RF  re-hospitalisations  were  50  (placebo)  vs.  60  (serelaxin)  yielding  HRs  of 0.70 (95% CI: 0.39, 1.26; p=0.23) and 1.21 (95% CI: 0.83, 1.76; p=0.32) respectively.

The Applicant correctly mentions that subjects who have died cannot experience rehospitalisation, and thus these risks are competing. The finding could imply that although both serelaxin  and  placebo  patients  were  frail,  some  of  those  treated  with  serelaxin  survived  to hospitalisation while their placebo-treated counterparts died. However, it could be expected that a genuine improvement in physical condition should improve both mortality and rehospitalisations. Because death is a competing event for hospitalisation, the applicant provided analyses using the cumulative incidence function. The results were close to the original analyses using Kaplan-Meier estimates and lead to the same conclusions.

Data on re-hospitalisations between Day 60 and 180 were not collected.

## Exploratory endpoints

A very large number of exploratory efficacy endpoints were investigated, sometimes at multiple time points or with multiple approaches (e.g. percentage responders and time-to-event). Some endpoints have been combined in various ways. Although hypothesis generation is the only valid justification for these endpoints, the hypotheses that could have been generated are sometimes difficult to imagine.

CV death through Day 180 was one of these exploratory endpoints and was reduced in serelaxin patients compared to placebo. Mortality is discussed under safety.

The  biomarkers  that  were  studied,  hs-cTnT,  Cystatin  C  and  NT-proBNP,  all  show  favourable changes in serelaxin patients compared to placebo. In all cases, these favourable changes were related  to  a  better  outcome  for  mortality  through  Day  180.  The  Applicant  claims  that  these biomarkers show (protection against) organ damage and thus explain the mortality findings. It is however not clear how this organ protection would be the result of vasodilatation as caused by serelaxin. As was shown in the PD trials, renal blood flow was increased by serelaxin, but not cardiac index.

Worsening heart failure (WHF) was assessed by the physicians and defined as worsening signs and/or  symptoms  of  HF  that  required  an  intensification  of  IV  therapy  for  HF  or  mechanical ventilatory or circulatory support. WHF through Day 5 occurred in 106/1143 patients (9.3 %), more frequently in placebo patients (69/573, 12.0%) than in serelaxin patients (37/570, 6.5%; p&lt;0.001).  As  discussed  above,  through  the  imputation  rules,  this  was  the  parameter  that actually  made  the  difference.  In  an  additional  analysis,  based  on  this  trial,  the  applicant  has shown that WHF increases the risk of a worse outcome by Day 180 in this trial.

Serelaxin patients were prescribed less furosemide than placebo patients (161 mg vs. 213 mg). Nevertheless,  weight  loss  through  Day  3  (both  groups  2.0  kg)  was  similar  and  slightly  more (placebo v. serelaxin) at Day 5 (3.0 vs 2.7 kg) and Day 14 (3.6 vs 3.0 kg). This suggests that serelaxin may  have  had  diuretic effects in these patients.  However, in the PD  study RLX030A2202, no effect on diuresis or natriuresis could be concluded.

<div style=\"page-break-after: always\"></div>

While the applicant has treated diuretic dose primarily as an outcome measure, the Applicant investigated also if higher-dose diuretic usage affected the outcomes of the trial. In an analysis of outcomes (VAS dyspnoea, weight change, renal function, potassium) stratified by cumulative dose of furosemide through Day 5, it was shown that the results were not driven by furosemide dose.

## Summary of main efficacy results

The following Table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment.

## Table  Summary of efficacy for trial RELAX-AHF

| Title: A phase II/III, multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Relaxin in subjects with AHF   | Title: A phase II/III, multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Relaxin in subjects with AHF                                    | Title: A phase II/III, multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Relaxin in subjects with AHF                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                             | RLX.CHF.003 (RELAX-AHF)                                                                                                                                                                       | RLX.CHF.003 (RELAX-AHF)                                                                                                                                                                       |
| Design                                                                                                                                                       | Randomisation within 16 hours after hospitalisation for AHF. Eligible patients were randomized in a 1:1 ratio to receive either IV placebo or serelaxin in a double-blind manner for 48 hours | Randomisation within 16 hours after hospitalisation for AHF. Eligible patients were randomized in a 1:1 ratio to receive either IV placebo or serelaxin in a double-blind manner for 48 hours |
| Design                                                                                                                                                       | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                | 48 hours treatment. Observations for primary endpoint through Day 5, for secondary endpoint through Day 60 for exploratory and safety endpoint through Day 180. N/A N/A                       |
| Hypothesis                                                                                                                                                   | Superiority Primary endpoints were combined using Hochberg approach Secondary endpoints were only tested if primary endpoint was achieved and combined using Hochberg approach                | Superiority Primary endpoints were combined using Hochberg approach Secondary endpoints were only tested if primary endpoint was achieved and combined using Hochberg approach                |
| Treatments groups                                                                                                                                            | Placebo                                                                                                                                                                                       | Placebo, N = 580                                                                                                                                                                              |
| Treatments groups                                                                                                                                            | Serelaxin                                                                                                                                                                                     | Serelaxin 30 µg/kg/day, N = 581                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions                       | Co-Primary endpoint                                                                                                           | VAS AUC                                                                                                                       | Area Under the Curve (AUC) representing the change in patient-reported dyspnoea from baseline measured by a 100-mm Visual Analogue Scale (VAS) through Day 5          | Area Under the Curve (AUC) representing the change in patient-reported dyspnoea from baseline measured by a 100-mm Visual Analogue Scale (VAS) through Day 5          |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                       | Co-Primary endpoint                                                                                                           | Likert                                                                                                                        | Moderately or markedly better patient-reported dyspnoea relative to the start of study drug on the 7-point Likert scale at 6, 12 and 24 hours (at all 3 time-points). | Moderately or markedly better patient-reported dyspnoea relative to the start of study drug on the 7-point Likert scale at 6, 12 and 24 hours (at all 3 time-points). |
| Endpoints and definitions                       | Secondary endpoint                                                                                                            | DAOOH                                                                                                                         | Days alive and out of hospital through Day 60                                                                                                                         | Days alive and out of hospital through Day 60                                                                                                                         |
| Endpoints and definitions                       | Secondary endpoint                                                                                                            | CV death or rehosp                                                                                                            | Cardiovascular death or rehospitalisation due to HF or RF through Day 60.                                                                                             | Cardiovascular death or rehospitalisation due to HF or RF through Day 60.                                                                                             |
| Study period                                    | First patient enrolled: 11-Oct-2009 (first patient first visit) Last patient completed: 14-Aug-2012 (last patient last visit) | First patient enrolled: 11-Oct-2009 (first patient first visit) Last patient completed: 14-Aug-2012 (last patient last visit) | First patient enrolled: 11-Oct-2009 (first patient first visit) Last patient completed: 14-Aug-2012 (last patient last visit)                                         | First patient enrolled: 11-Oct-2009 (first patient first visit) Last patient completed: 14-Aug-2012 (last patient last visit)                                         |
| Results and Analysis                            | Results and Analysis                                                                                                          | Results and Analysis                                                                                                          | Results and Analysis                                                                                                                                                  | Results and Analysis                                                                                                                                                  |
| Analysis description                            | Primary Analysis                                                                                                              | Primary Analysis                                                                                                              | Primary Analysis                                                                                                                                                      | Primary Analysis                                                                                                                                                      |
| Analysis population and time point description  | Intent to treat                                                                                                               | Intent to treat                                                                                                               | Intent to treat                                                                                                                                                       | Intent to treat                                                                                                                                                       |
| Descriptive statistics and estimate variability | Treatment group                                                                                                               | Treatment group                                                                                                               | Placebo                                                                                                                                                               | Serelaxin                                                                                                                                                             |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                            | Number of subjects                                                                                                            | 580                                                                                                                                                                   | 581                                                                                                                                                                   |
| Primary endpoints                               | VAS AUC (mean) mm h                                                                                                           | VAS AUC (mean) mm h                                                                                                           | 2308                                                                                                                                                                  | 2756                                                                                                                                                                  |
| Primary endpoints                               | 95% CI                                                                                                                        | 95% CI                                                                                                                        | 2057, 2559                                                                                                                                                            | 2545, 2966                                                                                                                                                            |
| Primary endpoints                               | Likert scale (n (%)) Moderately or markedly improved at 6, 12, and 24 h timepoints                                            | Likert scale (n (%)) Moderately or markedly improved at 6, 12, and 24 h timepoints                                            | 150 (25.9%)                                                                                                                                                           | 156 (26.9%)                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Secondary endpoints                            | DAOOH                                           | 47.7                                            | 48.3                                            |
|------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Secondary endpoints                            | 95% CI                                          | 46.7, 48.7                                      | 47.3, 49.2                                      |
| Secondary endpoints                            | CV death or rehosp (Kaplan-Meier estimate %)    | 13.0                                            | 13.2                                            |
| Secondary endpoints                            | 95% CI                                          | 10.5, 16.1                                      | 10.7, 16.3                                      |
| Effect estimate per comparison                 |                                                 | Comparison groups                               | Serelaxin v Placebo                             |
| primary endpoints                              | VAS AUC                                         | Mean difference                                 | 447.7                                           |
| primary endpoints                              | VAS AUC                                         | 95% CI                                          | 120.0, 775.4                                    |
| primary endpoints                              | VAS AUC                                         | P-value (t-test)                                | 0.0075                                          |
| primary endpoints                              | VAS AUC                                         | P-value (Wilcoxon rank sum test)                | 0.082                                           |
| primary endpoints                              | Likert scale (n (%))                            | P-value (Chi-Square test)                       | 0.70                                            |
| secondary endpoints                            | DAOOH                                           | P-value (Wilcoxon rank sum test)                | 0.37                                            |
| secondary endpoints                            | CV death or rehosp                              | Hazard Ratio                                    | 1.02                                            |
| secondary endpoints                            | CV death or rehosp                              | 95% CI                                          | 0.74, 1.41                                      |
| secondary endpoints                            | CV death or rehosp                              | P-value (log rank test)                         | 0.89                                            |
| Analysis description                           | Exploratory analysis                            | Exploratory analysis                            | Exploratory analysis                            |
| Analysis population and time point description | Pooled Safety Set (Pre-Relax AHF and RELAX-AHF) | Pooled Safety Set (Pre-Relax AHF and RELAX-AHF) | Pooled Safety Set (Pre-Relax AHF and RELAX-AHF) |
| Descriptive statistics                         | Treatment group                                 | Placebo                                         | Serelaxin                                       |

<div style=\"page-break-after: always\"></div>

| and estimate variability       | Number of subject                            | 631               | 610                 |
|--------------------------------|----------------------------------------------|-------------------|---------------------|
| Exploratory endpoint           | Mortality Day 180 N, Kaplan-Meier estimate % | 72 11.7%          | 44 7.4%             |
| Effect estimate per comparison |                                              | Comparison groups | Serelaxin v Placebo |
| Exploratory endpoint           | Mortality Day 180                            | Hazard Ratio      | 0.61                |
| Exploratory endpoint           |                                              | 95% CI            | 0.42, 0.89          |
| Exploratory endpoint           |                                              | P-value           | 0.0110              |

## Analysis performed across trials (pooled analyses and meta-analysis)

N/A

## Clinical studies in special populations

Efficacy trials in the special populations of severe renal impairment and hepatic impairment were not performed. A paediatric investigation plan is agreed, but no results are available.

In the RELAX-AHF trial, most participants were elderly subjects. The CSR provides data for the following age groups: &lt;65, ≥ 65, &lt;75 and ≥ 75 years. The results in the elderly populations are similar to the younger populations.

As the number of non-white participants was very low, the subgroup analysis by race was noninformative.

## Supportive study(ies)

N/A

## 2.5.3. Discussion on clinical efficacy

Study RELAX-AHF was the single pivotal trial submitted in this dossier. This was a randomised controlled trial, in which the patients with AHF were treated with placebo or serelaxin (nominally 30 μg/kg/day intravenously) for up to 48 hours, on top of standard of care. The inclusion criteria were  not  strict  about  'acuteness'  of  the  heart  failure  episode.  It  is  not  clear  how  early  the treatment should be initiated to provide benefit optimally. Randomisation was allowed until 16 hours after presentation, but as most symptomatic improvement is made during the first hours of  hospitalisation  (e.g.  Figure  3),  the  moment  of  initiation  of  a  symptomatic  therapy  (like serelaxin) will affect the maximum benefit that can be achieved.

<div style=\"page-break-after: always\"></div>

The guideline-preferred endpoint ( EMA Guidance on clinical investigations of medicinal products for the treatment of cardiac failure/Addendum on acute heart failure [CPMP/EWP/2986/03] ) for trials in AHF is 30-Day all-cause mortality, but symptomatic relief (dyspnoea relief), which was chosen  in  RELAX-AHF,  can  be  an  acceptable  endpoint  too.  The  EMA  scientific  advice  (2010) stressed the importance of fast relief of dyspnoea, as measured in this trial by the Likert scale endpoint  at  6,  12  and  24  hours.  Contrary  to  the  advice,  the  Applicant  chose  a  parallel assessment of persistent dyspnoea relief (0-5 Days) in a co-primary endpoint. These endpoints were  combined  using  the  Hochberg  procedure,  which  implied  that  the  trial  could  be  declared positive  on  persistent  dyspnoea  relief  alone,  as  in  fact  happened.  The  predefined  level  of statistical significance, which was agreed in the scientific advice, for an application based on a single pivotal trial, was not met. The Applicant believes that the beneficial effects on mortality by Day 180 could compensate for this lack of statistical persuasive power, but this is not agreed. Also  other  conditions  for  an  application  based  on  a  single  clinical  trial  are  not  fulfilled,  e.g. internal validity (VAS v. Likert) and clinical relevance of the primary effect size.

The included patients are representative of non-hypotensive AHF patients that are hospitalised. However, consistent with clinical practice, most subjects had acute decompensated chronic heart failure, with limited data on other HF classes. The majority of participants were elderly persons, and subjects up to 97 years of age were included. A history of hypertension was present in 87% of subjects. Randomisation has worked well and no important differences between the treatment groups were found. Serelaxin showed greater efficacy in patients with HF-pEF as shown by the concurrent significant improvement of Likert and VAS scales compared to patients with HF-rEF where a marginal, questionable clinical effect, was noted only on the VAS scale.

In RELAX-AHF the comparator was inactive placebo and it is a matter of fact that the protocol produced  post  randomization  heterogeneities  between  the  study  arms,  the  most  important  of these being a major difference in arterial pressure throughout the infusion period of Serelaxin {difference of systolic pressure &gt;5 mmHg at 9 hours [serelaxin 15.9 (95%CI: 14.5-17.3) and placebo 10.1 (95%CI: 8.6-11.6]}. Arterial pressure is a main component of cardiac afterload, a determinant of heart work and a key target for therapy. Actually some of the outcomes observed during  the  hospital  phase  can  be  influenced  by  the  differences  in  afterload  generated  by  the study  protocol  and  deserve  careful  evaluation  and  discussion.  Although  the  scientific  advice EMA/CHMP/SAWP/784780/2010  accepted  placebo  as  a  comparator  for  this  trial,  the  advice required that the protocol would define use of vasodilatators such as nitrates, thus preventing treatment imbalances between arms. However, the study protocol did not lead to a reasonable use of i.v. nitroglycerine (no difference compared to serelaxin group) while the vasolilator effect of Serelaxin resulted in the above mentioned difference in arterial pressure and heart workload. The  placebo  arm  was  therefore,  during  the  infusion  phase  of  the  protocol,  undertreated compared to the active arm.

The first co-Primary Endpoint, the mean AUC of change from baseline in VAS through Day 5 was 2756  mm-hours  and  2308  mm-hours  in  the  serelaxin  and  placebo  groups,  respectively.  The mean difference in VAS AUC between treatment groups was 447.7 mm-hours (95% CI 120.0, 775.4;  t-test  p=0.0075).  Applying  the  Hochberg  procedure  as  specified  in  the  protocol, superiority of serelaxin over placebo for dyspnoea relief was concluded.

The trial was powered to detect a mean difference of 4 mm in the VAS endpoint as measured at different  time  points  for  dyspnoea  relief  (captured  as  AUC);  an  effect  size  of  15  to  20%  was

<div style=\"page-break-after: always\"></div>

considered clinically relevant by the trial Executive Committee but the clinical relevance of this choice is not further justified. As can be learnt from Figure 4, most subjects improve about 30 mm in 5 days as effect of the current standard of care. According to SCE Table 3-8, the mean improvement  in  the  placebo  group  in  RELAX-AHF  (with  all  imputations)  was  2308 mm hr, corresponding  to  an  average  of  19,7  mm.  The  treatment  effect  corresponds  to  a  mean improvement of 3.83 mm, 19.4% of the placebo response.

Even in the main analysis on the intention-to-treat population, zero values were imputed for VAS (and 'markedly worse' for Likert) after WHF, although these data were not truly missing as they were collected anyhow. The Applicant has justified this, stating that the assessments were not really representative of the investigative drug's treatment effect. However, it seems to contradict the principles of an intention-to-treat analysis.

The  Applicant  states  that  imputation  with  the  worst  observed  VAS  score  is  justified,  because imputing with missing values is too optimistic, dyspnoea is not measured at the moment WHF occurs, and because the clinical course after WHF is fundamentally different. Although based on these arguments it is reasonable to conclude that treating the VAS scores after WHF as missing may  be  appropriate,  it  does  not  justify  imputation  with  the  worst  observed  value.  The  same argumentation could be used to justify imputation using baseline values, but this model was not chosen by the applicant.

The  Applicant  has  discussed  extensively  the  prognosis  of  subjects  experiencing  WHF  but  has failed to show that the clinical state (symptomatic burden) of the patient at time of WHF and the impact  of  administered  rescue  therapy  justify  ignoring  the  subsequent  VAS  values  that  were observed. Although the diagnosis of WHF may have prognostic significance, this does not indicate symptomatic  improvement  or  worsening.  Bearing  all  these  factors  in  mind,  a  reasonable  ITT approach after WHF would be to impute missing values within the stratum of WHF patients (but not discard any values that were actually observed). The results of such an analysis would be very similar to Figure 5.

In  the  sensitivity  analysis  on  the  VAS  AUC  data,  imputing  values  after  WHF  as  the  patient's baseline value, the mean AUC was 2748 mm-hr for the placebo group and 2922 mm-hr for the serelaxin group, resulting in a difference of 174 mm-hr (95% CI: -85, 434; p = 0.19 by t-test), corresponding  to  a  mean  difference  in  VAS  of  1,5  mm  at  all  time  points.  Other  sensitivity analyses provided similar results, which were all not statistically significant.

The second co-Primary Endpoint, dyspnoea by Likert scale, did not reach statistical significance. The  requirement  of  moderate  or  marked  improvement  of  dyspnoea  at  each  of  the  three  time points  of  6,  12,  and  24  hours  was  reached  similarly  in  both  trial  groups  (placebo:150/580 (25.9%),  serelaxin:  156/581  (26.9%),  p=0.702,  Chi-square  test).  The  applicant  has  stressed that the Likert scale and the VAS score are distinct entities. In this trial, the main difference is the timeframe for the observation (VAS: 0-5 days, Likert: 6-24 hours). In the scientific advice, the early timeframe was considered most important and in the Pre-RELAX trial, only the early timeframe showed a statistically significant result (Table 2). The Likert scale endpoint worked as a responder analysis and required moderate or marked improvement at the chosen endpoints. Contributing  factors  to  the  apparent  difference  between  VAS  and  Likert  outcomes  include  the early (6-hour) Likert assessment that was required to become a 'responder', the non-parametric approach to evaluation of the Likert-scale endpoint (not as powerful as the parametric test for

<div style=\"page-break-after: always\"></div>

VAS) and the cumulative effect of WHF which biased the VAS endpoint but much less the Likertscale endpoint, because WHF affected only 4% of subjects at the 24 hour time point and also because WHF-subjects were counted as 'did not reach moderate or marked improvement' (or 'non-responder') for the Likert endpoint.

No  clear benefits were  shown  in  the  secondary  endpoints,  where  length  of the index hospitalisation  and  CV  mortality  favoured  serelaxin,  but  re-hospitalisations  favoured  placebo. Because death is a competing event for hospitalisation, the applicant provided analyses using the cumulative incidence function. The results were close to the original analyses using Kaplan-Meier estimates and lead to the same conclusions.

The biomarkers that were studied, hs-cTnT, Cystatin C and NT-proBNP, show favourable changes in  serelaxin  patients  compared  to  placebo.  The  Applicant  claims  that  these  biomarkers  show (protection  against)  organ  damage  and  thus  explain  the  mortality  findings.  It  is  however  not clear how this organ protection would be the result of vasodilatation as caused by serelaxin. A clear result on cardiac output or renal blood flow, as may be provided by the on-going PD trials, would help in understanding these interesting findings.

Worsening heart failure (WHF) was assessed by the physicians and defined as worsening signs and/or  symptoms  of  HF  that  required  an  intensification  of  IV  therapy  for  HF  or  mechanical ventilatory  or  circulatory  support.  WHF  through  Day  5  occurred  more  frequently  in  placebo patients  (69/573,  12.0%)  than  in  serelaxin  patients  (37/570,  6.5%;  p&lt;0.001).  As  discussed above, through the imputation rules, this was the parameter that actually made the difference. In an additional analysis, based on this trial, the applicant has shown that WHF increases the risk of a worse outcome by Day 180 in this trial.

Serelaxin patients were prescribed less furosemide than placebo patients (161 mg vs. 213 mg). Nevertheless,  weight  loss  through  Day  3  (both  groups  2.0  kg)  was  similar  and  slightly  more (placebo  v.  serelaxin)  at  Day  5  (3.0  vs  2.7  kg)  and  Day  14  (3.6  vs  3.0  kg).  Also  in  the  PD studies, no clear diuretic or natriuretic effect of serelaxin could be concluded.

More generally, the treating physicians' opinion of the serelaxin patients' condition seems to have been  more  positive  than  of  the  placebo-treated  patients.  This  is  evident  in  the  findings  on physical examination (of these, 'dyspnoea on exertion', 'oedema'  and  'rales'  showed improvement,  'orthopnoea'  and  'jugular  venous  pulse'  did  not),  the  (less)  prescribing  of diuretics, more frequently starting of ACE inhibitors (placebo: 4.1%, serelaxin 7.7%), less use of IV inotropic medications, shorter hospital stay and less WHF. It may be difficult to capture this 'opinion'  numerically.  Moreover,  the  clear  BP  effects  of  serelaxin  may  have  hampered  the blindness of the study, especially in the patients where the BP effect was most pronounced.

## Additional expert consultation

At Day 180 List of Outstanding Issues (LoOIs) the CHMP decided to consult the Cardiovascular Scientific Advisory Group (SAG CVS) and adopted the List of Questions to the SAG CVS at this point of time. A SAG CVS was convened on 9 December 2013. The CHMP questions to SAG and SAG experts' answers are presented below:

<div style=\"page-break-after: always\"></div>

## Question 1

## The SAG is asked to comment on the clinical relevance of the findings in RELAX-AHF as well as phase II studies with respect to

## a) relief of dyspnoea, taking into account  the

- clinical relevance of the improvement on the dyspnoea VAS scale taking into account the  estimate of the effect size in relation to the predefined level of clinical significance,
- impact of imputations that were applied when rescue therapy was given (WHF),
- lack of significant effect using the Likert-scale in RELAX-HF,

## b) reduction of WHF taking into account its definition and characteristics in RELAX,

- c) numerical difference in mortality at 6 months, taking into account the
- strength of  statistical evidence,
- lack of an effect at 60 days,
- discrepancy  between  the  outcomes  of  hospitalisation  for  heart  failure and mortality,

## d) changes in haemodynamics,

## e) relevance of the background therapy in the (PRE) RELAX-AHF trial in particular concerning the use of nitrates.

## Answer to question 1:

a) The Visual Analogue Scale (VAS) is a tool not used in every day clinical care. Thus it is difficult to translate a small reduction into clinical benefit.

A  4  mm  reduction  in  VAS,  as  proposed  in  the  study  protocol,  seems  to  be  a  very  small improvement and unlikely to be clinically relevant, especially since most patients used 5 or 10 mm  increments  in  the  VAS  to  mark  their  dyspnoea  status  as  it  has  been  applied  in  scaled design. Moreover,  the  predefined  level  of  4  mm  has  not  been  reached  (3.84  mm  have  been reached). 1 mm improvement on dyspnoea VAS, representing the non-imputed VAS results, is certainly not clinically relevant.

The imputation approach chosen by the applicant of zeroing the VAS scores at the time of WHF occurrence (which was based on physician judgment) and on further time points up to five days does not render the VAS results as a measurement of dyspnoea alone. It combines a patient derived symptomatic score with a physician derived signs and symptom measurement and does not seem to measure exactly the primary endpoint variable. To impute the value of zero seems to  be  a  too  extreme  approach  and  carrying  it  beyond  the  time  of  WHF  for  the  rest  of  the measurement points seems too strict. The imputed VAS looses statistical significance if a more meaningful value would be used for imputation instead of zero.

<div style=\"page-break-after: always\"></div>

The  Likert  scale  provided  the  assessment  of  the  shorter  observation  period  (24  hours)  as compared  to  VAS  scale.  Furthermore,  the  interpretation  was  done  on  the  basis  of  responder status analysis rather than as a numerical evaluation. The Likert scale results are in line with the VAS results when the VAS values are not imputed.

b) It was noted that WHF was not among the primary or secondary endpoints in the protocol, as it was an exploratory endpoint only. Though the occurrence of WHF in the RELAX trial could be seen  as  a  marker  of  prognosis,  its  impact  on  the  course  of  heart  failure  is  not  completely understood based on the per protocol definition of WHF.

The reduction in WHF with serelaxin is difficult to interpret, since the definition criteria used in the  study  do  not  account  for  the  underlying  reason,  i.e.  do  not  take  into  account  heart  rate, occurrence of atrial fibrillation, peripheral oedema or infections like the occurrence of pneumonia.

The SAG members felt, that, although the increase in diuretics alone did not trigger the event, the  definition  of  WHF  was  not  detailed  enough  in  the  protocol  to  draw  firm  conclusions. Nevertheless,  WHF,  properly  defined  with  strict  adjudication  criteria  measured  at  the  time  of deterioration, is seen as a valuable clinical variable for future studies.

c) The  observed  difference  in  mortality  endpoint  at  6  months  lacks  a  pathophysiological explanation given only a short term administration of the drug (48 hours). It was an exploratory parameter and the study was not powered for measuring mortality as an efficacy endpoint. It was rather used as a safety parameter. The result was largely driven by CV mortality; however it has not been shown that a difference in the pump failure related events contributed to a relevant extent.  Stroke  contributed  significantly  to  the  overall  difference  and  death  attributed  to heartfailure  was  even  higher  in  patients  receiving  Serelaxin.  The  SAG  acknowledged  however that the mortality difference was observed in both the PreRELAX and Relax trials.

The increase in the mortality difference over time cannot be explained on the basis of the so far known biological activity of the compound and the short duration of infusion. Thus it would be warranted to study this parameter in a properly designed prospective trial.

d) A  clear  doses  response  is  being  questioned,  at  least  in  relation  to  symptoms  and  blood pressure (BP).

The  overall  hemodynamic  findings  including  lowering  of  filling  pressures  are  in  line  with decongestion. The lack of cardiac output increase (CI) was discussed and not felt to be a matter of major clinical concern, however it was not clearly understood given the reduction in systemic vascular resistance.

e) Only  a  small  cohort  of  the  study  population  was  given  nitrates  as  part  of  the  background therapy,  which  was  lower  than  expected  based  on  the  available  usage  data  (e.g.  Euro  Heart Survey) and common practice. The reason is probably partly investigators- and partly protocoldriven (iv. nitrates in patients with SBP below 150 mm Hg were not allowed). It is not clear to which extent and in which direction the low use of nitrates might have affected the results.

## Question 2

Based  on  the  responses  to  question  1,  do  the  SAG  members  regard  the  efficacy  of serelaxin as clinically meaningful in the targeted population, taking into account that

<div style=\"page-break-after: always\"></div>

## the  studied  population  may  not  be  representative  for  the  total  population,  or  are further confirmatory data needed?

## Answer to question 2:

The  population  investigated  is  representative  for  a  sizeable  subset  of  patients  with  AHF  with preserved or elevated systolic blood pressure. The early inclusion up to 16 hrs after admission is found appropriate. No data are available for patients with entry SBP under 125. This should be reflected in the indication.

The claim of symptomatic improvement has been questioned and is not sufficiently supported by the results (see answer to Q1).

## Question 3

## Do the members regard the safety characteristic of serelaxin as manageable in clinical routine  including  patients  with  normal-low  blood  pressure  and  those  at  risks  for coronary steal syndromes?

## Answer to question 3:

The  effect  of  serelaxin  on  haemoglobin  is  not  well  understood.  The  observed  hemodynamic response lacks a clear dose response relationship and thus dose adjustment would be difficult /impossible in clinical practice.

No data are available in patients with SBP below 125 mm Hg. A meaningful subset of patients with ischemic heart disease have been entered in RELAX without angina or myocardial infarction / ischemia being reported in a larger number of pts. Thus coronary steal seems not to be a major concern.  However,  data  on  the  occurrence  of  myocardial  infarction  have  not  been  collected beyond day 14.

## 2.5.4. Conclusions on the clinical efficacy

Although the Applicant has declared the trial to be positive, only the first co-primary endpoint (VAS AUC for dyspnoea relief) met the predefined significance criteria. The responder analysis (Likert  scale),  most  sensitivity  analyses  and  the  secondary  endpoints  measuring mortality and hospitalisation did not demonstrate benefits. The methodology used to assess the VAS endpoint has  measured  WHF  instead  of  direct  dyspnoea  relief  and  the  reported  results  are  considered inconclusive in terms of clinical benefit.

## 2.6. Clinical safety

## Patient exposure

The  primary  dataset  used  for  the  evaluation  of  safety  is  the  pooled  safety  population  of  PreRELAX-AHF  and  RELAX-AHF,  consisting  of  all  patients  who  received  at  least  one  dose  of  trial medication. This population consists of 737 AHF patients who received serelaxin and 631 patients who received placebo.  It  is  agreed  to  use  this  pooled  dataset,  excluding  the  Phase  2  and  PD trials.  These  latter  trials  recruited  a  somewhat  different  population  that  was  small  and

<div style=\"page-break-after: always\"></div>

RLX.CHF.001 included no placebo group (Table 5). The recently concluded Phase 2 trials (A2201, A2202), which were reported at Day 121, are not included in the integrated safety analysis.

Table 5 Summary of patients in serelaxin development program

|                    |   Relaxin | Placebo   | Total          |
|--------------------|-----------|-----------|----------------|
| 737                |       631 | 1368      | HF pooled      |
| 23                 |         4 | 27        | HF, not pooled |
|                    |       760 | 635 1395  | All HF         |
|                    |       590 | 287 877   | Non HF         |
| PK (A2101 & A2103) |        81 | 8 89      |                |
|                    |       671 | 295 966   | Non-HF & PK    |
| HF and non-HF      |      1431 | 930       | 2361           |

The  total  number  of  patients  exposed  to  serelaxin  and  analysed  is  1431.  The  information retrieved from the 'legacy' and healthy volunteer trials is supplementary only.

The RELAX program yields a database of 737 exposed patients in the proposed population and dose. The EMA scientific advice (EMA/CHMP/SAWP/784780/2010) considered that the size of the database might be sufficient. It was difficult to set safety requirements or evaluate the adequacy of  the  data  set  to  exclude  all  important,  but  rare,  safety  elements  without  knowing  the magnitude of benefit. Marginal benefit might require additional safety data compared to evidence for marked clinical improvement. Absence of a detrimental effect on mortality was important and the  Company  was  advised  to  seek  follow-up  advice  once  the  Phase  3  trials  results  would  be available.

In the pooled RELAX dataset, 610 patients were treated with serelaxin according to the proposed dosing  schedule.  In  RELAX  AHF,  dose  reductions  for  low  blood  pressure  occurred  in  103/570 (18.1%) placebo patients and 167/568 (29.4%) patients in the serelaxin group. Other patients have  received  less  study  drug  than  prescribed  due  to  AEs,  consent  withdrawal  or  medication errors. In the end, 376 of 578 (66.2%) patients received at least 98% of the 'calculated dose' in RELAX-AHF.

## Adverse events

As  per  protocol,  in  the  Pre-RELAX-AHF  trial,  AEs  and  SAEs  were  assessed  up  to  Day  30.  The RELAX-AHF  study  protocol  required  the  collection  of  all  AEs  through  Day  5  after  initiating treatment  and  all  SAEs  through  Day  14.  These  choices  were  based  on  the  short-term  IV exposure of serelaxin. In the Pre-RELAX-AHF trial, 38% of the AEs were reported after 5 days (assessor's count); similarly, 34% of the SAEs were reported after Day 15. Thus, the collection period for both SAEs and AEs was rather short, especially where the Applicant claims a beneficial effect after 180 days.

<div style=\"page-break-after: always\"></div>

## Disease-related events

In  both  Pre-RELAX-AHF  and  RELAX-AHF,  a  list  of  AEs  was  pre-specified  as  'disease-related events' or DREs (indicated with an asterisk), which were considered as part of the natural history of the underlying disease and therefore were to be anticipated for the condition. For 'expected' DREs  the  usual  24-hour  sponsor  notification  did  not  apply  (but  SUSARs  were  still  reported expeditely). DREs appear together with (S)AEs in the listings that are provided. It is confusing that  some  terms  appear  both  as  an  (S)AE  and  DRE  (e.g.  hypotension).  However,  this  'DRE' concept does not further impact the safety analysis and is acceptable.

## AEs by SOC

Approximately  50% of  the  patients  in  the  serelaxin  groups  experienced  at  least  one  AE  from study drug initiation to Day 5 with a slightly lower percentage compared to the placebo group. The  most  commonly  reported  primary  SOCs  were  cardiac  disorders  (201  patients,  14.7%), metabolism  and  nutrition  disorders  (158  patients,  11.5%),  gastrointestinal  disorders  (119 patients, 8.7%) and vascular disorders (118 patients, 8.6%). The incidence of cardiac disorders was lower in the serelaxin groups compared to the placebo group (table 6).

Table 6 Incidence of adverse events by system organ class from Study Drug Initiation to Day 5 (Population: Safety Set - Pooled RELAX-AHF and Pre-RELAX-AHF)

| System Organ Class                                | Placebo (N=631) n(%)   | RLX030 30 μg/kg/day (N=610) n(% )   | RLX030 <=30 μg/kg/day (N=650) n(% )   | AlI Serelaxin (N=737) n(%)   | Total (N=1368) n(%)   |
|---------------------------------------------------|------------------------|-------------------------------------|---------------------------------------|------------------------------|-----------------------|
| PatientsWithatLeastOneAE                          | 344 (54.5)             | 302 (49.5)                          | 331 (50.9)                            | 377 (51.2)                   | 721 (52.7)            |
| BloodAnd LymphaticSystemDisorders                 | 7 (1.1)                | 11 ( 1.8)                           | 11 (1.7)                              | 12 (1.6)                     | 19 ( 1.4)             |
| Cardiac Disorders                                 | 105 ( 16.6)            | 77 ( 12.6)                          | 87 (13.4)                             | 96 ( 13.0)                   | 201 ( 14.7)           |
| Congenital,Familial And Genetic Disorders         | 1 ( 0.2)               | 0 ( 0.0)                            | 1 (0.2)                               | 1 (0.1)                      | 2 ( 0.1)              |
| EarAnd LabyrinthDisorders                         | 4 ( 0.6)               | 2 ( 0.3)                            | 2 ( 0.3)                              | 2 ( 0.3)                     | 6 ( 0.4)              |
| EndocrineDisorders                                | 3(0.5)                 | 1 (0.2)                             | 1 ( 0.2)                              | 1(0.1)                       | 4 ( 0.3)              |
| Eye Disorders                                     | 1 ( 0.2)               | 3 (0.5)                             | 3 (0.5)                               | 3 (0.4)                      | 4 ( 0.3)              |
| Gastrointestinal Disorders                        | 61 (9.7)               | 48 ( 7.9)                           | 54 ( 8.3)                             | 58 (7.9)                     | 119 (8.7)             |
| GeneralDisordersAndAdministration Site Conditions | 42 (6.7)               | 34 (5.6)                            | 37 (5.7)                              | 42 (5.7)                     | 84 ( 6.1)             |
| HepatobiliaryDisorders                            | 10 (1.6)               | 1 ( 0.2)                            | 1 (μ 0.2)                             | 1 ( 0.1)                     | 11 ( 0.8)             |
| ImmuneSystemDisorders                             | 0 ( 0.0)               | 0 ( 0.0)                            | 0 ( 0.0)                              | 1 (0.1)                      | 1 ( 0.1)              |
| InfectionsAndInfestations                         | 30 ( 4.8)              | 27 ( 4.4)                           | 29 ( 4.5)                             | 34 ( 4.6)                    | 64 ( 4.7)             |
| Injury,Poisoning And Procedural Complications     | 1 (0.2)                | 4 (0.7)                             | 4 (0.6)                               | 4 ( 0.5)                     | 5 ( 0.4)              |
| Investigations                                    | 45 (7.1)               | 34 ( 5.6)                           | 35 (5.4)                              | 41 (5.6)                     | 86 ( 6.3)             |
| MetabolismAnd NutritionDisorders                  | 74 (11.7)              | 72 (11.8)                           | 77 (11.8)                             | 84 (11.4)                    | 158 ( 11.5)           |
| Musculoskeletal And ConnectiveTissue Disorders    | 22 ( 3.5)              | 28 ( 4.6)                           | 33 ( 5.1)                             | 39 ( 5.3)                    | 61 ( 4.5)             |

<div style=\"page-break-after: always\"></div>

| NeoplasmsBenign,MalignantAnd Unspecified (Inc. Cysts And Polyps)   | 2 ( 0.3)   | 4 (0.7)   | 4 ( 0.6)   | 4 ( 0.5)   | 6 (0.4)    |
|--------------------------------------------------------------------|------------|-----------|------------|------------|------------|
| Nervous System Disorders                                           | 51 ( 8.1)  | 32 ( 5.2) | 34 ( 5.2)  | 37 ( 5.0)  | 88 ( 6.4)  |
| PsychiatricDisorders                                               | 34 (5.4)   | 23 ( 3.8) | 23 (3.5)   | 27 (3.7)   | 61 (4.5)   |
| RenalAnd UrinaryDisorders                                          | 35 ( 5.5)  | 27 ( 4.4) | 28 ( 4.3)  | 33 ( 4.5)  | 68 ( 5.0)  |
| ReproductiveSystemAnd Breast Disorders                             | 0 (0.0)    | 2 ( 0.3)  | 3 ( 0.5)   | 4 (0.5)    | 4 ( 0.3)   |
| Respiratory,ThoracicAndMediastinal Disorders                       | 63 ( 10.0) | 32 ( 5.2) | 34 ( 5.2)  | 38 ( 5.2)  | 101 ( 7.4) |
| SkinAndSubcutaneousTissueDisorders                                 | 3 (0.5)    | 7 ( 1.1)  | 7 ( 1.1)   | 7 (0.9)    | 10 (0.7)   |
| VascularDisorders                                                  | 52 (8.2)   | 36 (5.9)  | 49 ( 7.5)  | 66 (9.0)   | 118 (8.6)  |

Note:PatientsarecountedonceperSoC

Note:IncidentAEs are considered thoseAEswith an onsetdate and time after theinitiationofstudy drug. Note:'PatientsWith at Least One AE'counts everypatient,who experienced an AE episode in this interval Source:[SCS-Appendix1-Table14.3.1-5]

## AEs by PT and Causality

Hypokalaemia* (7.1% in serelaxin 30 µg/kg/day, 7.2% in serelaxin ≤30 µg/kg/day and 6.0% in placebo) and hypotension (1.6% in serelaxin 30 µg/kg/day, 1.5% in serelaxin ≤30 µg/kg/day and 0.2% in placebo) were the most common AEs reported by higher percentages of patients in the  serelaxin  dose  groups  compared  to  the  placebo  group,  and  with  a  difference  of  ≥1.0% between serelaxin 30 µg/kg/day group and the placebo group. No other AEs were reported with a difference in incidence ≥1% in any of the serelaxin dose groups above placebo ( Table 7 ).

Table 7 Incidence of Adverse Events from study drug initiation to Day 5 (at least 1.0% in any group) (Population: Safety Set - Pooled RELAX-AHF and Pre-RELAX-AHF)

| Preferred Term                | Placebo (N=631) n(%)   | Serelaxin 30µg/kg/d (N=610) n(%)   | Serelaxin ≤30µg/kg/d (N=650) n(%)   | All Serelaxin (N=737) n(%)   |
|-------------------------------|------------------------|------------------------------------|-------------------------------------|------------------------------|
| Subjects With at Least One AE | 344 (54.5)             | 302 (49.5)                         | 331 (50.9)                          | 377 (51.2)                   |
| Hypokalaemia*                 | 38 (6.0)               | 43 (7.1)                           | 47 (7.2)                            | 50 (6.8)                     |
| Cardiac Failure Congestive*   | 39 (6.2)               | 23 (3.8)                           | 27 (4.2)                            | 31 (4.2)                     |
| Blood Creatinine Increased*   | 26 (4.1)               | 17 (2.8)                           | 18 (2.8)                            | 23 (3.1)                     |
| Headache                      | 33 (5.2)               | 16 (2.6)                           | 17 (2.6)                            | 19 (2.6)                     |
| Constipation                  | 16 (2.5)               | 15 (2.5)                           | 15 (2.3)                            | 15 (2.0)                     |
| Chest Pain*                   | 8 (1.3)                | 11 (1.8)                           | 12 (1.8)                            | 14 (1.9)                     |
| Diarrhoea                     | 20 (3.2)               | 11 (1.8)                           | 13 (2.0)                            | 14 (1.9)                     |
| Dyspnoea*                     | 25 (4.0)               | 11 (1.8)                           | 12 (1.8)                            | 14 (1.9)                     |
| Urinary Tract Infection       | 6 (1.0)                | 11 (1.8)                           | 11 (1.7)                            | 13 (1.8)                     |
| Hypoglycaemia                 | 17 (2.7)               | 10 (1.6)                           | 10 (1.5)                            | 11 (1.5)                     |

<div style=\"page-break-after: always\"></div>

| Hypotension              | 1 (0.2)   | 10 (1.6)   | 10 (1.5)   | 10 (1.4)   |
|--------------------------|-----------|------------|------------|------------|
| Hypotension*             | 13 (2.1)  | 10 (1.6)   | 18 (2.8)   | 31 (4.2)   |
| Renal Failure*           | 25 (4.0)  | 10 (1.6)   | 11 (1.7)   | 14 (1.9)   |
| Hyperuricaemia           | 10 (1.6)  | 8 (1.3)    | 8 (1.2)    | 8 (1.1)    |
| Insomnia                 | 10 (1.6)  | 8 (1.3)    | 8 (1.2)    | 9 (1.2)    |
| Vomiting                 | 7 (1.1)   | 8 (1.3)    | 9 (1.4)    | 10 (1.4)   |
| Back Pain                | 3 (0.5)   | 7 (1.2)    | 9 (1.4)    | 9 (1.2)    |
| Dizziness                | 12 (1.9)  | 7 (1.2)    | 8 (1.2)    | 8 (1.1)    |
| Hypertension*            | 23 (3.6)  | 7 (1.2)    | 11 (1.7)   | 14 (1.9)   |
| Anaemia                  | 2 ( 0.3)  | 6 ( 1.0)   | 6 ( 0.9)   | 7 ( 0.9)   |
| Asthenia                 | 10 (1.6)  | 6 (1.0)    | 6 (0.9)    | 8 (1.1)    |
| Hyperglycaemia           | 5 ( 0.8)  | 6 ( 1.0)   | 6 ( 0.9)   | 6 ( 0.8)   |
| Non-Cardiac Chest Pain*  | 6 (1.0)   | 6 (1.0)    | 7 (1.1)    | 7 (0.9)    |
| Pain In Extremity        | 6 (1.0)   | 6 (1.0)    | 8 (1.2)    | 9 (1.2)    |
| Cardiac Failure*         | 9 (1.4)   | 5 (0.8)    | 6 (0.9)    | 9 (1.2)    |
| Nausea                   | 13 (2.1)  | 5 (0.8)    | 5 (0.8)    | 7 (0.9)    |
| Phlebitis                | 7 (1.1)   | 5 (0.8)    | 7 (1.1)    | 7 (0.9)    |
| Pneumonia                | 7 (1.1)   | 5 (0.8)    | 5 (0.8)    | 5 (0.7)    |
| Confusional State        | 8 (1.3)   | 4 (0.7)    | 4 (0.6)    | 4 (0.5)    |
| Ventricular Tachycardia* | 12 (1.9)  | 4 (0.7)    | 6 (0.9)    | 7 (0.9)    |
| Anxiety                  | 6 ( 1.0)  | 3 ( 0.5)   | 3 ( 0.5)   | 4 ( 0.5)   |
| Atrial Flutter*          | 6 ( 1.0)  | 3 ( 0.5)   | 6 ( 0.9)   | 6 ( 0.8)   |
| Cough                    | 10 (1.6)  | 2 (0.3)    | 2 (0.3)    | 3 (0.4)    |

Note: Incident AEs are considered those AEs with an onset date and time after the initiation of study drug.

Source: [SCS-Table 2-2]

Potential ADRs were defined as those all-treatment emergent AEs through Day 5 that occurred with a 1% higher frequency in the serelaxin 30 µg/kg/day group compared to the placebo group in the pooled RELAX-AHF and Pre-RELAX-AHF population. Applying the 1% higher frequency vs.

<div style=\"page-break-after: always\"></div>

placebo, the AEs of 'hypokalaemia' and 'hypotension' (reported as symptomatic and asymptomatic hypotension) were also identified as potential ADRs for serelaxin.

The vast majority of the AEs of Hypokalaemia were observed in the two AHF studies RELAX-AHF and CRLX030A2201. In contrast, events were only sporadically reported in other HF and non-HF trials,  in  which  patients  were  exposed  in  part  to  even  higher  doses  and  for  longer  duration compared to serelaxin 30 µg/kg/day IV administered for up to 48 hours. In study RELAX-AHF, no baseline risk factors for developing hypokalaemia were identified except a slightly lower mean serum potassium level, which was well within the normal range. Kaplan-Meier estimates of the 'Time to first onset of the AE Hypokalaemia (days)' through Day 5 did not indicate that serelaxin poses an increased risk of Hypokalaemia compared to placebo. No clinically relevant changes in serum potassium through all HF and non-HF studies were identified.

The  fact  that  these  events  mainly  occurred  in  2  AHF  studies  and  the  absence  of  a  plausible mechanistic  explanation  make  it  likely  that  confounding  factors  in  AHF  patients,  such  as underlying  disease  and  background  therapy  (e.g.  diuretics)  known  to  interfere  with  the physiological potassium balance, have contributed to these events.

It  is  agreed  that  no  definite  conclusions  can  be  made  with  regard  to  hypokalaemia,  based  on currently  available  data.  This  issue  will  be  explored  further  in  an  upcoming  outcome  study, CRLX030A2301,  is  mentioned  in  SmPC  section  4.8  and  in  the  RMP  as  an  identified  risk. Furthermore it is considered that patients with AHF will be treated with diuretics, thus prompting monitoring of electrolytes. Based on current data, this approach is sufficient.

## Severity

The distribution of AEs by maximum severity was similar across the serelaxin treatment groups and placebo treatment group, and graded as mild (26.2 to 27.1% of patients), moderate (18.2 to 21.2% of patients) or severe (4.9% to 7.0% of patients). There were specifically fewer severe cardiac  failure  congestive  events  in  the  serelaxin  dose  groups  (0.2  to  0.3%)  compared  with placebo (1.4%). Similarly, there were fewer events of moderate or severe grade renal failure AEs in the serelaxin dose groups compared with placebo.

## Reversibility

There are no clinical data suggesting that serelaxin causes irreversible AEs.

## Events of special interest

Non-clinical  findings  and  findings  from  the  'legacy'  trials  are  captured  as  'events  of  special interest'.

AEs  indicative  of  renal  impairment  were  reported  by  a  lower  percentage  of  patients  in  the serelaxin 30 μg/kg/day dose group (5.9%) compared to the placebo group (9.2%) to Day 14.

The  clinical  presentation  of  the  typical  AHF  patient  often  includes  signs  and  symptoms  of congestion of the liver, with periods of hypotension, which may lead to abnormalities in LFTs. Hepatic events were reported by a lower percentage of patients in the serelaxin 30 µg/kg/day dose group (0.8%) compared to the placebo group (2.5%).

Potential  promotion  of  cancers is  an  AE  of  special  interest  based  on  theoretical  grounds. There are no clinical data supporting this, but the SAE capturing period of 14 days is too short to

<div style=\"page-break-after: always\"></div>

allow any conclusion. Based on the PRAC assessment, it was not necessary to include this as a potential risk in the RMP because it was considered too implausible.

There were four events of bone fracture in the serelaxin database. Two events occurred in the serelaxin  arm  in  Pre-RELAX-AHF  and  occurred  at  Day  30  following  serelaxin  infusion  of  10 µg/kg/day (finger fracture, 57 year old Male) and at Day 36 following infusion of 250 µg/kg/day (pelvic  fracture,  82  year  old  male).  Two  events  of  bone  fracture  also  occurred  in  the  30 µg/kg/day serelaxin arm in the RELAX-AHF study, both in the setting of falls (hip fracture in a 90 year old female on Day 4 and femoral neck fracture in an 85 year old male on Day 12); neither of these events was suspected to be drug-related. The event onset, location of fractures, and/or the circumstances of these cases (e.g., falls) make a causal relationship between serelaxin and these fractures unlikely. Based on the PRAC assessment, it was not necessary to include this as a potential risk in the RMP because it was not considered relevant to single dose administration in humans.

No adverse effects indicating arrhythmogenic or QT prolonging properties of serelaxin have been observed  in  clinical  trials.  In  the  pooled  dataset  of  study  Pre-RELAX-AHF  and  RELAX-AHF,  no differences were observed in AEs related to cardiac arrhythmias.

## Serious adverse event/deaths/other significant events Deaths

A  lower  percentage  of  patients  in  the  serelaxin  dose  group  30  µg/kg/day  (44  patients,  K-M estimate 7.4%) compared to the placebo group (72 patients, K-M estimate 11.7%) died due to all causes through Day 180 (hazard ratio (HR) = 0.61, 95% CI: 0.42, 0.89, p=0.0110) ( Figure 10 ).  K-M  estimates  of  all-cause  mortality  were  in  favour  of  the  serelaxin  dose  group  30 µg/kg/day (3.6%, 95% CI: 2.4, 5.5) compared to the placebo group 5.4%, 95% CI: 3.9, 7.5) at Day 60. This analysis is consistent in subgroups, with two notable exceptions: Baseline SBP &lt; 130 mmHg (SBP &gt; 125 mmHg was an inclusion criterion for the trials; placebo: 21/129 (17,0%); serelaxin 30 µg/kg/day: 19/108 (18,0%) HR 1.04, 95% CI 0.56-1.94) and Baseline eGFR ≥ 60 mL/min/m² (serelaxin 30 µg/kg/day: 11/171 (6,6%) placebo: 8/187 (4,4%); HR: 1.51, 95% CI: 0.61-3.74). The Applicant ascribes these findings to possible chance and this is accepted.

## Figure  10  Kaplan-Meier  plot  of  all-cause  mortality  through  Day  180  (ITT  set,  pooled Pre-RELAX-AHF and RELAX-AHF)

<div style=\"page-break-after: always\"></div>

## Comparison=Placebo vs Serelaxin 30ug/kg/d

<!-- image -->

Hazard ratio (hazard ratio&lt;1.0 favours serelaxin) and 95%  CI:  0.63  (0.43, 0.91), pvalue=0.0134

Source: [SCE Figure 3-10]

Adjudicated causes of death are shown in Table 8.

A higher proportion of patients in the placebo group (53 patients, K-M estimate 9.4%) compared to the serelaxin group (34 patients, K-M estimate 6.0%) were reported as having deaths due to CV causes. The most commonly reported CV causes of death were heart failure/pump failure (37 patients, 3.3%), sudden death (24 patients, 2.2%). Heart failure/pump failure was reported by similar percentages of patients (3.6% in serelaxin and 3.1% in placebo), while sudden death was reported  by  a  higher  percentage  of  patients  in  the  placebo  group  compared  to  the  serelaxin group (3.0% in placebo vs. 1.5% in serelaxin.

CV Mortality was an exploratory efficacy endpoint in RELAX-AHF and all-cause mortality was a safety  measure  in  the  RELAX  program.  The  potential  benefit  however,  is  important  and  the hypothesis  is  intriguing.  It  is  not  easy  to  link  the  primary  pharmacology  of  serelaxin  (as demonstrated  in  humans)  to  this  potential  mortality  benefit.  A  similar  benefit  has  not  been shown for other vasodilatators like nitrates. Exploratory analyses presented in the dossier have linked  the  mortality  finding  to  prevention  of  WHF,  worsening  renal  failure  and  to  biomarkers related  to  organ  damage  (Heart  -  troponin-T,  Kidney  -  Cystatin-C)  and  congestion  (NT-proBNP).

<div style=\"page-break-after: always\"></div>

Table 8 Adjudicated causes of death in RELAX-AHF through Day 180.

|                                           |                                          | Placebo (N=570)   | RLX030 (N=568)   | Total (N=1138)   |
|-------------------------------------------|------------------------------------------|-------------------|------------------|------------------|
| Best Available Classification of Causeof  | Best Available Classification of Causeof |                   |                  |                  |
| Death ThroughDay180[1]                    |                                          |                   |                  |                  |
| All causes                                | n （8)                                    | 64(11.3)          | 41(7.3)          | 105(9.3)         |
| Cardiovascular cause                      | n (%)                                    | 53(9.4)           | 34(6.0)          | 87(7.7)          |
| Heart Failure/Pump Failure                | n (8)                                    | 17(3.1)           | 20(3.6)          | 37(3.3)          |
| Sudden Death                              | n (%)                                    | 16(3.0)           | 8 (1.5)          | 24(2.2)          |
| Acute coronary syndrome                   | n (8)                                    | 1 (0.2)           | 1 (0.2)          | 2(0.2)           |
| Cardiac Procedure Complication            | n                                        | 1 (0.2)           | 0 (0.0)          | 1 (0.1)          |
| Other Cardiac Death                       | n (8)                                    | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Cerebrovascular Accident/stroke           | n (8)                                    | 8 (1.5)           | 1 (0.2)          | 9 (0.8)          |
| Peripheral Vascular Disease               | n (8)                                    | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Systemic Embolus                          | n (8)                                    | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Pulmonary Embolus                         | n (8)                                    | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Vascular Procedure Complication           | n (%)                                    | 3 (0.6)           | 0 (0.0)          | 3 (0.3)          |
| Other Vascular Death                      | n (8)                                    | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Renal Failure                             | n (8)                                    | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Pulmonary                                 | (8)                                      | 2 (0.4)           | 0 (0.0)          | 2 (0.2)          |
| Pneumonia                                 | u n                                      | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Sepsis                                    | n (8)                                    | 6 (1.2)           | 3 (0.6)          | 9 (0.9)          |
| Other Infection                           | n (告)                                    | 0 (0.0)           | 2 (0.4)          | 2 (0.2)          |
| Gastrointestinal                          | n (%)                                    | 0 (0.0)           | 1 (0.2)          | 1 (0.1)          |
| Seizure                                   | n                                        | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Other Neurologic                          |                                          |                   | 0 (0.0)          | 0 (0.0)          |
|                                           | n (8)                                    | 0 (0.0)           |                  |                  |
| Hematologic Maligmancy                    | n (%) n (%)                              | 1 (0.2) 2 (0.4)   | 0 (0.0) 1 (0.2)  | (0.1) 3 (0.3)    |
| Other Non-cardiovascular                  | n (8)                                    | 0 (0.0)           | 0 (0.0)          | 0(0.0)           |
| Non-cardiovascular Procedure Complication | (%)                                      | 0 (0.0)           | 0 (0.0)          | 0(0.0)           |
| Presumed Cardiovascular Death/Unknown     | n （)                                     | 7 (1.3)           | 4 (0.7)          | 11(1.0)          |
| Investigator Classificationof Cause of    |                                          |                   |                  |                  |
| Death Through Day180 All causes           | n                                        | 64 (11.3)         | 41(7.3)          | 105(9.3)         |
| Cardiovascular cause                      | n (8)                                    | 50 (8.9)          | 34(6.0)          | 84(7.5)          |
| Heart failure/pump failure                | n (%)                                    | 18(3.3)           | 18(3.2)          | 36(3.3)          |
| Sudden death                              | n (8)                                    | 9 (1.7)           | 8(1.5)           | 17(1.6)          |
| Acute coronary syndrome                   | n (%)                                    | 1 (0.2)           | 1(0.2)           | 2(0.2)           |
| Cardiac procedure                         | n (8)                                    | 1 (0.2)           | 1 (0.2)          | 2 (0.2)          |
| Other cardiac                             | n (%)                                    | 1 (0.2)           | 2 (0.4)          | 3 (0.3)          |
| Cerebral vascular accident(cVA)/stroke    | n                                        | 6 (1.1)           | 2 (0.4)          | 8 (0.7}          |
| Peripheral vascular disease               | n (%)                                    | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Systemic embolus                          | n                                        | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Pulmonary embolus                         | n (%)                                    | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Vascular procedural complication          | n (名)                                    | 1 (0.2)           | 0 (0.0)          | 1 (0.1)          |
| Other vascular death                      | n                                        | 1 (0.2)           | 0 (0.0)          | 1 (0.1)          |
| Renal                                     | n (8)                                    | 1 (0.2)           | 1 (0.2)          | 2 (0.2)          |
| Pulmonary                                 | n (%)                                    | 3 (0.6)           | 0 (0.0)          | 3 (0.3)          |
| Pneumonia                                 | n (%)                                    | 2 (0.4)           | 0 (0.0)          | 2 (0.2)          |
| Sepsis                                    | n                                        | 4 (0.8)           | 3 (0.6)          | 7 (0.7)          |
| Other infection                           | n                                        | 0 (0.0)           | 1 (0.2)          | 1 (0.1)          |
| Gastrointestinal                          | n (%)                                    | 0 (0.0)           | 1 (0.2)          | 1 (0.1)          |
| Seizure                                   | n ()                                     | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          |
| Other neurological                        | n (%)                                    | 3 (0.6)           | 0 (0.0)          | 3 (0.3)          |
| Hematological                             | n                                        | 0 (0.0)           | 0 (0.0)          | 0(0.0)           |
| Malignancy                                | n                                        | 1 (0.2)           | 1 (0.2)          | 2(0.2)           |
| Other non-cardiovascular                  | n (%)                                    | 0 (0.0)           | 0 (0.0)          | 0(0.0)           |
| Unknown                                   | n (%)                                    | 12(2.3)           | 2 (0.4)          | 14(1.3)          |

[1] Classification by CEc.

Note:Percentagesrepresent Kaplan-Meierestimate of the Day 180 eventrate.

The mortality findings are regarded as hypothesis-generating and the hypothesis that serelaxin improves the outcome for patients with AHF deserves further investigation

## SAEs

<div style=\"page-break-after: always\"></div>

A higher percentage of patients in the serelaxin 30 µg/kg/day dose group (92 patients, 15.1%) compared to the placebo group (82 patients, 13.0%) reported at least one SAE from study drug initiation  to  Day  14.  Similar  percentages  of  patients  in  each  serelaxin  dose  group  reported  at least one SAE from study drug initiation to Day 14. The Applicant has not summarised the total number of SAEs. ( Table 9 ).

Table 9 Incidence of Serious Adverse Events (SAEs) From Study Drug Initiation to Day 14 (Population: Safety Set - Pooled RELAX-AHF and Pre-RELAX-AHF)

| System Organ Class                                                   | Placebo (N=631) n(%)   | Serelaxin 30 µg/kg/d (N=610) n(%)   | Serelaxin ≤30 µg/kg/d (N=650) n(%)   | Serelaxin All (N=737) n(%)   | Total (N=1368) n(%)   |
|----------------------------------------------------------------------|------------------------|-------------------------------------|--------------------------------------|------------------------------|-----------------------|
| Patients with at least one SAE                                       | 82 (13.0)              | 92 (15.1)                           | 97 (14.9)                            | 108 (14.7)                   | 190 (13.9)            |
| Blood and Lymphatic System Disorders                                 | 3 (0.5)                | 1 (0.2)                             | 1 (0.2)                              | 1 (0.1)                      | 4 (0.3)               |
| Cardiac Disorders                                                    | 45 (7.1)               | 39 (6.4)                            | 42 (6.5)                             | 44 (6.0)                     | 89 (6.5)              |
| Gastrointestinal Disorders                                           | 3 (0.5)                | 2 (0.3)                             | 2 (0.3)                              | 2 (0.3)                      | 5 (0.4)               |
| General Disorders and Administration Site Conditions                 | 0 (0.0)                | 3 (0.5)                             | 3 (0.5)                              | 3 (0.4)                      | 3 (0.2)               |
| Hepatobiliary Disorders                                              | 3 (0.5)                | 0 (0.0)                             | 0 (0.0)                              | 0 (0.0)                      | 3 (0.2)               |
| Infections and Infestations                                          | 14 (2.2)               | 9 (1.5)                             | 10 (1.5)                             | 13 (1.8)                     | 27 (2.0)              |
| Injury, Poisoning and Procedural Complications                       | 0 (0.0)                | 5 (0.8)                             | 6 (0.9)                              | 6 (0.8)                      | 6 (0.4)               |
| Investigations                                                       | 1 (0.2)                | 2 (0.3)                             | 2 (0.3)                              | 2 (0.3)                      | 3 (0.2)               |
| Metabolism and Nutrition Disorders                                   | 1 (0.2)                | 6 (1.0)                             | 7 (1.1)                              | 8 (1.1)                      | 9 (0.7)               |
| Musculoskeletal and Connective Tissue Disorders                      | 1 (0.2)                | 0 (0.0)                             | 0 (0.0)                              | 0 (0.0)                      | 1 (0.1)               |
| Neoplasms Benign, Malignant and Unspecified (Incl. Cysts and Polyps) | 3 (0.5)                | 3 (0.5)                             | 3 (0.5)                              | 3 (0.4)                      | 6 (0.4)               |
| Nervous System Disorders                                             | 6 (1.0)                | 8 (1.3)                             | 8 (1.2)                              | 8 (1.1)                      | 14 (1.0)              |
| Psychiatric Disorders                                                | 0 (0.0)                | 3 (0.5)                             | 3 (0.5)                              | 3 (0.4)                      | 3 (0.2)               |
| Renal and Urinary Disorders                                          | 7 (1.1)                | 10 (1.6)                            | 10 (1.5)                             | 12 (1.6)                     | 19 (1.4)              |

<div style=\"page-break-after: always\"></div>

| System Organ Class                              | Placebo (N=631) n(%)   | Serelaxin 30 µg/kg/d (N=610) n(%)   | Serelaxin ≤30 µg/kg/d (N=650) n(%)   | Serelaxin All (N=737) n(%)   | Total (N=1368) n(%)   |
|-------------------------------------------------|------------------------|-------------------------------------|--------------------------------------|------------------------------|-----------------------|
| Respiratory, Thoracic and Mediastinal Disorders | 6 (1.0)                | 13 (2.1)                            | 13 (2.0)                             | 15 (2.0)                     | 21 (1.5)              |
| Skin and Subcutaneous Tissue Disorders          | 1 (0.2)                | 0 (0.0)                             | 0 (0.0)                              | 0 (0.0)                      | 1 (0.1)               |
| Surgical and Medical Procedures                 | 1 (0.2)                | 0 (0.0)                             | 0 (0.0)                              | 0 (0.0)                      | 1 (0.1)               |
| Vascular Disorders                              | 2 (0.3)                | 2 (0.3)                             | 2 (0.3)                              | 4 (0.5)                      | 6 (0.4)               |

Note: Patients are counted once per SOC.

The most commonly reported primary SOCs were cardiac disorders (6.4% vs.7.1%), infections and  infestations  (1.5%  vs.  2.2%),  respiratory,  thoracic  and  mediastinal  disorders  (2.1%  vs. 1.0%) and renal and urinary disorders (1.6%vs. 1.1%) in the serelaxin 30 µg/kg/day dose group and placebo group, respectively. Cardiac failure* was reported by a higher percentage of patients in the serelaxin 30 µg/kg/day dose group (8 patients, 1.3%) compared to the placebo group (4 patients,  0.6%;)  and  the  incidence  of  CHF  through  Day  14  when  three  related  PTs  of  cardiac failure  acute,  cardiac  failure  congestive,  and  cardiac  failure  were  combined  were  22  patients (3.6%) vs. 19 patients (3.0%) in the serelaxin and placebo groups, respectively.

Respiratory,  Thoracic  and  Mediastinal  Disorders  were  the  only  SOC  that  occurred  ≥1%  more frequently in the serelaxin group (placebo 6/631 (1.0%) vs serelaxin 13/610 (2.1%)).

## Laboratory findings Haematology

In  the  pooled  RELAX-AHF  and  Pre-RELAX-AHF  studies,  higher  proportions  of  patients  in  the serelaxin group compared to the placebo group reported &gt;20% decrease from baseline to Day 14  for  haemoglobin  (9  patients,  1.5%  vs.  4  patients,  0.6%,  respectively),  haematocrit  (10 patients, 1.6% vs. 4 patients, 0.6%, respectively) and red blood cells (RBC) (7 patients, 1.1% vs. 4 patients, 0.6%, respectively. It is not clear if these events occurred in the same patients.

On Day 2 in RELAX AHF, the median change from baseline for Haemoglobin was +0,1 g/dL in the placebo group vs -0,2 g/dL in the serelaxin group (RELAX AHF CSR, Table 14.3-6.1.1).

The  applicant  attributes  these  changes  to  haemodilution,  which  would  be  consistent  with  the vasodilation caused by serelaxin. However, the 25% increase in plasma volume after initiation of treatment for AHF required to explain a 20% drop haemoglobin seems not realistic. Moreover, median decreases in weight were similar in the placebo and serelaxin groups of RELAX AHF

## Clinical Chemistry

In  the  RELAX-AHF  study,  in  general,  smaller  percentages  of  patients  had  serum  creatinine increases at any post-baseline visit in the serelaxin dose group 30 µg/kg/day compared to the

<div style=\"page-break-after: always\"></div>

placebo group for increases ≥ 0.3 mg/dL (52.5% vs. 58.4%), ≥ 0.5 mg/dL (27.7% vs. 33.3%), ≥ 1.0 mg/dL (7.4% vs. 9.0%) and &gt;50% increase from baseline (16.5% vs. 19.4%). This could be explained by a beneficial effect of serelaxin on the kidney or by differences in concomitant medication, e.g. diuretics.

In  the  Pre-RELAX  AHF  study,  there  was  a  trend  towards  more  frequently  increased  creatinine levels in the group that received 250 µg/kg/day serelaxin ( Table 1 ).

## ECGs

ECGs were evaluated in a total of 4 studies at various time points during or after study drug administration: in study R9401 conducted in 30 patients with systemic sclerosis, in RLX.CHF.001 in  16  patients  with  CHF,  study  RLXN.C.002  in  12  patients  with  systemic  sclerosis,  and  in  a substudy  in  RELAX-AHF  study  conducted  in  22  patients  who  met  ECG  analysis  eligibility requirements. Across all of these studies, no significant or apparently drug related changes were noted in ECG results.

The RELAX-substudy did not meet is objective in terms of included patients. It can be assumed that most patients in the (Pre-)RELAX-AHF program, being on a cardiology ward, had frequent ECG  examinations  and  important  changes  would  have  been  captured  as  AEs.  However,  for  a cardiology product, these data are very limited.

## Pulse, respiratory rate, body temperature, weight

Vital signs data for RELAX-AHF and Pre-RELAX-AHF were not pooled. No significant differences were detected in pulse, respiratory rate, body temperature or weight.

In RELAX-AHF, median change from baseline in weight was similar in the serelaxin and placebo groups (Day 3: serelaxin = placebo = -2.0 kg).

## Blood pressure

SBP &gt; 125 mmHg at the time of screening was required for inclusion in the RELAX-AHF trial. Mean values for SBP were comparable between the 30 µg/kg/day serelaxin group (142.6 mmHg) and placebo group (142.4 mmHg) at baseline. As expected from the PD effect of serelaxin, SBP was significantly decreased in the serelaxin group compared to the placebo group within 30 min. from the start of the infusion, reached a maximum at 8 hours, and persisted during the rest of the  infusion.  At  the  end  of  the  48-hour  infusion  period,  SBP  values  were  128.0  mmHg  in  the serelaxin group and 131.0 mmHg in the placebo group. SBP measurements were similar between the two groups by Day 4 (48 hours after cessation of infusion).

In both Pre-RELAX-AHF and RELAX-AHF, measures were proactively included in the protocol to manage  confirmed  blood  pressure  decrease  events  ( CBPDEs ).  BP  was  to  be  monitored periodically during the 48-hour treatment with serelaxin, and the dose adjusted if the patient's BP dropped below defined levels, which was documented as a CBPDE. In the RELAX-AHF study protocol,  dosing  adjustment  based  on  the  severity  of  confirmed  systolic  BP  decrease  was mandated: If  SBP  &gt;100  mmHg, but  has  decreased  by  &gt;40  mmHg  from  pre-treatment  value, adjust the serelaxin dose by reducing the infusion rate by 50% for the remainder of the 48-hour infusion time. If SBP &lt;100 mmHg, permanently terminate serelaxin infusion. This algorithm is also recommended in the SmPC.

<div style=\"page-break-after: always\"></div>

In  the  safety  population  of  RELAX-AHF,  a  greater  proportion  of  patients  on  serelaxin  (167 patients, 29.4%) compared to placebo (103 patients, 18.1%) experienced CBPDE during the 48hour  infusion  period.  The  proportion  of  placebo  patients  experiencing  a  CBPDE  is  surprisingly high; this may be related to (recovery from) the stress associated with AHF and hospitalisation.

SBP  at  baseline  did  not  predict  CBPDE.  In  the  relaxin  group,  the  mean  SBP  at  baseline  for patients with and without CBPDE were 144.1 and 142.0 mmHg respectively.

CBPDEs resulted in dose reduction (75 patients, 44.9% vs. 43 patients, 41.7%), discontinuation of study drug (107 patients, 64.1% vs. 71 patients, 68.9%) or a dose reduction followed by a discontinuation (16 patients, 9.6% vs. 12 patients, 11.7%) in the serelaxin group and placebo group, respectively. Following dosing adjustment, there was partial recovery of the SBP during the  first  60  minutes  by  approximately  10  mmHg.  The  recovery  in  the  placebo  group  was somewhat less. Five hours following event onset, the mean SBP reduction was 31.9 mmHg (from 47.8 mmHg at event onset) in the dose reduction group and 25.1 mmHg (from 41.7 mmHg at event  onset)  in  the  discontinuation  of  study  drug  subgroup.  Most  CBPDEs  had  no  or  few symptoms.

All-cause mortality (Day 180) and HF/RF rehospitalisation were higher in patients in the relaxin group of RELAX-AHF who experienced a CBPDE compared to those who did not ( Table 10 ).The effect was more pronounced in those patients who experienced a CBPDE leading to discontinuation,  i.e.  those  who  reached  SBP  &lt;100  mmHg.  Patients  who  developed  CBPDE requiring early discontinuation had lower baseline SBP (131.5 mmHg, n=91), compared to those managed with 50% dose reduction throughout the 48-hour infusion without early discontinuation (161.4  mmHg,  n=59);  in  addition,  a  higher  percentage  of  these  patients  were  in  NYHA  class III/IV (65% vs. 48%) with lower left ventricular ejection fraction (LVEF) (34% vs. 44%).

Table 10 Clinical outcomes in serelaxin group of RELAX-AHF with or without CBPDE

| Clinical outcome n(%)                     | Serelaxin (N=568)   | Serelaxin (N=568)   | Serelaxin (N=568)   |
|-------------------------------------------|---------------------|---------------------|---------------------|
| CBPDE                                     | No CBPDE            | Any CBPDE           | Discontinuation     |
| N (%) patients in category †              | 401 (70.6%)         | 167 (29.4%)         | 91 (16.0%)          |
| HF/RF rehospitalisations through Day 60 * | 38 (9.7)            | 20 (12.4)           | 13 (14.9)           |
| All-cause mortality through Day 180       | 28 (7.0)            | 13 (7.9)            | 11 (12.2)           |

Source: [SCE-Table 3-24]. 'Discontinuation' is a subgroup of 'Any CBPDE'.

The applicant claims that the treatment of patients with SBP &gt;125 mmHg only, combined with the management of SBP decreases in the protocol, has successfully managed the potential risk of hypotension. However, in RELAX-AHF, both baseline SBP &lt; 130 mmHg and CBPDE (SBP &lt; 100 mmHg)  are  associated  with  worse  outcomes.  Low  baseline  BP  is  related  to  the  risk  of  a discontinuation CBPDE. These worse outcomes might be attributable to chance.

## Safety in special populations

Most  subjects  in  the  pooled  Pre-RELAX-AHF  and  RELAX-AHF  trials  were  elderly  (77.5%  &gt;  65 years)  with  46.5%  even  older than  75  years.  In  the  elderly  patients  more AEs  were  reported

<div style=\"page-break-after: always\"></div>

than in younger patients, but in all age groups the incidence of AEs was higher with placebo than in  the  serelaxin-treated  patients.  The  events  'hypotension'  and  'hypokalaemia',  that  were classified as possible ADR based on &gt;1% higher incidence with serelaxin compared to placebo, occurred more frequently in all age groups, except hypokalaemia in the group ≥ 75 years (Table 11).

The AEs of special interest to older patients were analysed by the Applicant. Older patients have more AEs than younger patients, but this is  true  for  patients  treated  with  both  serelaxin  and placebo. Some categories in serelaxin-treated patients have a higher incidence of AEs compared to the corresponding placebo group, however this does not preferentially affect the (very) elderly and could easily be attributed to chance. The group &gt;85 years is too small to estimate the risk of AE subgroups accurately.

Table 11 Incidence of AEs by age

| Age                         | <65         | <65         | 65-75       | 65-75       | >=75        | >=75        |
|-----------------------------|-------------|-------------|-------------|-------------|-------------|-------------|
|                             | 279 (22.5%) | 279 (22.5%) | 385 (31.0%) | 385 (31.0%) | 577 (46.5%) | 577 (46.5%) |
|                             | s           | p           | s           | p           | s           | p           |
| Nr of patients (N)          | 151         | 128         | 180         | 205         | 279         | 298         |
| Incidence of AE             | 43,7%       | 48,4%       | 42,8%       | 50,7%       | 57,0%       | 59,7%       |
| blood creat increased*      | 2,0%        | 2,3%        | 1,1%        | 4,9%        | 4,3%        | 4,4%        |
| cardiac failure congestive* | 4,0%        | 7,8%        | 3,9%        | 6,3%        | 3,6%        | 5,4%        |
| hypotension                 | 1,3%        | 0,0%        | 1,1%        | 0,0%        | 2,2%        | 0,3%        |
| hypotension*                | 0,7%        | 1,6%        | 1,7%        | 2,4%        | 2,2%        | 2,0%        |
| hypokalaemia*               | 7,3%        | 3,1%        | 7,8%        | 5,4%        | 6,5%        | 7,7%        |

Notes: Assessor's table, after SCS 5.1.1.1.3. s = serelaxin 30 µg/kg/day, p = placebo

There are no data in the paediatric population.

The data summarised for safety on renal and hepatic impairment are restricted to PK evaluation, for  severe  renal  impairment  even  PK  data  are  lacking.  The  influence  of  renal  or  hepatic impairment  on  PK  is  limited.  It  is  mentioned  in  the  SmPC  that  efficacy  and  safety  in  these populations have not been studied.

## Immunological events

In RELAX AHF, anti-serelaxin antibody analysis was performed in a total of 1122 patients (559 serelaxin, 563 placebo). Anti-serelaxin antibodies were detected in one placebo-treated patient only . The Applicant decided not to analyse the Day 60 samples.

In non-HF studies development of serelaxin antibodies was also assessed. As an example, trial RLXN.C.005  was  a  randomised  controlled  Phase  II/III  Study  of  serelaxin  in  Subjects  with Systemic  Sclerosis  with  Diffuse  Scleroderma.  Study  drug  was  administered  via  continuous  SC infusion  by  a  portable  pump.  In  this  trial,  40%  of  patients  treated  with  serelaxin  developed antibodies (Table 12). However, the populationand route of administration may have contributed

<div style=\"page-break-after: always\"></div>

to this high number. Moreover, the production process of serelaxin in use at the time may not be completely comparable to the current production process.

Table 12 Incidence of anti serelaxin antibody formation in RLXN.C.005 (Scleroderma)

|                                          | Placebo   | rhRlx 10μg/kg/day   | rhRix 25μg/kg/day   | rhRlx Combined   |
|------------------------------------------|-----------|---------------------|---------------------|------------------|
| Evaluable subjects                       | 95        | 43                  | 91                  | 134              |
| Incidence ofanti-rhRix antibodyformation | 3(3%)     | 12(27%)             | 42 (46%)            | 54 (40%)         |
| Weeks to seroconversion (range)          | 4-16      | 4-24                | 2-20                | 2-24             |

Source: RLXN.C.005 CSR Table 6-16

The  screening  assays  applied  in  clinical  studies  (CRLX030A2101,  CRLX030A2103,  and  RELAXAHF, CRLX030A2201) and RLX.CHF.001 are sufficiently validated and are considered adequate.

According  to  the  guideline  on  immunogenicity  testing  ( EMA  Guideline  on  immunogenicity assessment  of  biotechnology-derived  therapeutic  proteins  [EMEA/CHMP/BMWP/14327/2006] ), the  sampling  schedule  for  detection  of  an  immune  response  should  be  adapted  and  selected individually for each product, taking into account also its pharmacokinetics. Because serelaxin is used for a single infusion with a maximum of 48 hours, it can be accepted that immunogenicity has been determined by measuring antibodies on a single time point, Day 14 (i.e. 10 days post dose).  For  most  immunogenic  events  (e.g.  vaccination)  the  antibody  response  develops  fully within  10 days.  In  cases  where  the  response  takes  longer,  after  10  days  the  antibody  titre  is already 50-80% of the maximum response. When looking at the PK, it is clear that the serum serelaxin level is very low again several hours after treatment. Therefore the time of exposure does not lead to a different conclusion with respect to the sampling time for the immunogenicity data. Based on this, the sampling time chosen by the Applicant can be accepted.

If, however, repetitive serelaxin treatments are foreseen, the immunogenicity testing has to be adapted accordingly and additional data will be required.

## Safety related to drug-drug interactions and other interactions

From  currently  available  information  in  the  RELAX-AHF  study,  concomitant  medications  most commonly used in the standard care of patients with AHF in the  hospital or emergency room setting  did  not  appear  to  alter  the  PK  or  safety  profile  of  serelaxin.  In  addition,  serelaxin  is unlikely to alter the PK of concomitant medications through direct effects on CYP enzymes, due to the lack of a potential mechanism for direct interaction.

No specific  studies  evaluating  pharmacodynamic interactions  for  serelaxin  and  other  medicinal products have been performed. The Applicant has presented theoretical considerations leading to the  conclusion  that  the  potential  for  pharmacodynamic  interactions  is  limited.  Moreover,  PD interactions did not raise concerns during RELAX-AHF. The lack of trials is clearly documented in the SmPC.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

Hypotension and Hypotension* caused 15 discontinuations in the serelaxin 30 µg/kg/day group v 8  in  the  placebo  group  (Table  13).  The  Applicant  attributes  this  to  the  protocol-specified discontinuation criteria, which are discussed above, as Confirmed Blood Pressure Decrease Event (CBPDE).  The  Applicant  has  documented  that  the  vast  majority  of  hypotension  events  were indeed captured as CBPDE.

<div style=\"page-break-after: always\"></div>

## Table 13 Incidence of Adverse Events (AEs) Leading to Study Drug Discontinuation From Study Drug Initiation to Day 5 (Population: Safety Set - Pooled RELAX-AHF and Pre-RELAX-AHF)

| System Organ Class PreferredTerm                 | Placebo (N=631) n(%)   | RLX030 30 μg/kg/day (N=610) n(%)   | RLX030 <=30 μg/kg/day (N=650) n(%)   | AlI Serelaxin (N=737) n(%)   | Total (N=1368) n(%)   |
|--------------------------------------------------|------------------------|------------------------------------|--------------------------------------|------------------------------|-----------------------|
| PatientswithAELeadingtoStudyDrug Discontinuation | 25 (4.0)               | 33(5.4)                            | 39(6.0)                              | 51(6.9)                      | 76(5.6)               |
| BloodAnd LymphaticSystemDisorders                | 0(0.0)                 | 2(0.3)                             | 2(0.3)                               | 2(0.3)                       | 2(0.1)                |
| HyperchromicAnaemia                              | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| NormochromicNormocyticAnaemia                    | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| CardiacDisorders                                 | 7(1.1)                 | 3(0.5)                             | 3(0.5)                               | 3(0.4)                       | 10(0.7)               |
| AcuteCoronarySyndrome                            | 0(0.0)                 | 1(0.2)                             | 1（0.2)                               | 1(0.1)                       | 1(0.1)                |
| Angina Pectoris*                                 | 1(0.2)                 | 0(0.0)                             | 0（0.0)                               | 0(0.0)                       | 1(0.1)                |
| AtrialFibrillation                               | 1(0.2)                 | 0(0.0)                             | 0(0.0)                               | 0(0.0)                       | 1(0.1)                |
| Atrial Flutter*                                  | 1(0.2)                 | 0(0.0)                             | 0(0.0)                               | 0(0.0)                       | 1(0.1)                |
| AtrioventricularBlockSecondDegree*               | 1(0.2)                 | 0(0.0)                             | 0(0.0)                               | 0(0.0)                       | 1(0.1)                |
| CardiacFailureAcute*                             | 1(0.2)                 | 0(0.0)                             | 0（0.0)                               | 0(0.0)                       | 1(0.1)                |
| CardiacFailureCongestive*                        | 2(0.3)                 | 0(0.0)                             | 0(0.0)                               | 0(0.0)                       | 2(0.1)                |
| CardiacFailure*                                  | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| VentricularFibrillation*                         | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| Gastrointestinal Disorders                       | 1(0.2)                 | 0(0.0)                             | 0(0.0)                               | 0(0.0)                       | 1(0.1)                |
| Nausea                                           | 1(0.2)                 | 0(0.0)                             | 0（0.0)                               | 0(0.0)                       | 1(0.1)                |
| Vomiting                                         | 1(0.2)                 | 0(0.0)                             | 0(0.0)                               | 0(0.0)                       | 1(0.1)                |
| GeneralDisordersAndAdministrationSite            | 0(0.0)                 | 3(0.5)                             | 3(0.5)                               | 3(0.4)                       | 3(0.2)                |
| Conditions                                       |                        |                                    |                                      |                              |                       |
| ChestPain*                                       | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| Fatigue                                          | 0(0.0)                 | 1（0.2)                             | 1（0.2)                               | 1(0.1)                       | 1(0.1)                |
| Hypothermia                                      | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| ImmuneSystemDisorders                            | 0(0.0)                 | 0(0.0)                             | 0(0.0)                               | 1(0.1)                       | 1(0.1)                |
| Drug Hypersensitivity                            | 0(0.0)                 | 0(0.0)                             | 0(0.0)                               | 1(0.1)                       | 1(0.1)                |
| InfectionsAnd Infestations                       | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| UrinaryTractInfection                            | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| Investigations                                   | 2(0.3)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 3(0.2)                |
| BloodPressureDecreased                           | 2(0.3)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 3(0.2)                |
| NervousSystemDisorders                           | 5(0.8)                 | 5(0.8)                             | 5(0.8)                               | 5(0.7)                       | 10(0.7)               |
| CerebrovascularAccident                          | 1(0.2)                 | 0(0.0)                             | 0(0.0)                               | 0(0.0)                       | 1(0.1)                |
| Dizziness                                        | 2(0.3)                 | 2(0.3)                             | 2(0.3)                               | 2(0.3)                       | 4(0.3)                |
| Embolic Stroke                                   | 1(0.2)                 | 0(0.0)                             | 0(0.0)                               | 0(0.0)                       | 1(0.1)                |
| Headache                                         | 1(0.2)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 2(0.1)                |
| Hypotonia                                        | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| Somnolence                                       | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| PsychiatricDisorders                             | 0(0.0)                 | 4(0.7)                             | 4(0.6)                               | 4(0.5)                       | 4(0.3)                |
| Anxiety                                          | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| Confusional State                                | 0（0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |
| Delirium                                         | 0(0.0)                 | 1(0.2)                             | 1(0.2)                               | 1(0.1)                       | 1(0.1)                |

<div style=\"page-break-after: always\"></div>

| MentalDisorderDueToAGeneralMedical Condition   | 0(0.0)   | 1(0.2)   | 1(0.2)   | 1(0.1)   | 1(0.1)   |
|------------------------------------------------|----------|----------|----------|----------|----------|
| RenalAndUrinaryDisorders                       | 1(0.2)   | 0（0.0)   | 0(0.0)   | 0(0.0)   | 1(0.1)   |
| Oliguria                                       | 1(0.2)   | 0（0.0)   | 0(0.0)   | 0(0.0)   | 1(0.1)   |
| Respiratory,ThoracicAndMediastinal             | 2(0.3)   | 2(0.3)   | 2(0.3)   | 3(0.4)   | 5(0.4)   |
| Disorders                                      |          |          |          |          |          |
| AcutePulmonaryOedema*                          | 1(0.2)   | 1(0.2)   | 1(0.2)   | 1(0.1)   | 2(0.1)   |
| AcuteRespiratoryFailure*                       | 0(0.0)   | 1（0.2)   | 1(0.2)   | 1(0.1)   | 1(0.1)   |
| Haemoptysis                                    | 0(0.0)   | 0(0.0)   | 0(0.0)   | 1(0.1)   | 1(0.1)   |
| RespiratoryFailure*                            | 1(0.2)   | 0(0.0)   | 0(0.0)   | 0(0.0)   | 1(0.1)   |
| SkinAndSubcutaneousTissueDisorders             | 1(0.2)   | 1(0.2)   | 1(0.2)   | 1(0.1)   | 2(0.1)   |
| Hyperhidrosis                                  | 1(0.2)   | 1(0.2)   | 1（0.2)   | 1(0.1)   | 2(0.1)   |
| VascularDisorders                              | 9(1.4)   | 15(2.5)  | 21(3.2)  | 31(4.2)  | 40 (2.9) |
| HotFlush                                       | 1(0.2)   | 0(0.0)   | 0(0.0)   | 0(0.0)   | 1(0.1)   |
| Hypotension                                    | 0(0.0)   | 8(1.3)   | 8(1.2)   | 8(1.1)   | 8(0.6)   |
| Hypotension*                                   | 8(1.3)   | 7(1.1)   | 13(2.0)  | 23(3.1)  | 31(2.3)  |

patientmayhaveexperiencedaneventineithercategoryatdifferenttimesduringthestudy.

*Disease-relatedevent(DRE).Theincidenceacrossthetwohypotensiontermscannotbe summed sincea

Note:Ateach levelof summation(SystemOrgan Class(SoC)andPreferred Term),patientsare counted once perSOCandpreferredterm.

Note:PatientsWithatLeastOneAEcountseverypatient,whoexperiencedanAEepisodeinthisinterval.

Note:IncidentAEsareconsidered thoseAEswithanonsetdateand timeaftertheinitiationofstudydrug.

Source:[SCS-Appendix1-Table14.3.1-8]

## Post marketing experience

## N/A

## 2.6.1. Discussion on clinical safety

The evaluation of safety is based on the pooled safety populations of Pre-RELAX-AHF and RELAXAHF,  and  describes  737  AHF  patients  who  received  serelaxin  and  631  patients  who  received placebo.  Data  from  the  older  ('legacy')  trials  suffer  from  differences  in  design,  dose,  route  of administration  and  manufacturing  processes  and  are  considered  supportive  only.  The  EMA scientific advice (EMA/CHMP/SAWP/784780/2010) considered that the size of the database might be sufficient, in relation to the benefits that would be demonstrated.

Approximately 50% of the patients in the serelaxin groups experienced at least one AE with a slightly  lower  percentage  compared  to  the  placebo  group,  driven  by  the  incidence  of  cardiac disorders. Hypokalaemia* (serelaxin: 7.1% placebo: 6.0%) and hypotension (1.6% in serelaxin 30 µg/kg/day, and 0.2% in placebo) were the only AEs reported by ≥1% more patients in the serelaxin group compared to the placebo group. These events were identified as potential ADRs for  serelaxin.  The  methods  of  the  Applicant's  AE  analysis  were  acceptable.  Hypokalaemia  was proposed to be followed as a potential risk in the EU RMP.

A  higher  percentage  of  patients  in  the  serelaxin  group  (92  patients,  15.1%)  compared  to  the placebo group (82 patients, 13.0%) reported at least one SAE from study drug initiation to Day 14.  Between  14  and  60  days,  only  hospitalisations  were  captured  (see  secondary  efficacy endpoint).

Hypotension  is  an  identified  risk  of  serelaxin  and  was  also  the  most  important  AE  leading  to discontinuation. In the AHF trials, measures were included in the protocol to mitigate this risk, including baseline SBP &gt; 125 mmHg, dose reduction if BP dropped by &gt;40 mmHg and treatment discontinuation  if  BP  &lt;100  mmHg.  This  occurred  in  more  patients  on  serelaxin  (29.4%) compared to placebo (18.1%) and resulted in dose reduction (44.9% vs. 41.7%), discontinuation (64.1% vs. 68.9%) or a dose reduction followed by a discontinuation (9.6% vs. 11.7%). These

<div style=\"page-break-after: always\"></div>

BP  events  were  associated  with  few  or  no  symptoms  in  most  patients.  Following  dosing adjustment, there was partial recovery of the SBP during the first 60 minutes by approximately 10 mmHg, somewhat less in the placebo group. Five hours following event onset, the mean SBP reduction  was  31.9  mmHg  (from  47.8  mmHg  at  event  onset)  after  dose  reduction  and  25.1 mmHg (from 41.7 mmHg at event onset) after discontinuation.

AEs  indicative  of  renal  impairment  were  reported  by  a  lower  percentage  of  patients  in  the serelaxin group (5.9%) compared to the placebo group (9.2%) to Day 14. Smaller percentages of patients had serum creatinine increases at any post-baseline visit in the serelaxin group. Also hepatic  events  (commonly  caused  by  congestion  in  these  patients)  were  reported  by  a  lower percentage of patients in the serelaxin group (0.8%) compared to the placebo group (2.5%).

Death (due to all causes by Day 180), occurred less in the serelaxin group (44 patients, K-M estimate 7.4%) compared to the placebo group (72 patients, K-M estimate 11.7%; hazard ratio (HR)  =  0.61,  95%  CI:  0.42,  0.89,  p=0.0110)  (Figure  10).  This  analysis  is  consistent  in subgroups, except in the group with baseline SBP between 125 and 130 mmHg (HR 1.04), and the group with baseline eGFR ≥ 60 mL/min/m² (HR: 1.51), which may be a chance finding The analysis of deaths adjudicated to CV causes (84% of deaths, HR = 0.63) is also consistent. The most commonly reported CV causes of death were heart failure/pump failure (3.6% in serelaxin and 3.1% in placebo) and sudden death (3.0% in the placebo group vs. 1.5% in the serelaxin group). Also non-CV deaths favoured serelaxin (7 vs. 10).

It is not easy to link the primary pharmacology of serelaxin (as demonstrated in humans) to this potential  mortality  benefit.  A  similar  benefit  has  not  been  shown  for  other  vasodilatators  like nitrates.  Exploratory  analyses  presented  in  the  dossier  have  linked  the  mortality  finding  to prevention of WHF, worsening renal failure and to biomarkers related to organ damage (Heart troponin-T, Kidney - Cystatin-C) and congestion (NT-pro-BNP).

No major laboratory findings were noted. Higher proportions of patients in the serelaxin group compared  to  the  placebo  group  reported  &gt;20%  decrease  from  baseline  to  Day  14  for haemoglobin (9 patients, 1.5% vs. 4 patients, 0.6%, respectively), haematocrit and red blood cells.  This  is  a  potential  risk  in  the  RMP  based  on  'legacy'  trials.  No  adverse  effects  indicating arrhythmogenic or QT prolonging properties of serelaxin have been observed in clinical trials. In the database, no differences were observed in AEs related to cardiac arrhythmias. No apparent changes were noted in ECG results, although only a very small number of patients were specially investigated.  There  were  no  clinically  significant  effects  on  heart  rate  in  the  RELAX  trials.  No significant differences were detected in pulse, respiratory rate, body temperature or weight. In RELAX-AHF,  median  change  from  baseline  in  weight  was  similar  in  the  serelaxin  and  placebo groups (Day 3: serelaxin = placebo = -2.0 kg).

Most subjects in the RELAX-AHF trials were elderly (77.5% &gt; 65 years) with 46.5% even older than 75 years. In the elderly patients more AEs were reported than in younger patients, but in all age groups the incidence of AEs was higher with placebo than in the serelaxin-treated patients.

In  RELAX  AHF,  anti-serelaxin  antibody  analysis  was  performed  on  Day  14.  Anti-serelaxin antibodies were detected in one placebo-treated patient only. The CHMP concluded that for this application immunogenicity poses no serious problem, but for repeat administration immunogenicity must be reassessed.

<div style=\"page-break-after: always\"></div>

In  the  RELAX-AHF  study,  routine  concomitant  medications  apparently  did  not  alter  the  PK  or safety  profile  of  serelaxin.  No  specific  studies  evaluating  pharmacodynamic  interactions  for serelaxin have been performed.

## 2.6.2. Conclusions on the clinical safety

Serelaxin has  a benign  safety profile. In the RELAX  trial, AEs  and  mortality, but not hospitalisations  favoured  serelaxin.  Hypotension  and  hypokalaemia  are  the  most  frequently occurring AEs, but they appear manageable when the right precautions are taken.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The CHMP considered that the Pharmacovigilance system Master File included in Module 1.8.1 of the submitted dossier fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means  for  the  notification  of  any  adverse  reaction  suspected  of  occurring  either  in  the Community or in a third country.

## 2.8. Risk Management Plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

Based  on  the  PRAC  review  of  the  Risk  Management  Plan  version  1.2,  the  PRAC  considers  by consensus that the risk management system for serelaxin is acceptable.

This advice is based on the following content of the Risk Management Plan:

## Safety concerns

The applicant identified the following safety concerns in the RMP:

Table 14 Summary of the Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                    |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | - Hypotension                                                                                                                                                                                                                                                 |
| Important potential risks    | - Hemoglobin/hematocrit transient decrease - Hypokalemia                                                                                                                                                                                                      |
| Missing information          | - Repeat use of serelaxin continuous IV infusion for up to 48 hours (including immunogenicity) - Patients with severe renal impairment (GFR <30 mL/min /1.73 m2) - Use in patients with relevant co-morbidities: • Cardiac diseases: Left-ventricular outflow |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | obstruction physiology (e.g. severe valvular aortic stenosis, obstructive cardiomyopathy), severe aortic regurgitation, severe mitral stenosis, acute myocarditis, cardiomyopathy (hypertrophic, restrictive or constrictive), recent acute coronary syndrome or significant arrhythmias (ventricular tachycardia, bradycardia <45 bpm, second/third degree AV block, atrial fibrillation/flutter with a ventricular response rate of >120 bpm), severe heart failure requiring mechanical support (e.g. intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device), low cardiac output or systolic blood pressure below 110 mmHg; • Severe cerebrovascular events: Recent events such as stroke; • Concomitant diseases: Active infection, fever, pulmonary disease, non-cardiac pulmonary oedema, or organ transplant. - Use in pregnant and breast-feeding women - Use in non-Caucasian patients - Use in paediatric patients <18 years |

The PRAC agreed.

## Pharmacovigilance plans

Table 15: Ongoing and planned studies in the PhV development plan

| Activity/Study title (category 1-3)*                            | Objectives                                                                                                                                                                       | Safety concerns addressed   | Status   | Date for submission of interim or final reports   |
|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|----------|---------------------------------------------------|
| Phase 3, outcome study (CRLX030A2301) Interventional Category 3 | Assess frequency, safety, tolerability and outcome, in case a patient experiences a BP decrease event. Monitor compliance with study protocol mandated study drug dose reduction | Hypotension                 | started  | Q4 2016                                           |

<div style=\"page-break-after: always\"></div>

| Activity/Study title (category 1-3)*                              | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Safety concerns addressed                                                                     | Status   | Date for submission of interim or final reports   |
|-------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------|---------------------------------------------------|
|                                                                   | and discontinuation. Assess frequency, safety, tolerability and outcome, in case a patient experiences a transient decrease in hemoglobin/hematocrit or any associated AE. Assess frequency, safety, tolerability and outcome, in case a patient experiences serum potassium decrease or any associated AE indicative of Hypokalemia. Proposed activity aims to collect data in non- Caucasian patients exposed to serelaxin, in case this become available, and | Hemoglobin/ hematocrit transient decrease Hypokalemia Use in non- Caucasian patients          |          |                                                   |
| Phase 2, repeat dose study CRLX030A2209 Interventional Category 3 | Proposed activity aims to collect data on repeat use of serelaxin continuous IV infusion for up to 48 hours and evaluate safety, tolerability and efficacy. In particular, the repeat dose study will evaluate potential anti-serelaxin Ab formation and AEs indicative of hypersensitivity reactions/immune disorders after single and                                                                                                                          | Repeat use of serelaxin continuous IV infusion for up to 48 hours (including immunogenic ity) | planned  | Q3 2016                                           |

<div style=\"page-break-after: always\"></div>

| Activity/Study title (category 1-3)*                                                                                       | Objectives                                                                                                                                                                                               | Safety concerns addressed                                              | Status   | Date for submission of interim or final reports   |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|----------|---------------------------------------------------|
|                                                                                                                            | repeat dosing and assess safety and tolerability.                                                                                                                                                        |                                                                        |          |                                                   |
| Phase 1, renal impairment PK study CRLX030A2102 Interventional Category 3                                                  | Renal impairment PK study will investigate the pharmacokinetics and safety of serelaxin in subjects with severe renal impairment (eGFR <30 mL/min/1.73 m2, not requiring dialysis) and matched controls. | Use in patients with severe renal impairment (GFR <30 mL/min /1.73 m2) | started  | Q3 2014                                           |
| PIP (EMEA 001168- PIP01-11-M01): • Phase 2 study CRLX030A2208 • Phase 3 study CRLX030A2303/ CRLX030A2303E 1 Interventional | The pediatric program is designed to evaluate the use of serelaxin for the treatment of pediatric patients from birth to <18 years with AHF following surgical repair of a congenital heart defect.      | Use in pediatric patients <18 years                                    | planned  | Q1 2021                                           |

The  PRAC,  having  considered  the  data  submitted,  was  of  the  opinion  that  the  proposed  postauthorisation  PhV  development  plan  is  sufficient  to  identify  and  characterise  the  risks  of  the product.

The PRAC also considered that routine PhV is sufficient to monitor the effectiveness of the risk minimisation measures.

## Risk minimisation measures

Table 16: Summary table of Risk Minimisation Measures

| Safety concern                              | Routine risk minimisation measures   | Additional risk minimisation measures   |
|---------------------------------------------|--------------------------------------|-----------------------------------------|
| Hypotension                                 | Labelling in SmPC/PIL                | None                                    |
| Haemoglobin/ haematocrit transient decrease | Labelling in SmPC/PIL                | None                                    |
| Medication error                            | Labelling in SmPC/PIL                | None                                    |

<div style=\"page-break-after: always\"></div>

| Microbial Contamination                                                                      | Labelling in SmPC/PIL   | None   |
|----------------------------------------------------------------------------------------------|-------------------------|--------|
| Repeat use of serelaxin continuous IV infusion for up to 48 hours (including immunogenicity) | Labelling in SmPC/PIL   | None   |
| Use in non- Caucasian patients                                                               | Labelling in SmPC/PIL   | None   |
| Use in patients with severe renal impairment (GFR <30 mL/min /1.73 m2 )                      | Labelling in SmPC/PIL   | None   |

The PRAC, having considered the data submitted, was of the opinion that the proposed routine risk  minimisation measures are sufficient to minimise the risks of the product in the proposed indication.

The CHMP endorsed this advice without changes.

## 2.9. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

Relaxin is a naturally occurring heterodimeric peptide hormone (containing a 24 amino acid Achain  and  a  29  amino  acid  B-chain);  serelaxin  is  human  recombinant  relaxin.  Relaxin  has  a physiologic  role  during  pregnancy  to  facilitate  the  adaptation  of  the  body  to  the  different circulation  of  pregnancy.  A  Marketing  Authorisation  is  sought  for  the  treatment  of  acute  heart failure (AHF) in patients with systolic blood pressure above 125 mmHg.

Pharmacodynamic  effects  of  serelaxin  in  the  vasculature  are  initiated  upon  binding  to  its  Gprotein coupled relaxin/insulin-like family peptide receptor 1 (RXFP1) and trigger the activation of  the  endothelial  endothelin  type  B  (ETB)  receptor  and  nitric  oxide  (NO)  synthase.  The  NO mediated vaso-relaxation results in a reduction of Pulmonary Capillary Wedge Pressure (PCWP), mean Pulmonary Arterial Pressure (PAP) and systemic Blood Pressure (BP). These changes are confirmed in a haemodynamic study in patients with AHF using the proposed dose as 20 hours IV infusion (Study CRLX030A2201). In this trial no change in Cardiac Index was found. Serelaxin has been shown to increase Renal Blood Flow (RBF) but not Glomerular Filtration Rate (GFR) in Study CRLX030A2202, a placebo-controlled study investigating the renal haemodynamic effects

<div style=\"page-break-after: always\"></div>

of  serelaxin  at  the  proposed  dose  rate  as  IV  infusion  for  24  hours  compared  to  placebo  in patients with chronic heart failure (CHF).

The efficacy dossier consists of one pivotal study RELAX-AHF (RLX.CHF.003). This was a Phase III,  randomised,  double-blind,  study  with  patients  receiving  a  continuous  intravenous  (IV) infusion of placebo or serelaxin (nominally 30 μg/kg/day) for up to 48 hours, in a randomised ratio of 1:1. Patients in both treatment groups also received standard therapy for AHF. Eligible patients were hospitalised for AHF and had required ≥40 mg IV furosemide since presentation. Entry  criteria  further  required  stable  systolic  blood  pressure  &gt;125  mmHg  and  impaired  renal function  (eGFR  between  30-75  mL/min/1.73  m²).  In  general  the  AHF  observed  in  the  trial population was not particularly severe or acute. In contrast to other HF trials, subjects with SBP &lt; 125 mmHg were excluded, which is consistent with the BP lowering effects of serelaxin. A total of  1161  patients  were  randomised  to  the  study  RELAX-AHF.  Vital  status  at  Day  180  was  not available for only 14 (1.2%) patients indicating adequate follow-up. Baseline characteristics were well balanced between groups.

The  first  co-primary  endpoint  was  sustained  relief  of  dyspnoea,  measured  by  the  AUC  (area under curve) representing the change in patient-reported dyspnoea from baseline measured by 100-mm  VAS  (Visual  Analog  Scale)  through  Day  5.  This  endpoint  is  acceptable  in  the EMA Guideline on the development of medicinal products for the treatment of AHF (CPMP/EWP/2986/03) ,  although 30-day all-cause mortality is preferred. The results were 2756 mm-hours  and  2308  mm-hours  in  the  serelaxin  and  placebo  groups,  respectively.  The  mean difference in VAS AUC between treatment groups was 447.7 mm-hours (95% CI 120.0, 775.4; ttest p=0.0075; Wilcoxon rank-sum test p=0.0819). The study was considered to have met the primary objective of demonstrating efficacy of serelaxin in dyspnoea relief if either co-primary endpoint was statistically significant at the two-sided 0.025 level, or if both tests were significant at the two-sided 0.05 level (Hochberg procedure). With these results, the study met this primary objective.

There  were  two  dose-response  studies  carried  out.  In  the  Phase  1  study  (RLX.CHF.001),  16 patients were treated with escalating doses (10-960 µg/kg/day) to establish a dose range to be tested. The Phase II study (Pre-RELAX-AHF, n=234), study evaluated 4 doses of serelaxin (10, 30,  100,  and  250  µg/kg/day)  vs.  Placebo.  The  30  µg/kg/day  dose  level  showed  a  statistically significant  positive  result on  the  primary  outcome (dyspnoea by Likert scale to 24 hours) and was selected for further development. Higher doses were not consistently more effective and the trial failed to identify a dose-response relationship.

In  the  RELAX-AHF  trial,  most  participants  were  elderly  subjects.  The  clinical  study  report provides data for the following age groups: &lt;65, ≥65, &lt;75 and ≥75 years. The efficacy results in the elderly populations are similar to the younger populations. As serelaxin is not metabolised and intrinsic factors like age, gender and race do not affect the pharmacokinetics of serelaxin, the product can be safely used from a pharmacokinetic point of view in such special populations.

## Uncertainty in the knowledge about the beneficial effects.

In RELAX-AHF the comparator was inactive placebo and the protocol did not strictly prescribe the use of vasodilatators (nitrates) in the control arm. This produced post-randomisation heterogeneities  between  the  study  arms,  most  importantly  a  difference  in  arterial  pressure throughout the infusion period of serelaxin (change from baseline systolic blood pressure at 9

<div style=\"page-break-after: always\"></div>

hours serelaxin 15.9 mmHg (95%CI: 14.5-17.3) and placebo 10.1 mmHg (95%CI: 8.6-11.6). Arterial pressure is a main component of cardiac afterload, a determinant of heart work and a key  target  for  therapy.  Because  the  study  protocol  did  not  lead  to  a  reasonable  use  of  i.v. nitroglycerine  (no  difference  compared  to  serelaxin  group)  while  the  vasodilatator  effect  of serelaxin resulted in the above mentioned difference in arterial pressure and heart workload, the placebo arm was undertreated during the study-drug infusion phase compared to the active arm. This casts doubts on the validity of the trial and its outcomes.

The  validity  and  clinical  relevance  of  the  findings  regarding  improvement  in  dyspnoea  were seriously  questioned  (major  objection).  VAS  measurements  for  the  primary  analysis  were imputed in patients who had died or met the criteria for the outcome Worsening Heart Failure (WHF) during the measurement period: the worst score observed in any patient at any timepoint was carried forward for all time-points after the time of onset of the event, regardless of whether  the  score  was  missing  or  not.  Thus,  despite  there  were  additional  measurements available  after  an  event  of  WHF,  the  imputed  values  were  used  instead.  This  is  an  unusual approach; the measured values should be included in the analysis (irrespective of whether WHF occurred or not) and in case of truly missing values multiple imputation is the preferred method (and not the imputation by the worst value or baseline value as the Applicant did). In RELAX-AHF the  results  were  driven  by  the  values  that  were  imputed  after  the  subject  was  classified  as having  an  event  of  WHF.  The  impact  of  these  imputed  values  was  assessed  by  sensitivity analyses. One of these employed only observed data. The mean AUC was 2908 mm-hr for the placebo group and 3034 mm-hr for the serelaxin group, resulting in a difference of 126 mm-hr (95% CI: -128,381; p = 0.33 by t-test). This corresponds to a mean improvement of only 1.1 mm, with the 95% CI including zero difference.

The clinical relevance of the AUC of VAS change from baseline as reported was questioned. The AUC-difference that was considered clinically relevant for the sample size calculation was based on an experts' opinion and was not achieved during the study. The sample size was adequate to detect a minimally clinically meaningful treatment difference of 468 mm-hour (4 mm difference across  time  points  on  average).  Compared  to  a  mean  improvement  in  VAS  of  25  mm  in  the placebo  group,  the  clinical  relevance  of  this  4  mm  difference  seems  rather  limited.  The  value observed corresponds to a mean improvement of 3.8 mm.

In  addition,  the  positive  results  on  dyspnoea  measured  by  VAS  AUC  were  not  confirmed  by  a similar effect on the co-primary endpoint measured by the Likert scale.  Apart from the effect on the dyspnoea, the results pertaining to the secondary endpoints, including effects on cardiovascular morbidity by measuring 'Days alive and out of hospital' through Day 60 and CV death or rehospitalisation through Day 60 are not supportive of a beneficial treatment effect.

A very large number of exploratory efficacy endpoints were investigated. All-cause mortality was assessed  as  a  safety  measure  at  various  time  points.  A  lower  percentage  of  patients  in  the serelaxin dose group 30 µg/kg/day (44 patients, K-M estimate 7.4%) compared to the placebo group (72 patients, K-M estimate 11.7%) died due to all causes through Day 180 (hazard ratio (HR) = 0.61, 95% CI: 0.42, 0.89, p=0.0110). Most (84%) deaths were cardiovascular; the HR for the risk of cardiovascular deaths was similar (0.63, 95% CI 0.43, 0.93). The reason for this difference  remains  unexplained.  It  could  be  a  chance  finding,  certainly  in  view  of  the  limited effects  shown  on  other  secondary  outcomes.  However,  the  haemodynamic  findings  seem favourable  and  could  contribute  to  prognostic  improvement.  Other  beneficial  effects  may  be

<div style=\"page-break-after: always\"></div>

derived from less WHF as assessed by the physicians (6.5% vs. 12%) and less use of furosemide (161  vs.  213  mg)  but  are  difficult  to  interpret.  The  biomarkers  that  were  studied,  hs-cTnT, Cystatin  C  and  NT-proBNP,  all  show  favourable  changes  in  serelaxin  patients  compared  to placebo  that  were  related  to  improved  survival  at  Day  180,  but  their  implications  remain uncertain.

Consistent  with  clinical  practice,  the  large  majority  of  participants  had  'acute  worsening  of chronic heart failure', leading to limited data on other types of patients with AHF; however the data are likely representative of the entire target population. As confirmed by the Applicant and by  investigator  during  the  GCP  inspection,  patients  were  considered  for  inclusion  only  after routine evaluations had confirmed their (potential) eligibility. This reduces the risk of selection bias. Efficacy trials in the special populations of severe renal impairment and hepatic impairment were not performed. A paediatric investigation plan was agreed, but no results of the studies agreed therein are available.

Further concerns have arisen from the number of Amendments dealing with major aspects of the study  conduct  (#3  that  increased  sample  size)  and  endpoint  adjudication  (#5  defining  the endpoint  'worsening  heart  failure').  Both  Amendments  were  introduced  in  a  late  phase  after study  initiation.  However,  after  clarifications  by  the  Applicant,  the  CHMP  agreed  that  these amendments do not jeopardise the interpretation of the trial.

As stated above, the two dose-response studies failed to identify a dose-response relationship and  higher  doses  were  not  consistently  more  effective.  The  dose-response  curves  for  the pharmacological effects of serelaxin may well be U-shaped, further complicating the characterisation of the dose-effect relations. The large number of endpoints explored and wide margin for 'favourable trend' (p &lt; 0.20) in the Phase II trial carry the risk of chance findings.

## Risks

## Unfavourable effects

The  primary  dataset  used  for  the  evaluation  of  safety  is  the  pooled  safety  population  of  PreRELAX-AHF  and  RELAX-AHF,  consisting  of  all  patients  who  received  at  least  one  dose  of  trial medication. This population consists of 737 AHF patients who received serelaxin and 631 patients who received placebo.

The number of AEs was slightly smaller in the serelaxin group compared to placebo. Two AEs were noted that occur ≥1% more frequently with serelaxin: 'hypotension' and 'hypokalaemia'. Hypotension  is  clearly  related  to  the  vasodilatatory  effect  of  serelaxin  and  was  included  as identified risk in the RMP for this product. It is not accompanied by an increase in heart rate. An SBP  of  at  least  125  mmHg  was  required  for  inclusion  in  the  trials.  The  trial  protocol  further included criteria to reduce the dose (if SBP had decreased by 40 mmHg compared to baseline) or discontinue  treatment  (if  SBP  decreased  below  100  mmHg).  These  criteria  applied in  167/568 (29.4%) of the patients in the serelaxin group of RELAX-AHF and 103/570 (18.1%) of placebo patients in the same trial. These forced dose reductions were termed 'Confirmed Blood Pressure Decrease Events' (CBPDE) in this dossier. The vast majority of hypotensive events were captured as  CBPDE.  Hypotension  was  also  the  most  frequent  AE  leading  to  discontinuation  of  the  trial. Hypokalaemia was captured as an AE in 7.1% of patients in the serelaxin 30 µg/kg/day group and  6.0%  in  the  placebo  group.  This  finding  is  not  confirmed  by  a  change  in  mean  serum

<div style=\"page-break-after: always\"></div>

potassium, although the PD trial showed a small difference in potassium excretion. The Applicant has not been able to link hypokalaemia to the mechanism of action of serelaxin and concomitant medications  are  known  to  influence  serum  potassium  levels.  Hypokalemia  was  included  as  a potential  risk  in  the  RMP  and  should  be  followed  up  in  future  trials.  Because  of  the  effects  of concomitant  medications,  serum  potassium  levels  should  be  monitored  in  clinical  practice irrespective of serelaxin use.

The number of patients who experienced at least one SAE was higher in the serelaxin group (92 patients,  15.1%)  compared  to  the  placebo  group  (82  patients,  13.0%).  There  was  no  clear pattern in these SAEs, as 'Respiratory, Thoracic and Mediastinal Disorders' was the only SOC that occurred  ≥1%  more  frequently  in  the  serelaxin  group  (placebo  6/631  (1.0%)  vs.  serelaxin 13/610 (2.1%)); cardiac SAEs were slightly less frequent with serelaxin than with placebo.

Most subjects in the RELAX-AHF trials were elderly (&gt;65 years: 77.5%) with 46.5% even older than 75 years. The analysis of AEs, SAEs and mortality is consistent over age groups.

## Uncertainty in the knowledge about the unfavourable effects

The safety database consists of 1431 AHF serelaxin-treated patients, 737 of which were treated with IV serelaxin at the proposed regimen and 410 received the full dose, which are rather small numbers, especially in a common disorder like AHF.

In  the  pooled  RELAX-AHF  and  Pre-RELAX-AHF  studies,  higher  proportions  of  patients  in  the serelaxin group compared to the placebo group reported &gt;20% decrease from baseline to Day 14  for  haemoglobin  (9  patients,  1.5%  vs.  4  patients,  0.6%,  respectively),  haematocrit  (10 patients, 1.6% vs. 4 patients, 0.6%, respectively) and red blood cells (RBC) (7 patients, 1.1% vs.  4  patients,  0.6%,  respectively.  The  applicant  attributed  these  changes  to  haemodilution, which would be consistent with the vasodilation caused by serelaxin. However, the 25% increase in  plasma  volume  after  initiation  of  treatment  for  AHF  required  to  explain  a  20%  drop haemoglobin seems not realistic. The Applicant agreed that a potential contribution of serelaxin to haemodilution cannot be excluded based on the available data. Moreover, currently a modest antidiuretic effect cannot be excluded. The SAG members confirmed that this issue is not well understood. The issues of 'Hemoglobin/hematocrit transient decrease' was included as important potential risks in the proposed RMP.

Although there are no signals concerning ECG changes or arrhythmias from the safety database or  from  preclinical  studies,  systematic  ECG  analysis  has  only  been  performed  in  very  few patients; a designated substudy of the RELAX-AHF  trial included only 22 patients.

The data summarised for safety on renal and hepatic impairment are restricted to PK evaluation. The influence of renal or hepatic impairment on PK is limited. Given that no outcome data for efficacy  and  safety  in  these  populations  were  presented,  this  information  was  reflected  in  the proposed SmPC.

Usual medications in AHF are not likely to exhibit pharmacokinetic interactions with serelaxin, based on its properties as an endogenous hormone and lack of effects on cytochrome P (CYP) enzymes.  However,  no  specific  studies  evaluating  pharmacodynamic  interactions  for  serelaxin and other products have been performed. The potential for pharmacodynamic interactions is low on theoretical grounds and the experience in RELAX-AHF.

<div style=\"page-break-after: always\"></div>

The immunologic risk of repeat administration of serelaxin in AHF cannot be assessed because of the lack of data, therefore repeated administration cannot be recommended currently.

## Benefit-risk balance

The  benefit  of  serelaxin  in  terms  of  improvement  of  dyspnoea  and  improved  survival  has  not been conclusively demonstrated due to methodological issues and questionable clinical relevance.

## Importance of favourable and unfavourable effects

The treatment focus in AHF may include rapid relief of congestion, improvement in haemodynamic status, correction of the underlying cause and reduction in mortality. According to the  EMA Guidance on clinical  investigations  of  medicinal  products  for  the treatment  of  cardiac failure/Addendum  on  acute  heart  failure  (CPMP/EWP/2986/03) ,  reduction  in  mortality  is  the preferred  primary  endpoint,  but  provided  that  a  deleterious  effect  on  mortality  is  ruled  out, improvement of symptoms and correlation of haemodynamic improvement with clinical findings can be accepted as evidence of efficacy. Based on the RELAX-AHF trial, a deleterious effect of serelaxin  on  mortality  is  unlikely;  however,  any  beneficial  effect  on  mortality  needs  to  be confirmed  by  a  separate  clinical  trial.  In  the  pharmacodynamic  trials  submitted  with  the responses  to  the  Day  12O  List  of  Questions,  the  Applicant  has  shown  that  haemodynamic improvements as an objective measure of clinical efficacy are observed.

Relief of dyspnoea was assessed for both short-term relief (6-24 h), and for persistent relief (0-5 Days). A significant effect was observed for the latter using the VAS-scale but not on the former using the Likert-scale. The VAS results turn out to be driven by imputations which were applied after rescue therapy had become necessary (termed 'worsening heart failure' or WHF). This WHF may be important in itself (see below), but the imputed values are not reflective of the dyspnoea of the patients. Moreover, the clinical relevance of the effect size was questioned.

Both all-cause and cardiovascular (CV) mortality were assessed as exploratory endpoints on Day 30,  60  and  180.  All-cause  mortality  showed  a  potential  benefit  (Hazard  ratio:  0.63;  95%  CI (0.43, 0.91), p=0.013) that even tested statistically significant at 180 days. Also reassuring in terms  of  safety,  these  exploratory  results  should  be  considered  as  hypothesis-generating  and warrant further confirmation, in particular as re-hospitalisations were in favour of placebo and the secondary endpoint 'Days Alive and Out Of Hospital' (capturing mortality, indexhospitalisation  and  re-hospitalisations)  at  Day  60  showed  a  neutral  result.  The  suggested mechanism of action (prevention of organ damage) needs further clarification, in particular the effects observed on the biomarkers such as troponins and cystatin C.

The treating physicians had a more favourable opinion about the status of the serelaxin-treated patients than about placebo patients. This is evident from exploratory variables rating physical examination  over  time,  length  of  hospital  stay,  use  of  IV  diuretics  and  occurrence  of  WHF. However,  these  findings  are  not  measures  of  patient  well-being  or  validated  surrogates  for survival.

The safety profile of serelaxin is benign, although there are some uncertainties. The database size is limited but can be accepted as discussed in the EMA scientific advice. Re-hospitalisations were  higher  with  serelaxin  but  mortality  plus  re-hospitalisations  were  roughly  in  line  for  both groups.  Pharmacodynamic  drug-drug  interactions  have  not  been  studied  specifically,  although

<div style=\"page-break-after: always\"></div>

serelaxin was investigated on top of standard of care. Management of hypotension did not result in many adverse events (AEs). Hypokalaemia may or may not be an adverse drug reaction (ADR) of serelaxin, but potassium will be routinely followed in these patients anyway. Even though not directly  relevant  for  this  assessment,  the  concern  was  raised  that  repeat  administration  and immunogenicity could pose a problem later. Fractures and promotion of cancer are rare (if at all existent) and seem unlikely ADRs after use for only 48 hours.

## Benefit-risk balance

## Discussion on the benefit-risk balance

In general, this Application was considered by the CHMP to be premature and major questions remain with regard to the clinical relevance of the findings presented in current application, the methodology  used  and  the  background  medication.  Only  one  single  pivotal  trial  has  been submitted  and,  in  accordance  with  the EMA  Points  to  Consider  on  application  with  (1) Metaanalyses (2) One pivotal study (CPMP/EWP/2330/99) such a submission has to show at least statistically compelling and clinically relevant results. In this dossier these conditions are not met and confirmatory data are needed to support evidence of clinical benefit.

In their responses to the Day 180 List of Outstanding Issues, the Applicant has provided further information about WHF as it was observed in RELAX. Although most (88%) WHF events were treated with an increase of IV diuretics, there were also 178 patients in whom the diuretic dose was doubled without WHF being defined as an endpoint.

A scientific advisory group (SAG) was convened to further discuss the clinical relevance of the findings  in  terms  of  clinical  relevance  of  the  findings  in  the  study,  the  used  methodology  and background therapy. The SAG concluded that a 4 mm reduction in VAS seems to be a very small improvement and unlikely to  be  clinically  relevant,  especially  when  most  patients  used  5  mm increments in the VAS to mark their dyspnoea status as it has been applied in scaled design. To impute  the  value  of  zero  when  WHF  has  occurred  seems  to  be  a  too  extreme  approach  and carrying it beyond the time of WHF for the rest of the measurement points too strict. The Likert scale results are in line with the VAS results when the VAS values are not imputed. The SAG experts did not consider possible to value 'clinical worsening' per se in terms of dyspnoea. These entities are too different to be combined in a single measure. The SAG commented that the VAS is  clearly  patient-reported,  but  the  classification  of  WHF  is  a  (subjective)  physician  decision. Therefore,  the  endpoint  has  characteristics  of  a  composite  endpoint.  The  attempt  to  combine these measurements by imputations after WHF is considered not robust. Thus, the Applicant has still failed to relate a mean improvement on the dyspnoea VAS scale to a relevant decrease in the  patient's  feeling  of  dyspnoea.  Instead,  in  the  responses  to  Day  18o  List  of  Outstanding Issues, the Applicant has shifted focus from the relevance of the VAS score to the relevance of WHF, far beyond what was predefined.

The definition of WHF is not yet universally agreed and it is currently not considered a parameter that can be used as a surrogate endpoint to study effects of medicinal products on cardiovascular outcome. A future role of this parameter, e.g. in guidelines, would need to be discussed further. The SAG commented that the definition criteria used in RELAX do not account for the underlying reason, i.e. do not take into account ventricular rate, occurrence of atrial fibrillation, peripheral oedema or infections like the occurrence of pneumonia, which makes the interpretation difficult.

<div style=\"page-break-after: always\"></div>

With respect to mortality, the SAG noted that the observed difference in the mortality endpoint at 6 months lacks a pathophysiological explanation given only a short term administration of the drug. It was an exploratory parameter and the study was not powered for measuring mortality as an efficacy endpoint. It was rather used as a safety parameter. The result was largely driven by CV mortality; however it has not been shown that a difference in the pump failure related events  contributed  to  a  relevant  extent.  Stroke  (placebo:  8  events,  serelaxin:  1  event) contributed significantly to the overall difference. The increase in the mortality difference over time cannot be explained on the basis of the biological activity of the compound, as known so far. Thus, it might be of added value to study this parameter in a properly designed prospective trial.

According to the SAG, the overall haemodynamic findings including effect on filling pressures are in line with decongestion. The lack of cardiac index (CI) increase was discussed and not felt to be a matter of major clinical concern, however it was not clearly understood given the reduction in systemic  vascular  resistance.  The  observed  haemodynamic  response  lacks  a  dose  response relationship explanation in the data provided so far and thus dose adjustment would be difficult if not impossible in clinical practice.

Only a small cohort of the study population was given nitrates as part of the background therapy, which was lower than the SAG members would have expected based on the available usage data (e.g.  Euro  Heart  Survey)  and  common  practice.  The  reason  is  probably  partly  investigators and partly protocol-driven (iv. nitrates in patients with SBP below 150 mm Hg were not allowed). It is not clear to which extent and in which direction the low use of nitrates might have affected the results.

Repeat  administration  has  not  been  studied  but  raises  issues  about  immunogenicity  and consequently pharmacokinetic changes and possibly hypersensitivity reactions. In this population the  indication  for  repeat  administration  will  certainly  arise.  A  clinical  trial,  as  proposed  in  the RMP, would be necessary.

It is agreed with the Applicant, based on theoretical considerations, that the risk of unexpected interactions  between  serelaxin  and  other  drugs  commonly  used  in  heart  failure  is  low.  The Applicant has initiated a large outcome trial to further define the clinical role of serelaxin.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy for Reasanz in the proposed indication of:

'the  symptomatic  treatment  of  acute  heart  failure  in  adults  with  normal  to  elevated  blood pressure  systolic  blood  pressure  above  125  mmHg.  It  should  be  used  on  top  of  standard  of care, including loop diuretics'

the CHMP considers by consensus that the efficacy of the above mentioned medicinal product is not sufficiently demonstrated. In accordance with Article 12(1) of the Regulation 726/2004 the CHMP therefore recommends the refusal of the granting of the Marketing Authorisation for the

<div style=\"page-break-after: always\"></div>

above mentioned medicinal product.

This is based on the following grounds:

- Clinical  relevance. The  Applicant  has  failed  to  relate  a  mean  improvement  on  the dyspnoea Visual Analogue Scale (VAS) scale to a relevant decrease in the patient's feeling of dyspnoea.
- Used methodology. The estimate of the effect size is not robust. The results were driven by the imputations that were applied for non-missing data after event of Worsening Heart Failure (WHF) with a large difference between the estimate according to the protocol and a conservative intention-to-treat approach based on observed values. Worsening Heart Failure cannot robustly be combined with the Visual Analogue Scale area under curve (VAS AUC) results and its use as an endpoint needs further justification.
- Background therapy. In  the  trial,  the  use  of  i.v.  nitrates  in  the  placebo  arm  was  lower than expected based on current guidelines.  Nitrates, similar to serelaxin, have vasodilating properties contributing to their therapeutic effect. Thus, this undertreatment with nitrates in the  placebo  arm  may  have  well  contributed  to  the  observed  difference  in  afterload compared with seralaxin during the period in which the primary end point was assessed, potentially affecting the size of the outcome measurement.

For  an  application  based  on  a  single  pivotal  trial  in  acute  heart  failure,  the  effect  was  not sufficiently demonstrated and the pre-defined level of clinical significance was not met. Therefore further confirmation is needed.

For these reasons, the benefit/risk of serelaxin in the proposed indication:

' symptomatic treatment of acute heart failure in adults with normal to elevated blood pressure systolic  blood  pressure  above  125  mmHg.  It  should  be  used  on  top  of  standard  of  care, including loop diuretics ' is considered as negative.

Due  to  the  aforementioned  concerns  a  satisfactory  summary  of  product  characteristics, labelling,  package  leaflet,  pharmacovigilance  system,  risk  management  plan  and  follow-up measures  to  address  other  concerns  as  outlined  in  the  list  of  outstanding  issues  cannot  be agreed at this stage.

Furthermore, the CHMP, in light of the negative recommendation, is of the opinion that it is not appropriate to conclude on the new active substance status at this time.

<div style=\"page-break-after: always\"></div>

## 5. Re-examination of the CHMP opinion of 23 January 2014

Following  the  CHMP  conclusion  that  Reasanz  (serelaxin)  was  not  approvable  in  the  proposed indication:

' symptomatic treatment of acute heart failure in adults with normal to elevated blood pressure systolic  blood  pressure  above  125  mmHg.  It  should  be  used  on  top  of  standard  of  care, including loop diuretics ', because for an application based on a single pivotal trial in acute heart failure, the effect was not sufficiently demonstrated and the pre-defined level of clinical significance was not met, the applicant submitted detailed grounds for the reexamination of the grounds for refusal.

## 5.1 Detailed grounds for re-examination submitted by the applicant

The  applicant  provided  with  the  grounds  for  re-examination  a  revised  Summary  of  Product Characteristics (SmPC), including the modified proposed indication:

Reasanz  is  indicated  for  the  treatment  of  acute  heart  failure  in  adults  with  systolic  blood pressure  above  125  mm  Hg.  It  should  be  used  on  top  of  standard  of  care,  including  loop diuretics.

The applicant presented in their submission the following grounds for re-examination:

## Ground 1a

## Clinical relevance. The Applicant has failed to relate a mean improvement on the dyspnoea Visual Analogue Scale (VAS) scale to a relevant decrease in the patient's feeling of dyspnoea.

## Summary of the Applicant's response

The  RELAX-AHF  study  met  its  primary  objective  with  serelaxin  demonstrating  a  19.4  % improvement on the dyspnea visual analog scale (VAS) area  under the  curve  (AUC)  endpoint through Day 5 versus placebo on top of standard of care (SoC). This effect is highly significant with a p-value of 0.0075 and consistent in all demographic and clinical subgroups. This result reflects  mild  improvement  in  the  patients'  shortness  of  breath  and  includes  the  clinically important 47 % reduction of worsening heart failure (WHF) episodes. Of note, this was observed following approximately 8 hours of SoC treatment before randomization and also in the context of lower diuretic use in the serelaxin group.

Importantly, the VAS AUC primary endpoint was designed as a multicomponent endpoint that captured 1) change in dyspnea score, 2) occurrence of in-hospital WHF and 3) death, making it sensitive to the entire range of patients' treatment responses. WHF represents a deterioration of the  patient's  clinical  condition  and  consequently  a  treatment  failure.  This  potentially  life threatening event profoundly alters the patient's subsequent clinical course. This is evidenced by

<div style=\"page-break-after: always\"></div>

a significant association of WHF with prolonged use of IV diuretic therapy, changes indicating a worsening  in  the  status  of  cardiovascular  and  renal  biomarkers  including  troponin  T,  longer length of stay (LoS) and increased mortality. Overall the effect of serelaxin on the primary VAS AUC endpoint therefore indicates an important and clinically relevant improvement of the clinical course of the patient by reducing these important clinical events and improving prognosis beyond current SoC. Serelaxin is the first agent to do so without adversely effecting mortality.

In  addition,  the  robustness  of  the  findings  on the  VAS  AUC  primary  endpoint  in  RELAX-AHF is supported by:

- Significantly shorter time to moderate or marked dyspnea improvement using the Likert scale and consistency with VAS AUC results in an additional analysis of the Likert primary endpoint when accounting for both improvement and worsening.
- Improvement in physician assessed signs and symptoms  and clinically relevant biomarkers (i.e. troponin T, N-terminal pro-brain B-type natriuretic peptide (NT-proBNP) and Cystatin-C).
- Consistent results on dyspnea and multiple other endpoints including WHF, length of stay and  mortality  in  the  supportive  phase  II  Pre-RELAX-AHF  trial  in  a  similar  patient population.
- Objective improvements on several important hemodynamic parameters (PCWP, PAP and SVR) demonstrated in the Central Hemodynamic study CRLX030A2201.

The benefits of serelaxin were also observed in the high risk subgroup of patients with moderate renal impairment (estimated glomerular filtration rate (eGFR) 30 to &lt;60 mL/min/1.73 m2eGFR), in whom there is a significant unmet medical need for new AHF treatment options with favorable renal effects.

## Ground 1b

Used methodology. The estimate of the effect size is not robust. The results were driven by the imputations that were applied for non-missing data after event of Worsening Heart Failure (WHF) with a large difference between the estimate according to the protocol and a conservative intention-to-treat approach based on observed values. Worsening Heart Failure cannot robustly be combined with the Visual Analogue Scale area under curve (VAS AUC) results and its use as an endpoint needs further justification.'

## Summary of the Applicant's response

Incorporating  in-hospital  WHF  events  or  death  into  the  primary  efficacy  analysis  of  patientreported assessments of changes in dyspnea was prospectively defined in the study protocol of the  RELAX-AHF  Phase  II/III  program.  Use  of  the  worst-reported  dyspnea  score  to  supersede reported values after the WHF event is consistent with the fact that the in-hospital WHF event represents  a  patient's  deteriorating  clinical  condition  and  failure  of  the  randomized  treatment which requires immediate initiation of rescue therapy. Reported dyspnea VAS scores after WHF are  distorted  by  the  use  of  rescue  treatment  and  do  not  reflect  the  effect  of  the  randomized

<div style=\"page-break-after: always\"></div>

study treatment. Therefore, in order to appropriately represent the deteriorating clinical condition of  patients  with  WHF  in  an  ITT  analysis,  the  study  protocol  specified  the  worst  observed  VAS score  during  the  study  to  be  used.  A  WHF  event  alters  the  in-hospital  clinical  course,  as evidenced  by  prolongation  of  the  hospital  stay  and  increased  risk  of  post-discharge  mortality, which justifies the worst score assignment for the remainder of follow-up period in patients who experienced  such  an  event.  This  was  pre-specified  in  the  study  protocol  and  the  statistical analysis plan and under the null hypothesis both groups had an equal chance to be affected by this. This strategy follows precedence in AHF clinical trials and other indications.

Importantly,  several  pre-specified  and  post-hoc  sensitivity  analyses  were  performed  on  the primary  VAS  AUC  endpoint  using  various  approaches  to  account  for  the  occurrence  of  WHF. These included assignment of scores other than the pre-specified worst score (VAS = 0) to WHF events as well as alternative approaches that do not require the assignment of a value on the VAS scale. Taken together, these additional supportive analyses demonstrate that achievement of  success  on  the  VAS  AUC  primary  endpoint  in  the  RELAX-AHF  trial  did  not  depend  on  the assignment of a numerical score to patients with an unfavorable clinical course. If the clinical course of patients in the trial was characterized and ranked only according to clinical judgment, a favorable  effect  of  serelaxin  was  consistently  identified,  and  the  strength  of  evidence  for  this effect was very similar to the protocol-specified analytical approach.

Several pre-specified and post-hoc sensitivity analyses were performed on the primary VAS AUC endpoint  using  various  approaches  to  analyze  occurrence  of  WHF,  including  assigning  scores other than the pre-specified worst score (VAS = 0) to WHF events and alternative approaches that do not require the assignment of a value on the VAS scale. Overall, the results of sensitivity analyses were consistent with the pre-specified primary analysis.

## Ground 1c

Background therapy. In the trial, the use of i.v. nitrates in the placebo arm was lower than expected based on current guidelines. Nitrates, similar to serelaxin, have vasodilating properties contributing to their therapeutic effect. Thus, this undertreatment with nitrates in the placebo arm may have well contributed to the observed difference in afterload compared with serelaxin during the period in which the primary end point was assessed, potentially affecting the size of the outcome measurement.'

## Summary of the Applicant's response

In the absence of scientific evidence, consensus in the medical community, treatment guidelines or  agreed  blood  pressure  (BP)  targets,  the  use  of  vasodilators  varies  widely  from  one  region, country  or  even  institution  to  another  and  their  use  is  based  more  on  local  experience  and treatment algorithms. Most importantly, nitrate use in the RELAX-AHF trial is within the expected range of large international registries, especially if RELAX-AHF-like patients are considered.

Current treatment guidelines remain vague on when and how much nitrates should be used in the  treatment  of  AHF,  because  there  is  a  lack  of  evidence  for  clinically  meaningful  treatment benefit in this population. Hence, there is no consensus on the topic in the medical community, which  is  reflected  in  a  wide  variability  of  nitrate  use  in  both  the  RELAX-AHF  trial  and  AHF

<div style=\"page-break-after: always\"></div>

registries. Most importantly, nitrate use in the RELAX-AHF trial is within the expected range of registries, especially if RELAX-AHF-like patients are considered.

The level of evidence supporting the use of nitrates in the treatment of AHF is weak. The current ESC  AHF  guidelines  (McMurray  et  al  2012)  list  nitrates  as  a  Class  IIa/b  Level  B  treatment recommendation, indicating that there is conflicting evidence and/or divergent opinion on their efficacy based on a single randomized trial:

## 'Although vasodilators such as nitroglycerin […] reduce preload and afterload and increase stroke volume,  there  is  no  robust  evidence  that  they  relieve  dyspnea  or  improve  other  clinical outcomes.'

The 2012 ESC AHF treatment guidelines do not indicate a BP target, nor do they recommend a predefined  level  of  nitrate  use.  For  hypertensive  AHF  the  ESC  hypertension  guidelines  are referenced instead (Mancia et al 2013), where a target SBP of &lt;150 to &lt;140 mmHg (depending on  the  age  and  comorbidity  of  the  patient)  is  recommended.  This  highlights  the  absence  of evidence  to  support  a  more  aggressive  use  of  anti-hypertensive  medication,  which  is  actually associated  with  worse  outcome  (Peacock  et  al  2011).  In  the  RELAX-AHF  study  enrolment  of patients on nitrates was restricted but not the use of nitrates during the study.

In the RELAX-AHF trial, the placebo group received more IV nitrates than the serelaxin group, which  constitutes  indirect  proof  for  serelaxin's  efficacy.  In  addition,  data  from  the  RELAX-AHF study does not provide evidence that the difference in SBP between the placebo and serelaxin group impacted the trial results.

Based on the overall totality of evidence available for serelaxin and unmet medical need in AHF, the Applicant consider that it is justified for serelaxin to be given consideration for a conditional marketing authorization at the current time.

## Conditional Marketing Authorisation

The  applicant  proposed  justifications  for  consideration  of  its  application  for  a  conditional Marketing Authorisation in accordance with Article 14(7) of the Regulation (EC) No 507/2006 based on the following claims:

- According to Commission Regulation No 507/2006 falling within the scope of Regulation 726/2004, medicinal products which aim to treat seriously debilitating or life-threatening diseases, such as Reasanz for the treatment of AHF, fall within the scope of conditional Marketing Authorization.

A justification for how serelaxin meets the additional requirements from Article 4 of Commission Regulation No 507/2006 is summarised below:

- The benefit-risk  balance: the  results  of  the  RELAX-AHF  and  Pre-RELAX  AHF  studies indicate  that  serelaxin  provides  a  robust  improvement  on  a  number  of  signs  and symptoms  of  heart  failure  both  patient-reported  and  physician  assessed,  and  on  the clinically  relevant  prevention  of  worsening  heart  failure  (WHF).  The  patient-reported dyspnea  results  are  supported  by  objective  hemodynamic  measures  from  the  central hemodynamic study indicative of a reduction in congestion. In addition, significant effects

<div style=\"page-break-after: always\"></div>

of serelaxin have been observed on long-term clinically important endpoints, in particular a reduction in Day 180 cardiovascular and all-cause mortality by 37%. These findings are accompanied by significant reductions in biomarkers associated with cardiac wall stress and cardiomyocyte injury and  favorable effects on renal function.  Improvement of the patient's clinical status is also evident through lower use of diuretics and faster transition to  oral  diuretics  in  the  serelaxin-treated  patients  and  a  reduction  of  length  of  hospital stay of 0.9 days in the index heart failure hospitalization and of 0.3 days length of stay in the intensive care/coronary care unit. Serelaxin has a favorable safety profile. Hypotension  has  been  identified  as  safety  risk  following  serelaxin  exposure  that  is explained by the serelaxin vasodilatory properties. This risk is manageable with selection of the appropriate patients (i.e., systolic blood pressure &gt;125 mmHg prior to serelaxin treatment),  careful  blood  pressure  monitoring,  and  dose  reduction  or  discontinuation during  serelaxin  infusion  subsequent  to  the  systolic  blood  pressure  response.  Overall, serelaxin has demonstrated a positive benefit-risk ratio with a benign safety profile and with  clear  and  consistent  benefits  reproduced  across  two  studies  (Phase  3  RELAX-AHF study and Phase 2 Pre-RELAX-AHF) on signs and symptoms of congestion, reduction in worsening of heart failure, length of hospital stay, and mortality.

- It  is  likely  that  the  applicant  will  be  able  to  provide  comprehensive  data: The ongoing well-controlled Phase 3b study [RELAX AHF-2] (aiming to recruit 6375 patients with  AHF)  is  designed  to  evaluate  the  efficacy  of  serelaxin  compared  to  placebo  when used  on  top  of  standard  of  care  on  cardiovascular  mortality  through  180  days.  In addition, WHF, length of hospital stay, and all-cause mortality are assessed. This study is being conducted globally in overall 30 countries, including 22 EU countries. An interim analysis is planned by the time 60 % of the primary accrued events (308 cardiovascular deaths) are reached. Should the availability of serelaxin in the market impact the overall recruitment  in  the  RELAX-AHF-2  study,  Novartis  will  implement  mitigation  strategies, which include redistribution of the patient allocation to other non-impacted participating countries  as  well  as  potentially  adding  additional  countries  where  the  drug  is  not  yet approved.
- There  is  an  unmet  medical  need  in  acute  heart  failure: AHF  remains  a  lifethreatening  disease  and  a  major  and  growing  public  health  problem  with  a  very  poor prognosis and high mortality following AHF episodes. In Europe, approximately 15 million patients suffer from heart failure, of which close to 50 percent are expected to die within 5 years after their first admission in the hospital. Its incidence increases and currently available AHF standard-of-care treatments do not address a number of treatments goals. Current  AHF  therapies  are  generally  focused  on  achieving  dyspnea  relief  and  reducing congestion. None of the currently used therapies have been demonstrated to reduce inhospital WHF events safely and no agents have demonstrated evidence of a long-term mortality reduction.
- Benefits  to  public  health: any  potential uncertainty  about  serelaxin's mortality reduction would be clarified, when the Phase 3b RELAX-AHF-2 study results are available. A conditional marketing authorisation in 2014 would  allow patient access to serelaxin as a lifesaving treatment option earlier.

<div style=\"page-break-after: always\"></div>

In addition to the grounds for re-examination the applicant presented at an oral explanation on 20 May 2014.

## 5.2 Scientific Advisory Group on Cardiovascular Issues (SAG CVS)

Following  the  receipt  of  the  detailed  grounds  for  the  reexamination,  the  CHMP  convened  a Scientific Advisory Group on Cardiovascular Issues inviting the experts to provide their views on the CHMP grounds for refusal, taking into account the applicant's response.

## Report from the SAG CVS on 12 th  of May 2014

## The SAG should comment on the grounds for negative opinion in view of the grounds for re-examination submitted.

## Does the totality of data (haemodynamic, clinical and laboratory data) support a clinically relevant effect of serelaxin in the proposed target population or a subpopulation thereof?

## Has the Applicant demonstrated that serelaxin provides a clinically relevant improvement of dyspnoea?

It was acknowledged that formally speaking the RELAX-AHF study reached one of the co-primary endpoints:  relieve  of  dyspnoea  over  the  first  5  days  of  treatment  compared  to  placebo  as demonstrated  by  change  in  the  mean  area  under  curve  (AUC)  from  baseline  of  the  visual analogue  scale  (VAS),  [2756  mm-hours  on  serelaxin  versus  2308  mm-hours  on  placebo; p=0.0075].  Despite  this  and  taking  into  account  the  totality  of  the  data  available  to-date  for serelaxin the SAG was of the opinion that no clinically relevant improvement of dyspnoea was demonstrated.

This is due to the fact that the results of the primary endpoint were driven by the imputations used in case of the event classified as worsening heart failure (WHF), where zero values were imputed for VAS, although these were not missing data. The experts noted that the trial was powered  to  detect  a  mean  difference  on  4  mm  in  the  VAS  scale;  the  treatment  effect corresponded  to  3.83  mm  difference  and  only  1.5mm  difference  in  sensitivity  analyses  using measured, instead of imputed values. Moreover the experts believed that 4mm difference on the 100-points scale is very small and clinically relevant improvement was believed to be at least 20 mm.

Possible  relationship  between  the  length  of  stay  in  the  hospital  and  dyspnoea  was  noted  (for serelaxin 0.9 days less than placebo) but it was pointed out that different factors could play a role  in  the  duration  of  hospitalisation  and  clinical  relevance  of  the  finding  is  difficult  to  be interpreted (potential benefit should be coupled with reduction in re-admissions). Agents with a relatively  short  pharmacokinetic  profile  (half-life),  without  an  oral  analogue  for  maintenance therapy (e.g. serelaxin) may hasten stabilisation and discharge while administered in hospital. However, once withdrawn, they may potentially also incur a greater risk of acute heart failure (AHF) recrudescence and rehospitalisation. A drug used for heart failure with beneficial mortality effect would be expected to have an even greater impact on hospital re-admission and the fact that these two parameters move in opposite directions in this study increase the concern that the

<div style=\"page-break-after: always\"></div>

observed  mortality  reduction  may  be  a  chance  finding  and  as  such  should  be  regarded  as hypothesis generating only.

## Can the experts, focussing on the short term clinical course, comment the relevance of improvement in worsening of heart failure?

WHF as such was considered  to  be  a  valid  endpoint  in  the  opinion  of  experts.  However  they expressed a view that the trial was not appropriately designed to measure it; in particular the relationship between the use of diuretics and the WHF was not clearly understood. The definition of  WHF  used  in  the  trial  was  found  not  sufficiently  pre-specified  and  not  stringent  enough  to interpret the relevance regarding its efficacy value. Therefore, WHF definition in such a context of hospital admission for AHF should be standardized, especially for the up-coming RELAX-AHF 2 trial.

It  was  also  noted  that  the  dose  of  diuretics  used  in  the  first  5  days  since  randomisation  was relatively low (30 - 40 mg/day IV); much higher doses (up to 160mg IV BID) would be expected in  some  patients  with  AHF).  The  experts  pointed  out  that  probably  the  majority  of  patients included  in  the  trial  had  pulmonary  oedema  rather  than  volume  overload.  Indeed  a  large proportion of patients were hypertensive with preserved left ventricular function.

## Do you consider that serelaxin fulfils an unmet medical need, based on the current trial data on long-term outcome?

The experts confirmed that there is an unmet medical need regarding an appropriate treatment for AHF patients. However, it was clear, in the opinion of the Group, that serelaxin doesn't fulfil it based on the currently available data. Experts had doubts if this unmet medical need could be fulfilled when studying the AHF in the population of patients included specifically in the RELAXAHF  trial  and  given  the  objectives  of  this  trial.  Initial  main  objective  of  this  study  was  to demonstrate  efficacy  on  symptom  reduction,  which  was  not  clearly  obtained.  Mortality  was  a safety endpoint, not an efficacy endpoint and results may have been obtained by chance. So  for  justification  of  fulfilling  such  unmet  medical  need,  data  from  the  RELAX-AHF  study  are insufficient.  In  addition,  in  the  past  in  AHF  condition,  several  exploratory  results  on  long term cardiovascular  (CVS)  mortality  have  not  been  confirmed  with  other  drugs  (nesiritide  for example).

## In the expert's opinion, is there a remaining concern that there was an insufficient treatment with nitrates in the control arm?

Taking into account the type of the AHF population studied in the RELAX-AHF, the use of nitrates should be around 60% according to the results of EuroHeart Failure Survey II (EHFS II; a survey on hospitalized AHF patients). Given the mean blood pressure (BP) was about 140 - 150 mm Hg, much higher use of nitrates (or other BP-reducing agents) would be expected. The nitrates would be mainstay of initial management of hypertension in this clinical context. Therefore, the experts believed, that the use of nitrates was below what is considered to be current clinical practice. The view of the Group was that clinical trial design may have led to less use of nitrates/BP lowering therapy in placebo arm by protocol (even if not explicit) exaggerating the apparent treatment effect.  The  inclusion  criteria  in  the  RELAX-AHF  trial  were  also  probably  chosen  in  mind  of reducing the incidence of seralaxin induced hypotension.

<div style=\"page-break-after: always\"></div>

## 3. From your clinical perspective/experience and in view of the submitted data, do you have any plausible pathophysiological explanations for:

## the discrepancy between predefined secondary efficacy outcomes ('Days alive out of hospital' and 'CV death or re-hospitalization' at D60) and the observed mortality at day 180?

The experts did not consider the results at D60 ('Days alive out of hospital' and 'CV death or rehospitalization') and D180 (CVS mortality) necessarily contradictory. At D60 there seem to be a slight but not significant mortality advantage which becomes more apparent at D180. This could be a chance finding. Not sufficient data are available to draw conclusions (e.g. hospitalisation rate at D180 not known).

## the difference in mortality between the treatment arms at day 180?

The experts could not find any plausible pathophysiological explanation for the difference in CVS mortality  at  D180.  It  was  noted  that  the  D180  mortality  results  were  driven  by  stroke  and sudden cardiac death (SCD) and that SCD is a well-recognised consequence of heart failure and may well complicate AHF. A difference in non-cardiovascular deaths was noted as well, increasing the likelihood that this is a chance observation (procedure related deaths 4:0, pulmonary deaths 2:0, sepsis 6:3, malignancy death 2:1, haematology death 1:0, together 15:4).

It was pointed out that patients in placebo arm were more often treated with inotropic agents (dopamine,  dobutamine)  from  day  1  through  day  5  which  could  have  worsened  the  patient prognosis of the placebo group or which could indicate that they represented more serious cases of the AHF (although the percentages in each arm were small).

Given the observed and unexplained reduction in mortality, the SAG agrees that further study to more definitively  answer  this  question  is  justified.    It  is  hoped  that  this  study  will  also  more clearly define and adjudicate WHF in hospital, and examine rehospitalisation rate until D180.

The CHMP has considered the outcome of the advice provided by the SAG CVS.

## 5.3 Overall conclusion on grounds for re-examination

The  CHMP  assessed  all  the  detailed  grounds  for  re-examination  and  arguments  presented  in writing  and  in  an  oral  explanation  by  the  Applicant,  considered  the  views  of  the  Scientific Advisory Group and the justification for a conditional Marketing Authorisation.

## Clinical relevance

It  is  concluded  that  the  Applicant  has  failed  to  convincingly  demonstrate  a  clinically  relevant improvement in dyspnoea scores. The observed difference between the treatment groups of 4 mm on a 100 mm visual analogue scale must be regarded as small and even more so if the analysis  with  the  observed  values  is  considered  with  a  difference  of  1  mm.  The  difference expressed as 19% in overall dyspnoea score AUC is in itself difficult to translate into clinical relevance.  Serelaxin  was  not  associated  with  an  increased  proportion  of  'patients  with moderately or markedly improved dyspnea' on the Likert scale at the combined time points of 6,  12,  and  24  hours  compared  to  placebo  (serelaxin:  26.9%,  placebo:  25.9%;  p=0.7024),

<div style=\"page-break-after: always\"></div>

although numerical differences in favour of serelaxin were observed at each of the individual time points. The CHMP did not accept the Applicant's argumentation that the VAS-AUC-endpoint ought to be considered a multicomponent endpoint consisting of a) Change in dyspnoea score, b) Occurrence of in-hospital worsening heart failure and c) Death, and that it is 'conceptually similar'  to  a  composite  endpoint.  In  the  CHMP  opinion  the  predefined  primary  endpoint  is considered not more than a dyspnoea endpoint, which includes (an attempt for) correction for WHF and death. The Applicant's shift of focus on the clinical relevance of worsening of heart failure was not considered appropriate for addressing the CHMP's concern. Likert scores (better reflecting  patients'  perception  of  dyspnoea  change)  were  not  conclusively  anchored  to  the related VAS observations to enable a statement on the clinical meaningfulness of the magnitude of effect.

## Used methodology

It  is  concluded  by  the  CHMP  that  the  difference  in  VAS  dyspnoea  scores  between  the  study groups is largely driven by WHF with the imputation method used. For the evaluation of the effects  on  dyspnoea  the  imputation  rule  must  be  regarded  as  anticonservative.  A  range  of sensitivity  analyses  has  been  performed,  many  of  which  however  still  include  a  worst  case imputation. Other analyses must be categorized as being post-hoc and defined in a data driven manner.  Overall,  the  sensitivity  analyses  do  not  provide  any  essential  new  information  in addition to the analysis based on observed values, which reflects an example of a worst case scenario. Though several (post-hoc) results would meet the predefined criterion for statistical significance,  this  is  guided  by  the  family-wise  type  I  error  control  at  5%,  i.e.  the  Applicants position does not consider the one-pivotal trial situation.

Altogether the analyses are not sufficiently convincing and a robust and large treatment effect is not demonstrated. It is concluded that the results of the predefined primary end-point alone fail  to  provide  convincing  results  of  such  a  nature  as  would  be  needed  for  a  positive recommendation for approval in a one pivotal study application.

## Background therapy

Overall, while it was apparent, that intravenous nitrates use in RELAX-AHF ranges in the lower regions of prescription frequency compared to other relevant datasets, it is also evident that reported  nitrate  use  patterns  vary  considerably  between  regions  and  databases.  A  similar observation  can  be  made  between  study  sites  within  the  Relax-AHF  trial  (i.e.  prescription frequency ranging from 0 - 44%).

The CHMP noted the advice from the SAG CVS that taking into account the type of the AHF population  studied  in  the  RELAX-AHF,  the  use  of  nitrates  would  have  been  expected  to  be around 60% according to the results of EuroHeart Failure Survey II. Serelaxin and nitrates are assumed  to  largely  exert  comparable  therapeutic  effects  (i.e.  vasodilation  and  reduction  of afterload) and a higher nitrate use might 'compete' with serelaxin efficacy under this premise.

The CHMP noted that the slight imbalance between nitrate prescriptions did favour the placebo arm and that the additional analyses showed a trend towards better trial outcomes in those countries  with  a  nitrate  use  rate  &gt;15%  across  the  major  endpoints;  however  this  did  not completely alleviate the concern.

In  summary,  the  CHMP  was  of  the  view  that  the  major  objections  identified  in  the  original

<div style=\"page-break-after: always\"></div>

assessment  have  not  been  resolved.  There  are  still  major  concerns  regarding  the  clinical relevance of the observed dyspnoea benefit, the methodology of data imputation as well as the issue of  under-treatment  with  intravenous  nitrates.  The  applicant´s  decision  to  further investigate serelaxin's impact on cardiovascular mortality in the ongoing RELAX-AHF-II trial was considered  by  the  CHMP  the  logical  step  towards  confirming  the  promising,  yet  exploratory findings of RELAX-AHF. While it was agreed that the safety profile of serelaxin observed so far appears  relatively  benign,  the  robustness  and  clinical  relevance  of  efficacy  results  was questioned  by  the  CHMP.  WHF  and  mortality  findings,  although  promising,  are  considered exploratory in nature and confirmation from a second trial was considered necessary.

In conclusion, the CHMP believed that it is possible that the applicant would be able to provide comprehensive  data  following  the  completion  of  the  RELAX-AHF-2  study  and  that  there  is unmet medical need in the treatment acute heart failure. The CHMP pointed out however that the benefits to public health of the immediate availability of serelaxin do not outweigh the risks inherent in the fact that additional data are still required. In the view of the CHMP, the current benefit-risk balance of serelaxin remains negative and conditional marketing authorisation can therefore not be granted.

## 5.4 Recommendations following re-examination

Based  on  the  arguments  of  the  applicant  and  all  the  supporting  data  on  quality,  safety  and efficacy, the CHMP re-examined its initial opinion and in its final opinion concluded by majority decision  that  the  efficacy  of  the  above  mentioned  medicinal  product  is  not  sufficiently demonstrated,  and,  therefore  recommends  the  refusal  of  the  granting  of  the  conditional Marketing Authorisation for the above mentioned medicinal product. The CHMP considers that:

- The efficacy of Reasanz in the treatment of acute heart failure in adults with systolic blood pressure above 125 mm Hg on top of standard of care, including loop diuretics has not been sufficiently demonstrated;
- In  the  absence  of  established  efficacy,  a  positive  benefit-risk  balance  has  not  been established.

The CHMP considered that the requirements for a conditional approval laid down in Article 4 of the Commission Regulation (EC) No 507/2006, namely the benefit risk balance of the medicinal product,  as  defined  in  Article  1  (28a)  of  Directive  2001/83/EC,  being  positive,  has  not  been fulfilled.

Furthermore, the CHMP, in light of the negative recommendation, has not concluded on the new active substance status at this time.

Divergent positions to the majority recommendation are appended to this report.

<div style=\"page-break-after: always\"></div>

## APPENDIX DIVERGENT POSITION

<div style=\"page-break-after: always\"></div>

## Divergent Position

The undersigned members of CHMP did not agree with the CHMP's opinion recommending the refusal of the granting of a Marketing Authorisation for Reasanz.

The reasons for divergent opinion were as follows:

We, the undersigned, are of the view that the totality of the provided data support a conclusion that serelaxin has clinically relevant beneficial effects in the intended target population and that its use can contribute to a favourable clinical course. We believe that the Applicant has addressed the CHMP grounds for refusal sufficiently well allowing a recommendation for a conditional approval.

London, 22 May 2014

……………………………..……………

……………………………..……………

(Romania)

(Denmark)

……………………………..……………

…….………………………..…………

(Malta)

(Sweden)

……………………………..……………

……………………………..……………

(Ireland)

(Greece)

……………………………..……………

(Bulgaria)